topic
global
natur
resolut
relat
issu
problem
restrict
one
countri
region
topic
requir
cooper
countri
harmon
standard
climat
chang
pollut
water
suppli
good
exampl
issu
need
resolv
global
level
extend
across
border
public
health
includ
avail
relev
medicin
anoth
topic
need
consid
global
level
demonstr
recent
pandem
crise
appoint
second
term
function
collabor
center
manyfold
may
includ
follow
collect
collat
dissemin
inform
standard
terminolog
nomenclatur
technolog
diagnost
therapeut
prophylact
substanc
method
procedur
develop
applic
appropri
technolog
provis
refer
substanc
servic
particip
collabor
research
develop
organ
leadership
includ
plan
conduct
monitor
evalu
research
well
promot
applic
research
result
train
includ
research
train
coordin
activ
carri
sever
institut
given
subject
e
refer
made
expert
committe
collabor
center
essenti
costeffect
cooper
mechan
enabl
organ
fulfil
mandat
activ
har
resourc
far
exceed
gain
access
top
center
worldwid
institut
capac
ensur
scientif
valid
global
health
data
addit
provid
resourc
support
collabor
center
also
enhanc
nation
particip
collabor
activ
therefor
facilit
implement
agreement
project
line
polici
strategi
technic
cooper
also
particip
strengthen
countri
resourc
term
inform
servic
research
train
support
nation
health
develop
mani
aspect
increas
global
also
profound
implic
pharmaceut
regul
worldwid
gener
global
economi
increas
travel
peopl
exchang
good
financ
inform
also
global
pharmaceut
market
includ
develop
manufactur
distribut
activ
requir
increas
cooper
harmon
pharmaceut
standard
regul
pharmaceut
industri
ask
better
harmon
requir
develop
manufactur
pharmaceut
product
avoid
duplic
work
ultim
creat
delay
drug
avail
context
harmon
pharmaceut
regul
natur
becom
import
topic
discuss
among
worldwid
drug
regulatori
author
dra
past
sever
decad
work
end
isolationist
attitud
resolv
current
worldwid
issu
challeng
result
mani
cooper
initi
bilater
region
global
establish
harmon
effort
enhanc
initi
differ
scope
part
broader
harmon
initi
level
harmon
depend
polit
supportcommit
organ
well
structur
versu
simpl
discuss
advanc
establish
process
versu
pilot
project
work
toward
harmon
requir
andor
practic
increas
exchang
inform
regular
basi
eg
countri
intern
organ
australia
vietnam
agreement
share
inform
unit
state
food
drug
administr
us
fda
also
contribut
natur
converg
requir
practic
harmon
model
distinguish
scope
object
inde
spectrum
collabor
vari
simpl
technic
cooper
full
integr
system
regul
integr
model
type
agreement
time
driven
polit
decis
deeper
harmon
regul
achiev
creation
supran
central
author
order
support
integr
andor
creation
singl
market
eg
eu
associ
southeast
asian
nation
asean
case
harmon
standard
regul
critic
reduc
trade
barrier
model
countri
give
autonomi
certain
matter
transfer
power
make
decis
common
supran
author
automat
recogn
decis
parti
via
mutual
agreement
mechan
african
medicin
registr
harmon
amrh
initi
defin
five
identifi
level
harmon
figur
facilit
cooper
mutual
recognit
agreement
arrang
mra
sign
one
parti
mutual
recogn
accept
aspect
one
anoth
requir
conclud
technic
level
eg
statu
futur
plan
novemb
confidenti
arrang
us
fda
european
medicin
agenc
ema
mra
eu
australia
govern
level
eg
european
treati
multilater
initi
major
project
involv
multipl
organ
countri
repres
highest
degre
harmon
object
technic
scientif
intergovernment
cooper
global
discuss
scientif
issu
support
decis
made
individu
govern
intern
regulatori
bodi
order
achiev
global
scientif
consensu
goal
facilit
develop
new
medicin
make
avail
maximum
number
peopl
worldwid
intent
full
integr
system
regul
main
difficulti
face
initi
complex
manag
structur
due
import
number
particip
eg
world
health
organ
member
state
divers
need
challeng
level
develop
member
world
health
organ
establish
special
agenc
unit
nation
un
account
member
state
work
close
entiti
un
system
agenc
broad
scope
respons
direct
coordin
author
intern
health
matter
public
health
within
un
system
well
known
work
eg
coordin
influenza
surveil
monitor
activ
emerg
assist
peopl
affect
disast
mass
immun
campaign
action
human
immunodefici
virusacquir
immunodefici
syndrom
hivaid
tuberculosi
malaria
howev
undertak
mani
activ
respons
provid
leadership
global
health
matter
shape
health
research
agenda
set
norm
standard
articul
evidencebas
polici
option
provid
technic
support
countri
monitor
assess
health
trend
core
function
defin
gener
programm
work
reli
cooper
harmon
standard
focu
region
global
collabor
especi
aid
develop
countri
develop
countri
align
un
millennium
develop
goal
mdg
unit
nation
millennium
develop
goal
mdg
eight
intern
goal
un
member
state
intern
organ
agre
achiev
year
deriv
unit
nation
millennium
declar
sign
septemb
endors
framework
develop
commit
world
leader
combat
poverti
hunger
diseas
illiteraci
environment
degrad
discrimin
women
mdg
interdepend
sever
relat
either
directli
indirectli
health
therefor
involv
process
work
countri
achiev
healthrel
mdg
inde
object
mdg
countri
develop
partner
work
togeth
improv
global
situat
resolv
major
issu
number
specif
target
indic
identifi
monitor
progress
toward
goal
goal
develop
global
partnership
develop
specif
recogn
role
develop
nation
address
global
cooper
partnership
work
area
pharmaceut
sinc
creation
approxim
year
ago
time
mani
product
servic
creat
wide
recogn
core
function
role
pharmaceut
regul
base
constitut
mandat
variou
world
health
assembl
wha
resolut
support
twofold
one
aspect
relat
develop
intern
recogn
norm
standard
guidelin
second
relat
provid
guidanc
technic
assist
train
order
enabl
countri
implement
global
guidelin
meet
specif
medicin
regulatori
environ
need
countri
member
un
may
becom
member
accept
constitut
countri
may
admit
member
applic
approv
simpl
major
vote
world
health
assembl
wha
territori
respons
conduct
intern
relat
may
admit
associ
member
upon
applic
made
behalf
member
author
respons
intern
relat
member
group
accord
region
distribut
strength
lie
neutral
statu
nearli
univers
membership
today
repres
countri
two
associ
member
puerto
rico
tokelau
one
countri
observ
vatican
organ
head
directorgener
b
wha
suprem
decisionmak
bodi
gener
meet
geneva
switzerland
may
year
attend
deleg
member
state
main
function
determin
polici
organ
health
assembl
also
appoint
directorgener
nomin
execut
board
supervis
financi
polici
organ
review
approv
propos
budget
work
assembl
support
execut
board
elect
execut
arm
assembl
compos
member
technic
qualifi
health
field
member
elect
threeyear
term
main
board
meet
agenda
forthcom
health
assembl
agre
upon
resolut
forward
health
assembl
adopt
held
januari
second
shorter
meet
may
immedi
health
assembl
held
address
administr
matter
primari
function
board
give
effect
decis
polici
health
assembl
advis
gener
facilit
work
leadership
directorgener
c
peopl
countri
work
staff
includ
health
profession
includ
medic
doctor
public
health
specialist
epidemiologist
scientist
well
manag
economist
administr
profession
locat
countri
offic
six
region
offic
headquart
geneva
switzerland
one
uniqu
aspect
decentr
structur
work
great
combin
action
countri
region
global
level
effort
decentr
structur
aim
get
closer
ground
field
decis
made
respons
actual
need
inde
decentr
region
structur
provid
multipl
opportun
engag
countri
global
headquart
locat
geneva
switzerland
team
base
global
headquart
support
build
region
local
effort
set
global
polici
standard
facilit
technic
support
region
countri
monitor
public
progress
help
mobil
polit
financi
support
headquart
medicin
activ
conduct
within
cluster
health
system
servic
hss
coordin
depart
essenti
medicin
health
product
emp
depart
employ
staff
member
involv
harmon
pharmaceut
regul
coordin
variou
activ
area
qualiti
assur
eg
intern
pharmacopoeia
intern
nonproprietari
name
inn
prequalif
medicin
counterfeit
medicin
regul
legisl
eg
intern
confer
drug
regulatori
author
icdra
safeti
efficaci
eg
drug
alert
activ
compris
guidelin
develop
workshop
train
cours
coordin
promot
pharmacovigil
global
medicin
safeti
regulatori
inform
exchang
review
narcot
psychotrop
substanc
member
state
group
six
region
region
offic
region
offic
africa
brazzavil
republ
congo
region
offic
europ
copenhagen
denmark
region
offic
southeast
asia
new
delhi
india
region
offic
americaspan
american
health
organ
paho
washington
dc
unit
state
region
offic
eastern
mediterranean
cairo
egypt
region
offic
western
pacif
manila
philippin
region
offic
first
point
contact
countri
offic
need
extra
technic
financi
help
region
offic
also
give
special
attent
adapt
global
polici
fit
specif
need
region
inde
region
level
import
organ
link
global
strategi
plan
countri
realiti
need
play
key
role
implement
norm
standard
ensur
countri
region
need
taken
consider
norm
standard
develop
global
guidelin
intern
recogn
norm
standard
appropri
implement
region
context
specif
regulatori
environ
challeng
provid
guidanc
technic
assist
train
addit
global
activ
coordin
headquart
region
countri
offic
also
carri
varieti
medicinerel
activ
specif
region
addit
region
headquart
offic
countri
offic
cover
member
state
also
two
field
offic
humanitarian
assist
offic
pristina
kosovo
west
bank
gaza
offic
offic
cover
two
differ
area
usmexican
border
field
offic
el
paso
texa
us
offic
caribbean
program
coordin
barbado
also
establish
liaison
offic
key
locat
eg
european
union
brussel
belgium
african
union
econom
commiss
africa
addi
ababa
ethiopia
washington
dc
us
un
new
york
citi
technic
offic
eg
european
observatori
health
system
polici
berlin
germani
countri
physic
countri
offic
serv
repres
anoth
countri
instanc
repres
malaysia
cover
malaysia
also
brunei
darussalam
singapor
approxim
countri
offic
either
own
support
govern
ministri
health
countri
offic
locat
independ
premis
either
rent
own
other
locat
within
ministri
health
un
common
premis
countri
offic
led
head
offic
hwo
design
directorgener
respect
region
director
hwo
manag
core
function
countri
level
provid
leadership
follow
key
function
area
advocaci
partnership
represent
support
polici
develop
technic
cooper
administr
manag
import
note
focus
need
countri
emphas
particular
decentr
process
aim
increas
impact
health
develop
countri
level
countri
focu
tailor
technic
collabor
need
capac
member
state
special
emphasi
poorest
countri
fragil
context
key
principl
guid
cooper
countri
ownership
develop
process
project
countri
align
nation
prioriti
strengthen
nation
system
harmon
work
sister
un
agenc
partner
countri
toward
better
aid
effect
collabor
twoway
process
foster
member
state
contribut
global
health
agenda
countri
presenc
platform
effect
cooper
countri
advanc
global
agenda
contribut
nation
health
strategi
plan
bring
countri
realiti
perspect
global
polici
prioriti
accord
principl
structur
inde
abl
focu
countri
need
better
defin
prioriti
activ
support
develop
implement
monitor
assess
nation
health
polici
strategi
plan
also
allow
better
monitor
implement
global
agreement
millennium
develop
goal
mdg
intern
health
regul
ihr
activ
countri
govern
countri
cooper
strategi
cc
key
instrument
guid
work
countri
mediumterm
vision
gener
cover
four
six
year
technic
cooper
given
member
state
support
countri
nation
health
polici
strategi
plan
organizationwid
refer
guid
partnership
plan
budget
resourc
alloc
also
establish
depart
countri
focu
cco
support
advoc
countri
offic
develop
capac
countri
team
effect
engag
partnership
platform
facilit
monitor
engag
aid
effect
agenda
countri
level
exampl
cco
provid
support
develop
dissemin
use
countri
cooper
strategi
expert
committe
expert
committe
import
role
activ
defin
constitut
e
addit
constitut
regul
expert
advisori
panel
committe
also
includ
document
entitl
regul
expert
advisori
panel
committe
f
expert
committe
highest
offici
advisori
bodi
directorgener
well
organ
member
state
establish
wha
execut
board
decis
variou
type
expert
committe
exampl
expert
committe
specif
pharmaceut
prepar
ecspp
provid
year
recommend
tool
assur
qualiti
medicin
develop
phase
final
distribut
patient
also
expert
committe
biolog
standard
ecb
old
ecspp
addit
structur
organ
support
sinc
creation
collabor
center
institut
research
institut
part
univers
academi
design
directorgener
carri
activ
support
program
current
collabor
center
member
state
work
sever
area
one
pharmaceut
sever
collabor
center
may
exist
topic
eg
intern
classif
tradit
medicin
form
specif
network
help
regard
specif
topic
caus
death
also
start
publish
bulletin
today
intern
peerreview
monthli
journal
public
health
special
focu
develop
countri
j
earli
year
prioriti
prevent
control
specif
diseas
eg
malaria
tuberculosi
smallpox
yaw
onchocerciasi
vener
diseas
still
problem
today
also
focus
women
children
health
nutrit
environment
sanit
work
sinc
grown
cover
sometim
new
health
problem
includ
polio
hivaid
sever
acut
respiratori
syndrom
sar
also
work
control
tobacco
alcohol
use
promot
diet
physic
activ
prevent
four
main
noncommunic
diseas
cardiovascular
diseas
cancer
chronic
lung
diseas
diabet
also
increasingli
involv
global
regul
control
medicin
first
essenti
medicin
list
releas
two
year
wha
introduc
concept
essenti
drug
nation
drug
polici
one
hundr
fiftysix
countri
today
nation
list
essenti
medicin
also
fund
mani
project
year
facilit
global
cooper
harmon
standard
purpos
activ
pharmaceut
domain
aim
increas
global
equit
access
safe
effect
medicin
assur
qualiti
specif
goal
deriv
overal
object
improv
maintain
global
public
health
object
regularli
reiter
sever
wha
resolut
event
icdra
intern
confer
primari
health
care
almaata
kazakhstan
set
histor
goal
health
continu
aspir
recent
un
mdg
clarifi
object
prioriti
global
cooper
deriv
un
millennium
declar
sign
septemb
one
mandat
develop
establish
promot
intern
standard
respect
food
biolog
pharmaceut
similar
product
member
state
especi
develop
countri
reli
expertis
guidanc
regul
safeti
qualiti
assur
medicin
develop
promot
intern
norm
standard
guidelin
nomenclatur
achiev
goal
reli
cooper
use
decentr
organ
facilit
implement
project
agreedupon
standard
harmon
activ
initi
accord
medicin
strategi
trigger
action
initi
new
project
develop
standard
given
differ
level
bodi
ie
wha
execut
board
resolut
icdra
program
j
sinc
first
publish
bulletin
becom
one
world
lead
public
health
journal
flagship
period
bulletin
draw
expert
editori
advisor
review
author
extern
collabor
cluster
project
standard
develop
vast
global
consult
process
involv
member
state
nation
region
author
intern
agenc
specialist
industri
nation
institut
nongovernment
organ
etc
project
updat
approv
standard
becom
public
avail
extens
list
public
support
nation
region
global
health
strategi
k
global
dissemin
exchang
inform
import
secur
broad
intern
distribut
public
encourag
translat
l
ensur
widest
possibl
avail
authorit
inform
guidanc
health
matter
depart
emp
base
global
headquart
geneva
work
close
expert
committe
regul
relev
collabor
center
develop
implement
harmon
activ
depart
coordin
activ
global
support
region
advisor
countri
project
staff
region
offic
mani
countri
offic
region
offic
two
five
profession
coordin
medicin
strategi
countri
offic
fulltim
pharmaceut
polici
expert
worth
mention
addit
norm
activ
harmon
project
also
assist
countri
capac
build
assess
regulatori
system
facilit
cooper
inform
exchang
countri
provid
technic
support
import
involv
countri
whatev
develop
level
facilit
implement
norm
standard
final
develop
relationship
lot
nongovernment
civil
societi
organ
global
basi
via
civil
societi
initi
csi
also
region
nation
level
object
relat
nongovernment
organ
ngo
promot
polici
strategi
activ
facilit
implement
larg
repertoir
global
norm
work
relev
level
develop
area
medicin
lot
standard
norm
classif
develop
forumsnetwork
creat
enhanc
global
cooper
import
initi
present
k
publish
practic
manual
handbook
train
materi
intern
applic
guidelin
standard
review
analys
health
polici
program
research
stateoftheart
consensu
report
offer
technic
advic
recommend
decis
maker
also
technic
report
seri
make
avail
find
variou
intern
group
expert
provid
latest
scientif
technic
advic
broad
rang
medic
public
health
subject
l
world
health
assembl
turn
multilingu
polici
establish
six
offici
languag
arab
chines
english
french
russian
spanish
sinc
adopt
resolut
govern
bodi
document
corpor
materi
made
avail
onlin
offici
languag
intern
confer
drug
regulatori
author
icdra
provid
drug
regulatori
author
member
state
forum
meet
discuss
way
strengthen
collabor
harmon
pharmaceut
regul
key
accomplish
instrument
guid
dra
interest
stakehold
develop
nation
region
intern
medicin
regul
continu
cornerston
intern
harmon
medicin
regul
confer
held
sinc
involv
develop
develop
countri
icdra
held
singapor
novemb
decemb
involv
particip
agenc
icdra
took
place
tallinn
estonia
octob
attend
particip
countri
aim
confer
promot
exchang
inform
collabor
approach
issu
common
concern
topic
discuss
includ
qualiti
issu
herbal
medicin
homeopathi
regulatori
reform
medicin
safeti
counterfeit
regul
clinic
trial
harmon
new
technolog
ecommerc
recommend
propos
action
take
among
agenc
relat
institut
worth
mention
idea
creat
ich
began
formul
background
discuss
us
european
union
eu
japan
icdra
confer
pari
franc
platform
establish
develop
intern
consensu
icdra
continu
import
tool
dra
effort
harmon
regul
improv
safeti
efficaci
qualiti
medicin
worldwid
basi
constitut
mandat
product
intern
classif
health
intern
endors
classif
develop
network
import
facilit
storag
retriev
analysi
interpret
comparison
data
support
global
cooper
harmon
provid
consensu
framework
govern
healthcar
provid
consum
use
common
languag
also
permit
comparison
data
within
popul
time
also
popul
refer
classif
intern
classif
diseas
icd
intern
classif
function
disabl
health
icf
intern
classif
health
intervent
ichi
addit
relat
deriv
classif
base
refer
classif
also
develop
eg
anatom
therapeut
chemic
classif
defin
daili
dose
atcddd
classifi
design
number
collabor
center
work
develop
dissemin
mainten
use
intern
classif
therapeut
drug
accord
organsystem
act
chemic
pharmacolog
therapeut
properti
intern
clinic
trial
registri
platform
ictrp
global
initi
aim
make
inform
worldwid
clinic
trial
involv
human
publicli
avail
activ
launch
wha
n
follow
discuss
recommend
ministeri
summit
health
research
mexico
citi
mexico
novemb
ictrp
clinic
trial
registri
central
repositori
search
use
search
portal
http
appswhointtrialsearch
item
trial
registr
data
set
copi
individu
registri
onto
central
repositori
data
updat
regularli
inde
detail
clinic
trial
come
directli
one
primari
registri
registri
network
eg
european
clinic
trial
regist
becam
member
network
septemb
p
consolid
clinic
trial
inform
sever
worldwid
sourc
use
standard
data
set
formatcriteria
implement
unambigu
identif
ie
univers
trial
number
utn
ictrp
facilit
exchang
inform
also
promot
harmon
inform
harmon
also
achiev
proactiv
support
countriesregion
establish
whocompli
clinic
trial
registri
polici
trial
registr
qualiti
assur
widerang
concept
cover
matter
individu
collect
influenc
qualiti
product
major
public
health
challeng
particularli
light
grow
crossbord
health
issu
grow
intern
dimens
trade
qualiti
pharmaceut
concern
sinc
incept
develop
norm
standard
guidelin
promot
qualiti
assur
integr
part
constitut
endors
support
numer
wha
resolut
recent
mediumterm
strateg
plan
request
organ
develop
intern
standard
recommend
instrument
assur
qualiti
medicin
whether
produc
trade
nation
intern
n
resolut
wha
call
global
scientif
commun
intern
partner
privat
sector
civil
societi
relev
stakehold
establish
voluntari
platform
link
clinic
trial
regist
order
ensur
singl
point
access
unambigu
identif
trial
view
enhanc
access
inform
patient
famili
patient
group
other
primari
registri
registri
network
clinic
trial
registri
least
nation
remit
meet
registri
criteria
content
qualiti
valid
access
uniqu
identif
technic
capac
govern
administr
p
european
clinic
trial
regist
provid
public
access
inform
extract
eu
clinic
trial
databas
eudract
medicin
qualiti
assur
program
part
emp
depart
produc
norm
standard
guidelin
qualiti
assur
pharmaceut
regulatori
tool
prepar
vast
global
consult
process
ultim
approv
ecspp
q
meet
annual
report
meet
technic
report
seri
includ
newli
adopt
guidelin
annex
adopt
norm
standard
guidelin
becom
intern
harmon
standard
intend
use
nation
dra
manufactur
interest
parti
mani
import
intern
standard
project
develop
area
good
manufactur
practic
gmp
guidelin
regulatori
approv
eg
guidelin
stabil
test
registr
requir
establish
interchang
multisourc
gener
pharmaceut
product
propos
waiv
vivo
bioequival
requir
prequalif
medicin
laboratori
suppli
agenc
model
certif
qualiti
assurancerel
activ
qualiti
control
test
new
specif
inclus
basic
test
seri
intern
pharmacopoeia
intern
chemic
refer
substanc
icr
r
inn
program
intern
guidelin
project
develop
good
manufactur
practic
good
manufactur
practic
gmp
part
qualiti
assur
ensur
product
consist
produc
control
qualiti
standard
appropri
intend
use
requir
market
author
gmp
aim
primarili
diminish
risk
involv
pharmaceut
product
elimin
test
final
product
gmp
cover
aspect
product
start
materi
premis
equip
train
person
hygien
staff
detail
written
procedur
essenti
process
could
affect
qualiti
finish
product
panel
intern
pharmacopoeia
pharmaceut
prepar
r
icr
use
laboratori
test
pharmaceut
purpos
qualiti
control
substanc
mainli
use
valid
result
specif
test
primari
standard
calibr
secondari
standard
collect
icr
maintain
council
europ
european
director
qualiti
medicin
healthcar
edqm
also
distribut
substanc
worldwid
edqm
respons
obtain
candid
materi
test
ensur
puriti
suitabl
report
result
recommend
main
risk
follow
unexpect
contamin
product
caus
damag
health
even
death
incorrect
label
contain
could
mean
patient
receiv
wrong
medicin
insuffici
much
activ
ingredi
result
ineffect
treatment
advers
effect
recogn
import
gmp
intern
commerc
pharmaceut
product
develop
requir
earli
first
draft
text
gmp
prepar
group
consult
request
wha
subsequ
submit
wha
titl
draft
requir
good
manufactur
practic
manufactur
qualiti
control
medicin
pharmaceut
specialti
accept
revis
text
discuss
ecspp
publish
annex
report
text
reproduc
revis
supplement
edit
intern
pharmacopoeia
ph
int
sinc
defin
gener
principl
requir
regard
gmp
also
establish
sever
detail
guidelin
cover
specif
need
gmp
activ
pharmaceut
ingredi
pharmaceut
excipi
steril
pharmaceut
product
biolog
product
blood
establish
pharmaceut
product
contain
hazard
substanc
investig
pharmaceut
product
clinic
trial
human
herbal
medicin
product
radiopharmaceut
product
water
pharmaceut
use
final
also
develop
guidelin
gener
scope
valid
risk
analysi
technolog
transfer
inspect
creat
appropri
train
materi
countri
mani
countri
formul
requir
gmp
base
gmp
intern
pharmacopoeia
ph
int
compris
collect
qualiti
specif
pharmaceut
substanc
ie
activ
ingredi
excipi
dosag
form
togeth
support
gener
method
analysi
intend
serv
sourc
materi
refer
adapt
member
state
clearli
defin
step
follow
develop
new
monograph
ph
int
publish
goal
achiev
wide
global
harmon
qualiti
specif
select
pharmaceut
product
excipi
dosag
form
ph
int
part
legal
statu
whenev
nation
region
author
expressli
introduc
appropri
legisl
histori
ph
int
date
back
need
standard
terminolog
specifi
dosag
composit
drug
led
attempt
produc
intern
pharmacopoeia
compendium
first
confer
call
belgian
govern
held
brussel
result
agreement
unif
formula
potent
drug
ratifi
countri
outcom
consider
influenc
subsequ
public
nation
pharmacopoeia
interim
commiss
took
work
pharmacopoeia
previous
undertaken
health
organ
leagu
nation
wha
held
may
formal
approv
public
pharmacopoea
internationali
recommend
accord
articl
constitut
eventu
inclus
provis
author
respons
pharmacopoeia
thu
recommend
pharmacopoea
internationali
use
legal
pharmacopoeia
countri
unless
adopt
pharmacopoei
author
countri
first
edit
publish
aim
creat
worldwid
unifi
pharmacopoeia
reli
collabor
nation
pharmacopoeia
commiss
prepar
purpos
ph
int
reconsid
decid
public
focu
need
develop
countri
develop
countri
establish
pharmacopoeia
recommend
simpl
classic
chemic
techniqu
shown
sound
sinc
drug
appear
ph
int
therefor
select
list
essenti
drug
base
first
report
expert
committe
select
essenti
drug
also
whenev
possibl
classic
procedur
use
analyt
method
use
expens
equip
minim
applic
ph
int
facilit
implement
develop
countri
work
ph
int
carri
ecspp
collabor
member
expert
advisori
panel
intern
pharmacopoeia
pharmaceut
prepar
specialist
process
involv
consult
input
member
state
dra
collabor
center
nation
drug
qualiti
control
laboratori
six
region
standardset
organ
parti
includ
region
nation
pharmacopoeia
manufactur
around
world
wha
adopt
resolut
creat
intern
nonproprietari
name
inn
program
order
identifi
pharmaceut
substanc
unambigu
worldwid
basi
provid
univers
uniqu
nonproprietari
name
use
pharmacopoeia
monograph
began
oper
first
list
inn
pharmaceut
substanc
publish
today
program
coordin
emp
depart
select
new
inn
reli
strict
procedur
process
support
expert
advisori
panel
intern
pharmacopoeia
pharmaceut
prepar
provid
advic
propos
name
follow
applic
made
manufactur
inventor
procedur
also
involv
secretariat
examin
suggest
name
conform
gener
rule
similar
publish
inn
potenti
conflict
exist
name
time
period
object
laps
name
obtain
statu
recommend
inn
publish
drug
inform
object
rais
make
inn
univers
avail
formal
place
public
domain
henc
design
nonproprietari
name
also
known
gener
name
exist
intern
nomenclatur
pharmaceut
substanc
import
clear
identif
safe
prescript
dispens
medicin
patient
also
commun
exchang
inform
among
health
profession
scientist
regul
worldwid
provid
uniqu
univers
avail
design
name
identifi
pharmaceut
substanc
today
inn
name
wide
use
global
recogn
present
inn
publish
number
grow
everi
year
major
pharmaceut
substanc
use
medic
practic
design
inn
use
alreadi
common
research
clinic
document
nonproprietari
name
intend
use
pharmacopoeia
label
product
inform
advertis
promot
materi
drug
regul
scientif
literatur
basi
product
name
eg
gener
also
inn
collabor
close
numer
nation
drug
nomenclatur
bodi
use
inn
name
normal
requir
nation
author
also
european
commun
result
ongo
collabor
nation
name
british
approv
name
ban
commun
dcf
japanes
adopt
name
jan
unit
state
adopt
name
usan
nowaday
rare
except
ident
inn
addit
qualiti
standard
also
develop
norm
standard
pharmacovigil
promot
inform
exchang
medicin
safeti
aim
assur
safeti
medicin
ensur
reliabl
time
exchang
inform
drug
safeti
issu
promot
pharmacovigil
activ
intern
basi
encourag
particip
program
intern
drug
monitor
establish
program
intern
drug
monitor
respons
thalidomid
disast
end
countri
part
pharmacovigil
program
intern
system
monitor
advers
drug
reaction
adr
use
inform
deriv
member
state
establish
allow
issu
rapid
drug
alert
whenev
seriou
problem
safeti
medicin
product
aris
headquart
geneva
respons
polici
issu
oper
respons
program
rest
collabor
centr
intern
drug
monitor
uppsala
monitor
centr
sweden
common
report
form
develop
agreedupon
guidelin
enter
inform
formul
common
terminolog
classif
prepar
compat
system
transmit
store
retriev
dissemin
data
creat
adr
databas
uppsala
current
contain
three
million
report
suspect
adr
advisori
committe
safeti
medicin
product
acsomp
establish
guid
gener
specif
issu
relat
pharmacovigil
addit
network
inform
offic
establish
allow
direct
relationship
nation
dra
member
state
nation
inform
offic
charg
provid
inform
safeti
efficaci
pharmaceut
prepar
secur
prompt
transmiss
nation
health
author
regard
new
inform
seriou
advers
effect
certif
scheme
initi
adopt
wha
sinc
amend
administr
instrument
requir
particip
member
state
upon
applic
commerci
interest
parti
attest
compet
author
anoth
particip
member
state
wherebi
specif
product
author
placement
market
within
jurisdict
author
reason
author
accord
manufactur
plant
produc
subject
inspect
suitabl
interv
establish
manufactur
conform
gmp
recommend
submit
product
inform
includ
label
current
author
certifi
countri
primari
document
deliv
scheme
certif
pharmaceut
product
cpp
two
document
request
within
scope
scheme
first
statement
licens
statu
pharmaceut
product
second
batch
certif
pharmaceut
product
document
rare
appli
vaccin
sera
biolog
document
use
dra
import
countri
decis
approv
renew
extend
vari
licens
creat
model
confidenti
document
list
inform
certif
need
includ
oblig
certifi
author
need
fulfil
order
abl
deliv
certif
also
defin
possess
effect
nation
licens
system
pharmaceut
product
also
respons
manufactur
distributor
gmp
requir
agreement
recommend
manufactur
finish
pharmaceut
product
requir
conform
effect
control
must
place
monitor
qualiti
pharmaceut
product
regist
manufactur
within
countri
includ
access
independ
qualiti
control
laboratori
nation
pharmaceut
inspector
oper
arm
nation
dra
technic
compet
experi
resourc
assess
whether
gmp
control
effect
implement
legal
power
conduct
appropri
investig
ensur
manufactur
conform
requir
exampl
examin
premis
record
take
sampl
support
administr
capac
issu
requir
certif
institut
inquiri
case
complaint
notifi
expediti
compet
author
member
state
known
import
specif
product
subsequ
associ
potenti
seriou
qualiti
defect
hazard
gmp
standard
provid
basi
certif
scheme
reli
capac
experi
expertis
certifi
author
export
countri
scheme
great
exampl
cooper
countri
import
tool
support
regulatori
system
develop
countri
enough
capac
resourc
expertis
biolog
medicin
product
vaccin
blood
blood
product
diagnost
gene
therapi
biotechnolog
product
cytokin
growth
factor
cell
tissu
product
reli
heavili
intern
standard
ensur
qualiti
equival
across
manufactur
especi
true
due
increas
global
product
distribut
biolog
medicin
past
year
work
standard
biolog
materi
establish
intern
biolog
refer
materi
well
develop
intern
guidelin
recommend
product
control
biolog
product
technolog
guidelin
provid
gener
inform
rang
topic
interest
nation
dra
manufactur
eg
guidelin
evalu
similar
biotherapeut
product
sbp
wherea
recommend
establish
technic
specif
manufactur
qualiti
control
specif
product
eg
recommend
assur
qualiti
safeti
efficaci
bcg
vaccin
also
releas
mani
document
gener
topic
regul
licens
biolog
product
countri
newli
develop
regulatori
author
good
manufactur
practic
biolog
product
specif
type
product
eg
blood
product
relat
biolog
cell
tissu
cytokin
vaccin
facilit
control
biolog
product
worldwid
basi
norm
standard
develop
assist
member
state
ensur
qualiti
safeti
biolog
medicin
relat
vitro
biolog
diagnost
test
worldwid
adopt
guidanc
document
pharmacopoeia
equival
legisl
countri
ensur
product
produc
use
countri
conform
current
intern
standard
advis
nation
dra
manufactur
control
biolog
product
regulatori
guidanc
document
also
establish
harmon
regulatori
framework
product
intern
market
accomplish
biolog
program
collabor
center
ecb
member
ecb
scientist
nation
control
agenc
academia
research
institut
public
health
bodi
pharmaceut
industri
act
individu
expert
repres
respect
organ
employ
work
base
scientif
consensu
achiev
intern
consult
collabor
committe
directli
report
execut
board
met
annual
addit
particularli
activ
specif
field
blood
product
relat
biolog
provid
technic
guidanc
qualiti
assur
tool
dra
nation
control
laboratori
manufactur
support
implement
qualiti
safeti
system
product
control
blood
product
relat
vitro
diagnost
devic
worldwid
inde
mani
countri
signific
difficulti
fulfil
respons
field
process
blood
inher
variabl
due
natur
sourc
materi
highli
special
process
requir
high
degre
expertis
develop
intern
refer
materi
guidelin
support
technic
capac
nation
dra
assur
complianc
manufactur
qualiti
safeti
measur
global
order
prevent
transmiss
diseas
via
blood
product
also
contribut
technolog
transfer
global
cooper
harmon
regul
via
blood
regul
network
brn
final
involv
develop
standard
guidelin
regard
vaccin
due
import
product
public
health
v
moreov
establish
prequalif
vaccin
regard
accept
principl
vaccin
differ
sourc
suppli
help
unit
nation
children
fund
unicef
un
agenc
purchas
vaccin
final
regulatori
pathway
initi
also
help
address
challeng
face
develop
countri
target
clinic
trial
introduct
new
vaccin
regist
countri
manufactur
object
support
establish
regulatori
mechan
licens
product
countri
yet
fulli
develop
expertis
review
technic
applic
achiev
via
workshop
technic
assist
collabor
european
medicin
agenc
ema
articl
scientif
opinion
procedur
w
us
fda
nation
dra
develop
countri
develop
countri
vaccin
regul
network
dcvrn
creat
septemb
region
initi
also
establish
mani
countri
develop
undevelop
recognit
signific
need
research
develop
medicin
specif
pediatr
use
data
pediatr
studi
use
medicin
develop
adult
lack
pediatr
data
becam
import
problem
despit
mani
initi
differ
region
countri
lack
suitabl
pediatr
medicin
pair
inconsist
regulatori
framework
pose
signific
risk
particularli
vulner
patient
popul
overal
aim
pmrn
x
promot
avail
qualiti
medicin
includ
biolog
medicin
vaccin
children
facilit
commun
collabor
regulatori
harmon
across
manufactur
licens
research
specif
among
sever
object
network
tri
provid
forum
discuss
worldwid
dra
build
awar
pediatr
medicin
regulatori
consider
facilit
collabor
discuss
work
toward
consensu
regulatori
standard
pediatr
medicin
ie
develop
intern
recommend
common
standard
clinic
trial
registr
medicin
children
base
exist
ich
ema
us
fda
guidelin
strengthen
licens
approv
system
pediatr
medicin
increas
regulatori
cooper
inform
share
train
tradit
medicin
use
mani
countri
throughout
world
mani
centuri
today
medicin
still
repres
import
part
healthcar
countri
z
exampl
countri
regul
herbal
medicin
practic
tradit
medicin
vari
greatli
countri
countri
region
region
influenc
factor
cultur
histori
person
attitud
philosophi
howev
often
necessari
tailor
legisl
deliveri
reflect
need
tradit
individu
countri
number
theme
issu
common
import
practition
train
issu
relat
safeti
need
enhanc
research
product
practic
import
label
also
use
tradit
medicin
expand
global
gain
popular
last
decad
specif
practic
continu
use
primari
healthcar
poor
develop
countri
also
use
countri
convent
medicin
predomin
nation
healthcar
system
aa
tremend
expans
use
tradit
medicin
worldwid
safeti
efficaci
well
qualiti
control
herbal
medicin
tradit
procedurebas
therapi
becom
import
concern
mani
countri
reason
increasingli
involv
develop
intern
standard
technic
guidelin
type
medicin
also
increas
commun
cooper
countri
challeng
ensur
tradit
medicin
use
properli
determin
research
evalu
tradit
medicin
carri
support
sever
wha
execut
board
resolut
develop
issu
seri
technic
guidelin
eg
guidelin
assess
herbal
medicin
research
guidelin
evalu
safeti
efficaci
herbal
medicin
guidelin
clinic
acupunctur
research
develop
draft
guidelin
methodolog
research
evalu
tradit
medicin
final
approv
april
purpos
document
promot
proper
develop
registr
use
tradit
medicin
harmon
use
certain
term
tradit
medicin
moreov
establish
global
network
call
intern
regulatori
cooper
herbal
medicin
irch
allow
commun
exchang
worldwid
regulatori
author
respons
regul
herbal
medicin
mission
program
make
qualiti
prioriti
medicin
avail
benefit
need
achiev
evalu
inspect
activ
cooper
nation
dra
partner
organ
list
prequalifi
medicin
product
updat
regularli
use
princip
un
agenc
includ
unicef
joint
unit
nation
programm
hivaid
unaid
guid
procur
decis
list
also
becom
vital
tool
agenc
organ
involv
bulk
purchas
medicin
demonstr
global
fund
fight
aid
tuberculosi
malaria
strategi
appli
unifi
standard
accept
qualiti
safeti
efficaci
build
capac
staff
nation
dra
qualiti
control
laboratori
manufactur
privat
compani
ensur
qualiti
medicin
technic
assist
train
capac
build
import
part
program
product
includ
list
relev
product
dossier
evalu
manufactur
site
inspect
whoappoint
assessor
inspector
found
compli
standard
also
recogn
evalu
product
major
dra
appli
stringent
standard
qualiti
includ
limit
us
fda
ema
health
canada
bb
howev
import
note
inclus
product
laboratori
list
impli
approv
sole
prerog
nation
author
inspect
done
team
inspector
includ
inspectorexpert
one
pharmaceut
inspect
cooper
scheme
pic
countri
repres
inspectorexpert
inspector
inspector
observ
nation
dra
countri
laboratori
locat
end
list
prequalifi
medicin
includ
product
manufactur
countri
total
qualiti
control
laboratori
prequalifi
cover
region
program
also
prequalifi
first
activ
pharmaceut
ingredi
api
project
specif
relat
harmon
pharmaceut
regul
regulatori
standard
relat
medicin
product
howev
import
note
sever
project
directli
relat
harmon
pharmaceut
bb
product
list
refer
us
fda
ema
altern
list
procedur
use
product
ad
list
reli
assess
inspect
conduct
us
fda
ema
regul
cc
also
import
facilit
implement
common
system
agreement
terminolog
establish
forum
exchang
inform
also
expertis
experi
project
ultim
facilit
overal
dialogu
cooper
converg
harmon
countri
region
moreov
gener
project
also
promot
region
subregion
collabor
harmon
regul
exampl
one
principl
gener
ecacpwho
partnership
establish
dd
strengthen
exist
collabor
arrang
eg
pool
procur
caribbean
catalys
creation
new
one
work
togeth
achiev
pool
procur
common
polici
harmon
legisl
addit
publish
mani
document
regard
pharmaceut
regul
ie
newslett
period
report
statu
special
public
blue
book
allow
diffus
exchang
inform
data
everywher
world
exampl
drug
inform
quarterli
journal
launch
provid
overview
topic
relat
medicin
develop
regul
target
wide
audienc
health
profession
policymak
commun
latest
intern
news
trend
final
specif
project
also
import
facilit
implement
intern
standard
follow
project
need
review
even
though
directli
relat
harmon
pharmaceut
regul
demonstr
key
role
global
regulatori
system
therefor
show
organ
legitimaci
coordin
global
harmon
review
drug
regulatori
system
ensur
public
health
appropri
support
nation
regulatori
capac
need
regularli
assess
area
weak
need
identifi
necessari
measur
need
taken
object
review
strengthen
nation
regulatori
control
capac
identif
specif
need
provis
appropri
technic
support
train
done
via
evalu
exist
legal
framework
regul
control
activ
order
assess
nation
regulatori
capac
set
predefin
paramet
provid
technic
input
gap
identifi
activ
import
especi
develop
countri
ensur
intern
standard
appropri
implement
nation
level
also
import
tool
clear
statu
nation
regulatori
system
evalu
appropri
need
develop
countri
therefor
necessari
support
region
intern
organ
multicountri
studi
involv
countri
also
show
assess
repres
signific
opportun
learn
strength
weak
dra
differ
strategi
use
improv
drug
regul
perform
intern
health
regul
ihr
first
adopt
health
assembl
significantli
revis
consider
growth
intern
travel
trade
emerg
reemerg
intern
diseas
threat
public
health
risk
final
adopt
wha
may
enter
forc
june
ihr
intern
legal
instrument
bind
member
state
global
rule
develop
implement
enhanc
nation
region
global
public
health
secur
aim
help
intern
commun
prevent
respond
acut
public
health
risk
potenti
cross
border
threaten
peopl
worldwid
state
purpos
scope
ihr
prevent
protect
control
provid
public
health
respons
intern
spread
diseas
way
commensur
restrict
public
health
risk
avoid
unnecessari
interfer
intern
traffic
trade
ihr
use
pandem
crisi
revis
ihr
requir
countri
strengthen
core
surveil
respons
capac
report
certain
diseas
outbreak
public
health
event
build
uniqu
experi
global
diseas
surveil
alert
respons
ihr
defin
right
oblig
countri
report
public
health
event
establish
number
procedur
must
follow
work
uphold
global
public
health
secur
mention
document
specif
develop
pharmaceut
product
import
global
tool
enhanc
cooper
countri
world
inde
even
agreement
specif
relat
harmon
pharmaceut
regul
interest
mani
reason
first
project
help
strengthen
worldwid
capac
public
health
global
cooper
gener
import
implement
harmon
global
standard
importantli
one
first
agreement
manag
public
health
truli
global
issu
propos
action
use
integr
intern
approach
network
show
integr
global
cooper
area
health
center
cooper
coordin
effort
possibl
benefici
mission
program
medicin
pharmaceut
polici
support
achiev
healthrel
mdg
assist
govern
organ
ensur
global
equit
access
safe
effect
medicin
assur
qualiti
goal
ee
target
ff
particularli
applic
harmon
activ
pharmaceut
domain
mani
activ
pharmaceut
domain
support
achiev
mdg
global
resolut
major
public
health
issu
resolv
nationalloc
level
promot
collabor
countri
region
provid
tool
standard
allow
intern
collabor
sinc
creation
inde
play
signific
role
global
harmon
pharmaceut
regul
per
mandat
respons
defin
constitut
develop
maintain
numer
intern
standard
norm
guidelin
classif
nomenclatur
rigor
intern
independ
scientif
consult
process
addit
norm
role
also
establish
import
network
facilit
global
cooper
exampl
icdra
import
player
global
regulatori
harmon
launch
mani
project
facilit
promot
harmon
cooper
countri
cooper
project
also
pioneer
year
specif
interest
essenti
medicin
gg
prequalif
program
import
step
sinc
demonstr
cooper
domain
medicin
evalu
possibl
benefici
inde
program
posit
scope
continu
extend
sinc
creation
clearli
acceler
access
essenti
medicin
worldwid
especi
low
middl
incom
countri
model
use
develop
region
global
collabor
medicin
evalu
exampl
pilot
whoeast
african
commun
eac
collabor
procedur
initi
facilit
registr
prequalifi
medicin
eac
posit
overal
aim
identifi
framework
whoeac
joint
evalu
approv
dossier
inspect
medicin
manufactur
site
ensur
assess
integr
nation
regulatori
decis
make
two
assessor
three
eac
countri
kenya
tanzania
uganda
six
assessor
jointli
assess
two
product
dossier
submit
singl
manufactur
dossier
submit
parallel
ident
content
particip
eac
countri
product
prequalifi
princip
benefit
joint
assess
product
jointli
assess
approv
whoeac
grant
immedi
access
market
countri
particip
joint
assess
also
joint
assess
contribut
harmon
regulatori
requir
region
level
pilot
whoeac
project
also
exemplifi
role
provid
technic
assist
countri
support
local
capac
build
inde
acknowledg
import
role
adequ
system
implement
sound
effect
pharmaceut
regul
support
develop
countri
address
defici
capac
problem
variou
type
train
assess
regulatori
capac
recommend
institut
develop
plan
activ
benefici
past
work
need
continu
grow
domain
problem
still
exist
inde
extent
implement
standard
vari
one
region
anoth
number
factor
explain
observ
weak
medicin
regul
differ
countri
countri
depend
also
individu
health
system
countri
may
vari
regard
registr
system
implement
comprehens
medicin
evalu
registr
system
also
encourag
region
intern
collabor
among
nation
dra
order
promot
harmon
requir
practic
strengthen
profession
compet
howev
recogn
medicin
strategi
plan
cooper
region
harmon
initi
organ
enhanc
closer
cooper
coordin
also
sought
global
initi
ich
assist
countri
cooper
region
global
initi
inde
possibl
facilit
region
structur
specif
threelevel
organ
provid
multipl
opportun
engag
countri
headquart
focu
initi
develop
global
coordin
harmon
project
region
offic
focu
technic
support
build
nation
capac
support
implement
presenc
countri
also
allow
close
relationship
ministri
health
partner
insid
outsid
govern
work
region
countri
level
critic
ensur
local
region
need
challeng
taken
consider
intern
standard
project
develop
conclud
although
improv
may
address
current
challeng
success
benefici
member
state
develop
also
develop
countri
promot
evidencebas
debat
analysi
recommend
health
work
numer
formal
inform
network
collabor
center
around
world
network
facilit
live
cooper
scientist
across
nation
allow
govern
jointli
tackl
global
health
problem
develop
promot
global
norm
standard
medicin
one
effort
wide
perceiv
area
compar
advantag
advantag
due
recognit
global
leader
coordin
author
global
public
health
achiev
mdg
renew
primari
healthcar
inde
unthink
without
norm
standard
polici
guidelin
technic
cooper
develop
promot
global
norm
standard
area
continu
focu
inde
critic
continu
work
toward
better
harmon
cooper
pharmaceut
domain
acknowledg
uniqu
neutral
independ
role
numer
success
past
nearli
univers
membership
would
appropri
extend
leadership
domain
increas
respons
coordin
medicin
would
also
fulfil
mandat
act
direct
coordin
author
intern
health
work
intern
confer
harmon
technic
requir
registr
pharmaceut
human
use
ich
program
uniqu
initi
establish
object
bring
togeth
dra
europ
japan
unit
state
expert
pharmaceut
industri
three
region
discuss
scientif
technic
aspect
pharmaceut
product
registr
drug
regulatori
system
three
region
share
fundament
concern
safeti
efficaci
qualiti
medicin
howev
mani
timeconsum
expens
experi
repeat
three
region
meet
specif
region
requir
goal
ich
increas
harmon
technic
requir
ensur
safe
effect
highqual
medicin
develop
regist
effici
costeffect
manner
order
deliv
maximum
number
patient
world
without
delay
activ
undertaken
promot
public
health
prevent
unnecessari
duplic
clinic
trial
human
minim
use
anim
test
without
compromis
safeti
effect
make
recommend
way
achiev
greater
harmon
technic
requir
product
registr
object
inde
reduc
obviat
need
duplic
test
carri
research
develop
new
product
sinc
incept
ich
evolv
global
cooper
group
gcg
respond
increasingli
global
face
drug
develop
benefit
intern
harmon
better
global
health
realiz
worldwid
ich
mission
embodi
current
term
refer
maintain
forum
construct
dialogu
regulatori
author
pharmaceut
industri
real
perceiv
differ
technic
requir
product
registr
eu
us
japan
order
ensur
time
introduct
new
medicin
product
avail
patient
contribut
protect
public
health
intern
perspect
ad
upon
revis
monitor
updat
harmon
technic
requir
lead
greater
mutual
accept
research
develop
data
avoid
diverg
futur
requir
harmon
select
topic
need
result
therapeut
advanc
develop
new
technolog
product
medicin
product
facilit
adopt
new
improv
technic
research
develop
approach
updat
replac
current
practic
permit
econom
use
human
anim
materi
resourc
without
compromis
safeti
facilit
dissemin
commun
inform
harmon
guidelin
use
encourag
implement
integr
common
standard
ich
compris
repres
six
parti
found
member
ich
repres
regulatori
bodi
researchbas
industri
eu
japan
us
sinc
ich
initi
member
ad
intern
feder
pharmaceut
manufactur
associ
ifpma
global
nonprofit
nongovernment
organ
found
repres
researchbas
pharmaceut
biotech
vaccin
sector
member
compris
lead
intern
compani
nation
region
industri
associ
cover
develop
develop
countri
ifpma
involv
subject
relat
improv
global
health
close
associ
ich
sinc
incept
ensur
contact
researchbas
industri
especi
outsid
ich
region
ifpma
provid
ich
secretariat
import
group
nonvot
member
establish
link
ich
nonich
countri
region
ich
organ
consist
ich
steer
committe
ich
coordin
ich
secretariat
ich
work
group
ich
global
cooper
group
gcg
ich
medic
dictionari
regulatori
activ
meddra
manag
board
subcommitte
ich
steer
committe
steer
committe
bodi
govern
ich
determin
polici
procedur
select
topic
harmon
monitor
progress
harmon
initi
committe
establish
first
ich
meet
april
met
least
twice
year
sinc
locat
rotat
three
region
eu
japan
us
committe
meet
new
topic
consid
adopt
report
receiv
progress
exist
topic
mainten
implement
guidelin
discuss
six
ich
parti
two
seat
ich
steer
committe
observ
nomin
nonvot
particip
attend
ich
steer
committe
meet
ifpma
also
particip
nonvot
member
meet
ich
meddra
manag
board
ich
gcg
regul
forum
also
occur
week
steer
committe
meet
ich
work
group
key
player
ich
harmon
process
respons
develop
implement
mainten
ich
guidelin
six
ich
parti
repres
everi
work
group
offici
membership
expert
work
groupimplement
work
group
ewgiwg
usual
limit
two
offici
per
parti
one
topic
leader
one
deputi
topic
leader
one
topic
leader
nomin
rapporteur
sometim
second
nomin
corapporteur
steer
committe
ich
observ
interest
parti
hh
also
nomin
one
repres
pharmacopoei
author
repres
selfmed
industri
gener
industri
invit
particip
variou
work
group
final
three
regulatori
parti
steer
committe
offici
design
regulatori
chair
new
ich
topic
formal
adopt
regulatori
chair
design
among
three
regulatori
parti
regularli
present
report
steer
committe
ensur
close
collabor
rapporteur
time
execut
ich
process
adher
concept
paper
busi
plan
includ
scope
timelin
depend
type
harmon
activ
requir
steer
committe
endors
establish
one
three
type
work
group
expert
work
group
ewg
work
group
appoint
steer
committe
new
topic
accept
harmon
object
ewg
review
differ
requir
three
region
develop
scientif
consensu
requir
reconcil
differ
charg
develop
harmon
guidelin
meet
object
defin
concept
paper
busi
plan
implement
work
group
iwg
iwg
task
develop
question
answer
q
facilit
implement
exist
guidelin
inform
ewgiwg
work
group
form
prior
offici
ich
harmon
activ
object
develop
concept
paper
busi
plan
work
group
meet
week
steer
committe
report
progress
committe
oneweek
meet
key
ich
organ
allow
regular
review
effort
achiev
adjust
necessari
ich
discuss
group
establish
discuss
specif
scientif
consider
view
eg
gene
therapi
discuss
group
facilit
exchang
inform
specif
topic
ultim
harmon
requir
coordin
fundament
smooth
run
ich
nomin
six
parti
ich
coordin
act
main
contact
ich
secretariat
ensur
ich
document
distribut
appropri
person
within
area
respons
parti
also
establish
contact
network
expert
within
organ
region
order
ensur
discuss
reflect
view
polici
cosponsor
repres
way
network
oper
differ
accord
administr
structur
parti
concern
due
structur
differ
within
eu
mhlw
ich
technic
coordin
also
design
ema
pmda
respect
support
ich
coordin
facilit
everi
action
steer
committe
member
region
mainli
appli
scientif
knowledg
role
includ
act
contact
point
expert
within
ema
pmda
ich
coordin
main
regulatori
bodi
contact
point
ich
secretariat
ich
secretariat
oper
ifpma
offic
geneva
switzerland
provid
support
ich
steer
committe
secretariat
primarili
concern
prepar
document
meet
steer
committe
well
coordin
prepar
work
group
ewg
iwg
inform
wg
discuss
group
meet
secretariat
also
provid
administr
support
gcg
meddra
manag
board
maintain
ich
websit
meddra
manag
board
appoint
ich
steer
committe
overal
respons
direct
meddra
ich
standard
dictionari
medic
terminolog
board
overse
activ
meddra
mainten
support
servic
organ
msso
serv
repositori
maintain
develop
distributor
meddra
manag
board
compos
six
ich
parti
medicin
healthcar
product
regulatori
agenc
mhra
uk
health
canada
observ
ifpma
act
nonvot
observ
manag
board
also
chair
board
state
mission
statement
adopt
parti
may
group
promot
mutual
understand
region
harmon
initi
order
facilit
harmon
process
relat
ich
guidelin
region
global
facilit
capac
drug
regulatori
author
industri
util
group
ensur
benefit
ich
harmon
extend
beyond
three
ich
region
japan
eu
us
role
gcg
chang
time
focu
collabor
nonich
region
increas
creation
today
three
phase
differenti
first
phase
inform
share
outsid
ich
first
three
year
gcg
mandat
share
inform
outsid
ich
via
prepar
brochur
present
intern
meet
etc
object
make
avail
countri
pharmaceut
compani
request
inform
ich
ich
activ
ich
guidelin
end
group
creat
seri
brochur
intend
guid
activ
answer
request
inform
respond
nonich
regul
industri
second
phase
phase
integr
collabor
rhi
novemb
ich
gcg
releas
term
refer
extend
action
act
primari
repres
ich
steer
committe
outsid
ich
region
equal
conduit
nonich
parti
ich
steer
committe
group
develop
privileg
relationship
nonich
harmon
initi
key
activ
gcg
three
advantag
share
ich
discuss
action
nonich
region
allow
possibl
harmon
implement
ich
activ
worldwid
basi
promot
organ
involv
nonich
region
expert
ich
discuss
via
expert
meet
comment
step
guidelin
train
guidelin
facilit
interregion
collabor
order
promot
transpar
better
understand
challeng
potenti
solut
harmon
issu
leverag
collect
experi
knowledg
allow
easier
standard
develop
good
harmon
practic
gcg
decid
includ
repres
nonich
region
relationship
nonich
region
becam
collabor
proactiv
focu
shift
inform
share
twoway
dialogu
set
train
work
implement
result
collabor
allow
organ
workshop
region
eg
apec
workshop
clinic
research
inspect
thailand
sadc
qualiti
guidelin
workshop
zambia
apec
qualiti
guidelin
workshop
china
exampl
gcg
also
endors
apec
life
scienc
innov
forum
lsif
sponsor
workshop
ich
qualiti
guidelin
held
septemb
seoul
south
korea
workshop
great
success
spread
ich
concept
recommend
region
attend
particip
ie
regul
policymak
academia
industri
countri
type
workshop
allow
practic
explan
ich
guidelin
also
open
discuss
exchang
anticip
challeng
opportun
associ
implement
ich
guidelin
order
better
prepar
implement
particip
individu
countri
distinct
complementari
particip
offici
rhi
repres
june
inaugur
meet
expand
gcg
occur
today
key
focu
gcg
continu
implement
ich
guidelin
via
organ
train
began
train
inde
import
mean
promot
better
understand
ich
ich
guidelin
beyond
ich
region
develop
framework
mechan
polici
procedur
select
priorit
templat
train
request
definit
role
respons
organ
coordin
train
activ
clearinghous
train
event
public
access
train
activ
time
coordin
respect
rhi
involv
ich
expert
meet
octob
yokohama
japan
ich
steer
committe
also
decid
complement
gcg
regul
forum
ich
regul
forum
latest
idea
implement
ich
increas
commun
sow
relationship
worldwid
dra
order
ensur
adopt
implement
ich
guidelin
follow
propos
us
fda
first
meet
occur
portland
oregon
us
june
good
complement
gcg
activ
includ
author
three
ich
region
observ
rhi
individu
dra
australia
brazil
china
chines
taipei
india
korea
russia
singapor
ich
regul
forum
allow
frank
discuss
share
expertis
among
dra
regard
best
practic
challeng
relat
implement
ich
guidelin
impact
regulatori
system
discuss
assist
identifi
train
capac
need
action
gcg
importantli
also
build
mutual
understand
relationship
trust
mani
vari
effort
harmon
pharmaceut
regulatori
requir
conduct
first
european
commun
develop
singl
market
pharmaceut
shown
harmon
among
differ
countri
differ
medic
culturespractic
regulatori
system
possibl
time
bilater
discuss
europ
japan
us
possibl
harmon
ongo
concret
ad
hoc
discuss
happen
world
health
organ
intern
confer
drug
regulatori
author
icdra
pari
specif
plan
agre
follow
meet
three
author
approach
ifpma
discuss
joint
regulatoryindustri
initi
intern
harmon
spirit
concept
ich
agre
differ
parti
april
ich
offici
creat
inaugur
steer
committe
meet
host
efpia
brussel
belgium
repres
regulatori
agenc
industri
associ
europ
japan
us
met
primarili
plan
intern
confer
meet
wider
implic
term
refer
ich
also
discuss
first
meet
structur
includ
steer
committe
expert
work
group
focu
ich
activ
harmon
safeti
efficaci
qualiti
guidelin
human
drug
biolog
product
agre
eleven
topic
select
discuss
first
confer
final
agre
expand
membership
steer
committe
includ
repres
efta
canada
observ
harmon
guidelin
could
use
nonich
region
addit
agreement
reach
full
name
ich
name
chosen
one
object
group
organ
intern
confer
harmon
today
name
associ
overal
initi
ich
member
offici
confirm
commit
ich
statement
follow
steer
committe
meet
parti
cosponsor
confer
repres
steer
committe
meet
tokyo
octob
reaffirm
commit
increas
intern
harmon
aim
ensur
good
qualiti
safe
effect
medicin
develop
regist
effici
costeffect
manner
activ
pursu
interest
consum
public
health
prevent
unnecessari
duplic
clinic
trial
human
minimis
use
anim
test
without
compromis
regulatori
oblig
safeti
effect
confer
provid
uniqu
opportun
regul
industri
reach
consensu
step
need
achiev
object
greater
harmon
technic
requir
set
practic
realist
target
harmonis
requir
signific
obstacl
drug
develop
regulatori
process
identifi
recognis
substanti
progress
alreadi
made
achiev
harmon
within
europ
bilater
contact
europ
japan
us
region
confer
seek
make
progress
trilater
approach
clearli
defin
prioriti
method
work
recommend
industri
regulatori
author
whilst
confer
import
step
forward
seen
end
stage
develop
process
high
level
regul
industri
confer
prepar
followup
activ
conduct
open
transpar
manner
presenc
observ
regulatori
author
welcom
mean
ensur
benefit
progress
toward
harmon
util
worldwid
confer
look
exist
issu
base
past
experi
seek
minimis
futur
diverg
new
registr
requir
consequ
technic
progress
initi
ich
statement
import
provid
spirit
ich
follow
implement
subsequ
ich
activ
sinc
creation
initi
focu
ich
promot
technic
scientif
exchang
discuss
order
find
consensu
diverg
technic
requir
registr
medicin
product
ich
region
goal
inde
remov
redund
duplic
develop
review
process
singl
data
set
could
gener
demonstr
qualiti
safeti
efficaci
new
product
first
phase
activ
ich
structur
process
defin
lot
harmon
activ
start
sever
guidelinesstandard
develop
first
harmon
discuss
direct
technic
scientif
content
relat
qualiti
safeti
efficaci
topic
format
commun
tool
develop
start
meddra
electron
standard
transmiss
regulatori
inform
estri
common
technic
document
ctd
project
first
year
grow
interest
ich
product
beyond
ich
countri
ich
recogn
earli
harmon
within
ich
region
would
suffic
howev
first
year
discuss
activ
focus
mainli
harmon
among
ich
parti
even
though
ich
agre
includ
observ
link
nonich
region
import
start
process
limit
number
commit
parti
novemb
intern
confer
harmon
san
diego
california
us
mark
end
first
year
ich
activ
confer
provid
opportun
evalu
result
identifi
futur
need
area
intern
harmon
confer
result
present
survey
util
ich
guidelin
confirm
posit
contribut
ich
improv
intern
drug
regulatori
approv
process
thu
speed
avail
new
medicin
public
statement
titl
futur
ich
releas
steer
committe
emphas
intent
focu
second
phase
ich
implement
maintain
exist
guidelin
prevent
disharmoni
encourag
scientif
dialogu
harmon
new
area
undertak
effort
toward
global
cooper
nonich
region
countri
second
phase
ich
continu
develop
implement
tripartit
guidanc
specif
technic
requir
also
increas
effort
implement
harmon
regulatori
commun
tool
ie
meddra
ctd
estri
etc
author
industri
inde
one
area
focu
second
phase
ensur
adequ
implement
mainten
guidelin
develop
sinc
today
new
guidelin
continu
develop
less
frequent
new
guidelin
cover
import
technic
subject
relat
pharmacovigil
ie
guidelin
improv
qualiti
system
ie
guidelin
new
emerg
topic
gene
therapi
also
discuss
howev
main
challeng
ich
maintain
updat
collect
guidelin
alreadi
develop
ie
follow
evolut
scienc
experi
gain
etc
second
focu
prioriti
ich
phase
continu
extens
relationship
nonich
region
began
creation
gcg
subcommitte
ich
steer
committe
sinc
time
ich
develop
relationship
nonich
region
tri
facilit
implement
standard
guidelin
broader
territori
via
collabor
train
even
relationship
exist
gcg
key
geograph
extens
role
increas
time
move
inform
share
via
prepar
brochur
present
intern
meet
etc
collabor
proactiv
dialogu
via
incorpor
nonich
region
countri
group
evolut
ich
structur
gcg
term
refer
expect
continu
promot
greater
involv
global
regul
first
activ
ich
organ
confer
one
year
creation
order
exchang
point
view
discuss
diverg
among
differ
parti
involv
sinc
five
addit
confer
organ
tabl
regular
wellattend
confer
help
commun
result
harmon
activ
largest
possibl
audienc
design
open
forum
breakout
session
gather
addit
public
comment
provid
updat
ich
scientif
activ
six
confer
well
attend
eg
particip
repres
industri
author
countri
particip
repres
industri
author
countri
earli
ich
confer
import
increas
visibl
process
harmon
ensur
process
carri
transpar
manner
focus
primarili
final
complet
ctd
guidelin
last
ich
confer
organ
focus
area
new
technolog
global
cooper
regulatori
harmon
initi
outsid
ich
region
three
satellit
session
relat
partnership
harmon
gene
therapi
meddra
user
group
also
confirm
prioriti
meet
confer
opportun
new
challeng
regulatori
harmon
discuss
practic
implement
ctd
also
review
addit
intern
confer
schedul
plan
taken
place
europ
cancel
instead
may
ich
steer
committe
decid
replac
larg
intern
ich
confer
smaller
frequent
region
public
meet
time
ich
steer
committe
meet
region
order
benefit
presenc
steer
committe
member
ich
expert
ich
process
well
recogn
smaller
region
meet
allow
better
focu
region
issu
challeng
also
provid
everyon
opportun
meet
regul
industri
expert
involv
ich
activ
regularli
inform
recent
develop
exchang
inform
differ
hot
topic
follow
decis
region
meet
organ
europ
first
eu
region
public
meet
took
place
brussel
belgium
novemb
north
america
first
region
public
meet
took
place
washington
dc
us
octob
asia
first
region
public
meet
took
place
tokyo
japan
novemb
ich
process
first
drawn
steer
committe
meet
washington
dc
march
amend
tokyo
japan
septemb
sinc
ich
procedur
revis
sever
time
moreov
new
principl
govern
agre
ich
steer
committe
meet
june
revis
role
regul
suggest
new
harmon
initi
may
aris
number
forum
ich
region
guidelin
workshop
region
intern
confer
workshop
symposia
deal
research
develop
r
regulatori
affair
recogn
associ
test
registr
medicin
etc
suggest
new
harmon
action
develop
new
guidelin
modif
exist
guidelin
three
sequenti
step
submiss
concept
paper
ich
steer
committe
ich
parti
observ
endors
steer
committe
establish
work
group
concept
paper
start
ich
harmon
activ
document
provid
short
summari
propos
maximum
two
page
provid
inform
indic
type
harmon
action
propos
exampl
new
harmon
tripartit
guidelin
recommend
revis
exist
guidelin
indic
categori
procedur
statement
perceiv
problem
brief
descript
indic
magnitud
problem
current
caus
lack
harmon
anticip
harmon
action
taken
issu
resolv
summari
main
technic
scientif
issu
requir
harmon
background
propos
relev
inform
eg
origin
propos
refer
public
discuss
forum
type
expert
work
group
recommend
whether
ewg
sixparti
group
topic
relat
r
new
drug
substanc
product
extend
ewg
eg
gmp
necessari
document
report
may
ad
concept
paper
depend
categori
harmon
activ
busi
plan
may
also
requir
busi
plan
outlin
cost
benefit
harmon
topic
propos
concept
paper
ich
steer
committe
endors
concept
paper
appropri
busi
plan
harmon
activ
initi
preliminari
determin
made
whether
topic
suffici
interest
parti
accommod
within
ich
work
schedul
steer
committe
take
follow
point
account
discuss
concept
paper
object
expect
outcom
harmon
action
categori
ich
process
composit
ewg
iwg
appoint
discuss
technic
issu
set
timet
action
plan
ewgiwg
concept
paper
may
need
revis
updat
reflect
steer
committe
discuss
conclus
steer
committe
agre
topic
may
warrant
consider
busi
plan
need
develop
inform
ewgiwg
form
group
work
email
teleconfer
rare
facetofac
meet
first
task
inform
ewgiwg
final
concept
paper
develop
busi
plan
revis
concept
paper
busi
plan
sent
prior
present
next
steer
committe
meet
meet
yokohama
japan
june
ich
steer
committe
agre
final
version
concept
paper
busi
plan
avail
ich
websit
public
inform
depend
type
harmon
activ
propos
ich
steer
committe
endors
establish
either
ewg
iwg
ich
harmon
activ
fall
four
categori
present
tabl
four
categori
cover
creation
develop
stepwis
progress
implement
revis
mainten
guidelin
procedur
place
withdraw
exist
ich
guidelin
happen
rare
guidelin
stabil
data
packag
registr
applic
climat
zone
iii
iv
withdrawn
explanatori
note
releas
follow
endors
withdraw
ich
steer
committe
meet
yokohama
japan
june
withdraw
notif
also
releas
ema
mhlw
us
fda
formal
ich
procedur
formal
ich
procedur
follow
stepwis
approach
consist
five
step
decis
point
step
step
enabl
steer
committe
monitor
progress
harmon
topic
procedur
follow
harmon
new
ich
topic
streamlin
procedur
also
avail
necessari
procedur
initi
endors
steer
committe
concept
paper
busi
plan
ewg
membership
specifi
concept
paper
subsequ
establish
ewg
work
develop
draft
guidelin
bring
variou
step
procedur
culmin
step
implement
ich
region
harmon
tripartit
guidelin
step
consensu
build
steer
committe
adopt
concept
paper
new
topic
process
consensu
build
begin
ewg
prepar
initi
consensu
technic
document
base
object
set
concept
paper
consult
expert
design
ewg
initi
draft
success
revis
circul
comment
within
ewg
provid
fix
deadlin
receipt
comment
work
conduct
via
email
teleconfer
web
confer
endors
steer
committe
ewg
also
meet
facetofac
biannual
steer
committe
meet
interim
report
progress
draft
made
committe
regular
basi
consensu
reach
among
ewg
member
ewg
sign
step
expert
signoff
sheet
expert
document
ewg
signatur
submit
steer
committe
request
adopt
step
ich
process
step
reach
steer
committe
agre
base
report
ewg
suffici
scientif
consensu
technic
issu
technic
document
recommend
proceed
next
stage
regulatori
consultationthi
technic
document
made
public
ich
websit
basi
technic
document
three
ich
regulatori
parti
take
action
deem
necessari
develop
draft
guidelin
consensu
text
approv
three
regulatori
ich
parti
sign
three
regulatori
ich
parti
step
draft
guidelin
step
regulatori
consult
discuss
region
regulatori
consult
stage
guidelin
embodi
scientif
consensu
leav
ich
process
becom
subject
normal
widerang
regulatori
consult
three
region
eu
publish
draft
chmp
guidelin
japan
translat
issu
mhlw
intern
extern
consult
us
publish
draft
guidanc
feder
regist
step
guidelin
releas
consult
also
avail
ich
websit
dra
industri
associ
nonich
region
may
also
comment
draft
consult
document
provid
comment
ich
secretariat
obtain
regulatori
consult
result
ewg
organ
discuss
consensu
build
resum
procedur
describ
step
use
address
consult
result
step
final
document
draft
document
gener
result
step
call
step
draft
guidelin
step
document
regulatori
ewg
signatur
submit
steer
committe
request
adopt
step
ich
process
step
reach
steer
committe
agre
basi
report
regulatori
chair
regulatori
rapporteur
ewg
suffici
scientif
consensu
draft
guidelin
endors
base
signatur
three
regulatori
parti
ich
affirm
guidelin
recommend
adopt
regulatori
bodi
three
region
event
one
parti
repres
industri
strong
object
adopt
guidelin
ground
revis
draft
depart
substanti
origin
consensu
introduc
new
issu
regulatori
parti
may
agre
revis
document
submit
consult
case
ewg
discuss
may
resum
step
final
document
sign
steer
committe
signatori
regulatori
parti
ich
ich
harmon
tripartit
guidelin
step
ich
process
step
implement
reach
step
harmon
tripartit
guidelin
move
immedi
regulatori
implement
final
step
process
step
carri
accord
nation
region
procedur
appli
region
regulatori
guidelin
requir
eu
japan
us
inform
regulatori
action
taken
implement
date
report
back
steer
committe
publish
ich
secretariat
ich
websit
eu
ich
guidelin
submit
chmp
endors
timefram
implement
establish
usual
six
month
ich
guidelin
avail
ema
websit
japan
ich
text
translat
japanes
subsequ
pharmaceut
medic
safeti
bureau
notif
promulg
guidelin
written
japanes
issu
implement
date
notif
guidelin
japanes
also
english
attach
ich
text
avail
pmda
websit
us
us
fda
publish
notic
full
text
guidanc
feder
regist
step
guidanc
avail
use
date
publish
feder
regist
avail
us
fda
websit
q
procedur
q
procedur
follow
addit
guidanc
consid
necessari
aid
interpret
certain
ich
harmon
tripartit
guidelin
ensur
smooth
consist
implement
ich
region
beyond
q
procedur
initi
endors
steer
committe
concept
paper
case
major
implement
activ
steer
committe
may
also
consid
need
busi
plan
iwg
membership
specifi
concept
paper
subsequ
establish
develop
adopt
q
follow
establish
process
question
receiv
stakehold
collect
analyz
reformul
ultim
use
model
question
standard
answer
develop
post
ich
websit
incom
question
answer
individu
rather
serv
highlight
area
need
addit
clarif
use
develop
model
question
answer
q
document
base
level
guidanc
given
answer
iwg
assess
whether
q
document
step
document
publish
comment
step
document
publish
final
document
step
base
answer
provid
set
forth
substanti
new
interpret
guidelin
document
step
base
answer
provid
set
forth
exist
practic
minor
chang
interpret
polici
guidelin
document
follow
normal
path
step
document
per
formal
ich
procedur
revis
procedur
appli
exist
adopt
guidelin
need
revis
modifi
almost
ident
formal
ich
procedur
ie
five
ich
step
differ
final
outcom
revis
version
exist
guidelin
rather
new
guidelin
revis
guidelin
design
letter
usual
denomin
guidelin
guidelin
revis
document
name
new
revis
mainten
procedur
use
add
standard
exist
ing
guidelin
andor
recommend
provid
updat
base
new
inform
procedur
use
amend
addendum
guidelin
detect
toxic
reproduct
medicin
product
toxic
male
fertil
guidelin
mainten
ich
guidelin
nonclin
safeti
studi
conduct
human
clinic
trial
pharmaceut
novemb
current
applic
chang
guidelin
residu
solvent
annex
recommend
case
procedur
use
new
inform
ad
scientifictechn
content
outofd
longer
valid
guidelin
mainten
procedur
use
revis
permit
daili
exposur
pde
new
toxicolog
data
solvent
becom
avail
sinc
creation
pursuant
main
goal
ich
releas
number
guidanc
harmon
technic
requir
registr
medicin
product
technic
topic
relev
ewg
discuss
import
question
whether
scientif
justif
differ
region
requir
whether
would
possibl
develop
mutual
accept
guidanc
object
scientif
discuss
reach
scientif
consensu
whatev
time
effort
requir
compromis
would
unaccept
decreas
certain
region
requir
without
scientif
justif
basi
ich
also
work
broader
project
eg
meddra
ctd
critic
intern
exchang
inform
ultim
goal
ich
activ
remov
redund
duplic
develop
review
process
singl
set
data
could
gener
demonstr
qualiti
safeti
efficaci
new
medicin
product
steer
committe
given
prioriti
harmon
technic
content
section
report
data
first
ich
guidelin
deal
harmon
format
report
data
content
format
clinic
studi
report
guidelin
describ
singl
format
report
core
clinic
studi
make
clinic
section
registr
dossier
goal
develop
harmon
format
led
creation
ich
guidelin
common
technic
document
ctd
describ
first
ich
steer
committe
meet
decid
topic
select
harmon
would
divid
safeti
qualiti
efficaci
order
reflect
three
criteria
basi
approv
author
new
medicin
product
sinc
ich
creat
fourth
categori
call
multidisciplinari
cover
crosscut
topic
fit
uniqu
one
categori
anoth
therefor
today
ich
topic
divid
four
categori
qualiti
safeti
efficaci
multidisciplinari
ich
topic
code
assign
accord
categori
summari
harmon
topic
provid
updat
list
guidanc
includ
statu
also
download
ich
websit
also
us
fda
pmda
ema
websit
guidelin
categori
provid
harmon
inform
relat
develop
manufactur
test
medicin
specif
cover
stabil
test
valid
analyt
procedur
impur
test
pharmacopoei
text
harmon
interchang
qualiti
inform
biotechnolog
product
specif
test
procedur
accept
criteria
gmp
pharmaceut
develop
qualiti
risk
manag
pharmaceut
qualiti
system
addit
ich
steer
committe
endors
april
develop
new
guidanc
relat
develop
manufactur
drug
substanc
chemic
entiti
biotechnologicalbiolog
entiti
guidelin
categori
provid
harmon
inform
relat
vitro
vivo
preclin
studi
cover
preclin
studi
perform
develop
new
pharmaceut
product
carcinogen
studi
genotox
studi
toxicokinet
pharmacokinet
studi
toxic
studi
reproduct
toxicolog
studi
pharmacolog
studi
immunotoxicolog
studi
guidelin
specif
address
preclin
safeti
evalu
biotechnolog
product
ich
steer
committe
also
endors
may
develop
new
guidelin
provid
preclin
guidelin
oncolog
therapeut
develop
final
photosafeti
evalu
pharmaceut
endors
new
topic
ich
steer
committe
june
guidelin
categori
provid
harmon
inform
pertain
clinic
evalu
pharmaceut
product
guidelin
relat
assess
manag
safeti
data
guidelin
guidelin
cover
efficaci
guidelin
appli
therapeut
class
drug
ich
focus
discuss
gener
ie
nontherapeut
classspecif
guidanc
howev
therapeut
class
individu
drug
evalu
guidelin
among
three
region
differ
guidelin
result
obstacl
mutual
use
accept
clinic
data
steer
committe
meet
septemb
agre
adopt
new
area
work
ich
first
guidelin
undertaken
pilot
studi
assess
feasibl
extend
work
area
agre
develop
first
therapeut
classspecif
guidelin
antihypertens
drug
guidelin
clinic
evalu
specif
therapeut
categori
develop
sinc
guidelin
categori
creat
includ
guidelin
cover
topic
fit
uniqu
one
three
categori
addit
technic
guidelin
describ
previou
section
ich
set
ewg
harmon
medic
terminolog
meddra
drug
dictionari
format
organ
data
regulatori
applic
ctd
order
eas
exchang
inform
creation
electron
standard
estri
also
critic
quick
exchang
common
agreedupon
data
novemb
ich
steer
committe
endors
establish
ewg
electron
common
technic
document
ectd
assign
topic
code
even
though
work
relat
ectd
previous
undertaken
ewg
harmon
initi
critic
achiev
requir
lot
effort
respect
work
group
import
activ
greatli
contribut
intern
harmon
pharmaceut
regul
harmon
facilit
exchang
inform
regul
pharmaceut
compani
due
import
initi
detail
specif
subsect
guidelin
cover
specif
topic
relat
safeti
efficaci
issu
reason
classifi
multidisciplinari
topic
joint
safeti
efficaci
guidelin
provid
principl
nonclin
strategi
ie
scope
time
durat
nonclin
safeti
studi
relat
conduct
clinic
trial
help
reduc
differ
ich
region
also
provid
recommend
reduc
anim
use
research
develop
eg
inclus
vivo
evalu
addit
gener
toxic
studi
instead
perform
separ
studi
guidelin
definit
align
overal
ich
object
purpos
facilit
time
conduct
clinic
trial
reduc
use
anim
accord
reducerefinereplac
principl
reduc
use
drug
develop
resourc
clearli
promot
safe
ethic
develop
avail
new
pharmaceut
quickli
possibl
final
ich
steer
committe
endors
june
assess
control
dna
reactiv
mutagen
impur
pharmaceut
limit
potenti
carcinogen
risk
new
topic
meddra
develop
ich
ewg
earli
design
support
classif
retriev
present
commun
medic
inform
intern
throughout
product
regulatori
cycl
prior
meddra
differ
medic
dictionari
also
differ
version
dictionari
use
world
health
organ
advers
reaction
terminolog
whoart
code
symbol
thesauru
advers
reaction
term
costart
us
fda
japanes
advers
reaction
terminolog
jart
mhlw
time
sever
worldwid
author
look
costand
timeeffici
way
process
suspect
advers
reaction
report
eg
unit
kingdom
medicin
control
agenc
uk
mca
develop
new
system
code
call
adroit
becam
obviou
activ
fall
auspic
ich
goal
ich
develop
meddra
intern
recogn
standard
medic
rigor
wellmaintain
terminolog
facilit
commun
inde
one
import
ich
project
ensur
global
exchang
clinic
inform
intern
medic
terminolog
particularli
import
electron
transmiss
advers
event
report
preand
postmarket
area
well
code
clinic
trial
data
meddra
dictionari
multiaxi
terminolog
provid
set
term
consist
categor
medic
inform
includ
terminolog
symptom
sign
diseas
diagnos
therapeut
indic
organ
system
organ
class
soc
divid
highlevel
group
term
hlgt
highlevel
term
hlt
prefer
term
pt
final
lowerlevel
term
llt
meddra
dictionari
translat
mani
languag
terminolog
contain
specif
guidelin
use
ich
work
group
charg
develop
two
guid
meddra
term
select
point
consid
document
creat
achiev
consist
way
user
assign
particular
term
particular
symptom
sign
diseas
etc
meddra
data
retriev
present
point
consid
document
provid
guidanc
retriev
sort
present
data
understand
reproduc
way
benefit
drug
develop
pharmacovigil
risk
manag
two
document
provid
best
practic
approach
use
meddra
revis
new
meddra
version
releas
addit
meddra
dictionari
includ
standard
meddra
queri
smq
develop
collabor
ciom
facilit
retriev
meddracod
data
first
step
investig
drug
safeti
issu
pharmacovigil
clinic
develop
smq
group
term
one
meddra
system
organ
class
soc
relat
defin
medic
condit
area
interest
intend
aid
case
identif
terminolog
requir
constant
updat
mainten
agre
mainten
support
servic
organ
msso
would
need
carri
task
distribut
terminolog
licens
user
industri
regulatori
agenc
msso
contract
ich
technic
financi
oversight
meddra
manag
board
task
maintain
develop
distribut
meddra
sinc
releas
version
meddra
becom
accept
intern
standard
worldwid
regulatori
activ
meddra
yet
mandatori
us
singl
global
standard
medic
terminolog
meddra
speed
exchang
clinic
inform
facilit
research
safeti
monitor
make
regulatori
approv
process
effici
respons
differ
translat
meddra
releas
marchapril
meddra
also
implement
vigibas
provid
global
repositori
meddracod
safeti
data
use
substanti
tool
pharmacovigil
meet
octob
yokohama
japan
meddra
manag
board
announc
fee
reduct
lower
revenu
subscrib
reduct
keep
meddra
manag
board
goal
facilit
use
meddra
user
sinc
januari
access
meddra
free
academ
organ
hospit
healthcar
provid
user
involv
noncommerci
activ
object
electron
standard
transmiss
regulatori
inform
estri
project
facilit
intern
electron
commun
end
ich
multidisciplinari
expert
work
group
call
ewg
establish
ich
meet
brussel
belgium
ewg
evalu
recommend
estri
meet
requir
pharmaceut
compani
dra
three
ich
region
sinc
ewg
develop
technolog
framework
recommend
solut
intern
inform
exchang
obtain
gather
requir
assign
specif
task
evalu
intern
standard
product
recommend
function
architectur
project
includ
verif
procedur
consist
accur
inform
transfer
evalu
encrypt
technolog
key
certif
procedur
transfer
regulatori
inform
work
group
undertaken
test
project
defin
logic
electron
commun
standard
order
ensur
integr
inform
data
exchang
pharmaceut
compani
author
allow
flexibl
chang
activ
ewg
result
recommend
follow
formal
ich
step
process
agre
upon
ewg
sign
parti
ewg
endors
ich
steer
committe
differ
meet
recommend
modifi
improv
time
provid
variou
open
intern
standard
allow
intern
transmiss
inform
regardless
technic
infrastructur
facilit
use
recommend
ewg
also
develop
glossari
technic
term
today
six
recommend
avail
cover
standard
gener
aspect
also
choic
file
format
inform
transfer
describ
tabl
recommend
also
prepar
choic
physic
media
ie
floppi
disk
cdr
dvdram
physic
media
relev
anymor
recommend
retir
june
addit
recommend
ewg
also
develop
sever
specif
regard
electron
exchang
inform
first
specif
develop
ewg
relat
electron
transfer
individu
case
safeti
report
icsr
present
ich
guidelin
data
element
transmiss
individu
case
safeti
report
follow
develop
guidelin
becam
necessari
work
electron
specif
guid
pharmaceut
compani
provid
inform
requir
guidelin
inde
success
electron
transmiss
icsr
reli
definit
common
data
element
provid
guidelin
also
standard
electron
transmiss
procedur
first
version
specif
approv
steer
committe
step
sinc
specif
modifi
implement
use
align
evolut
ich
meddra
guidelin
result
activ
advers
event
ae
data
extract
popul
electron
transmit
manner
specifi
ich
icsr
messag
safeti
surveil
databas
even
requir
lot
work
implement
electron
report
icsr
base
ich
standard
progress
rapidli
across
ich
region
thank
standard
pharmaceut
compani
exchang
case
report
electron
via
gateway
dra
us
fda
ema
second
specif
develop
ewg
electron
common
technic
document
ectd
creat
electron
messag
common
technic
document
ctd
detail
ich
guidelin
specif
sinc
maintain
ectd
iwg
ectd
specif
base
xml
extens
markup
languag
technolog
allow
electron
submiss
ctd
applic
regul
take
consider
facilit
creation
review
lifecycl
manag
archiv
electron
submiss
tabl
content
consist
harmon
ctd
ectd
also
provid
harmon
technic
solut
implement
ctd
electron
ectd
specif
applic
modul
initi
registr
applic
submiss
inform
throughout
lifecycl
product
variat
amend
backbon
develop
handl
region
common
part
submiss
implement
ectd
begun
across
ich
partner
observ
region
exampl
sinc
januari
electron
submiss
us
fda
requir
ectd
format
ewg
publish
first
version
studi
tag
file
stf
specif
supplement
ectd
specif
sinc
modifi
sever
time
studi
includ
modul
ectd
submiss
stf
includ
inform
allow
identif
file
associ
specif
studi
addit
inform
ectd
backbon
file
alreadi
includ
mani
item
contain
enough
inform
subject
matter
sever
document
eg
studi
report
document
support
effici
process
review
applic
common
technic
document
ctd
one
major
wellknown
achiev
ich
like
big
harmon
project
ich
requir
much
effort
provid
harmon
structur
format
regulatori
applic
object
reduc
time
resourc
need
compil
applic
registr
medicin
differ
ich
region
addit
new
common
format
allow
dra
consist
review
help
perform
analysi
across
applic
exchang
inform
among
develop
ctd
region
requir
organ
technic
report
submiss
prepar
summari
tabl
japan
applic
prepar
gaiyo
organ
present
summari
technic
inform
europ
expert
report
tabul
summari
requir
written
summari
recommend
us
fda
specif
guidelin
regard
format
content
new
drug
applic
nda
ich
industri
repres
propos
assembl
inform
gener
develop
product
order
propos
follow
industri
survey
may
assess
time
resourc
need
convert
eu
market
author
applic
maa
us
nda
revers
survey
show
averag
three
four
month
peopl
requir
convers
one
format
accept
three
region
ctd
avoid
need
gener
compil
differ
region
version
registr
dossier
section
ctd
adopt
ich
topic
steer
committe
meet
took
place
meet
juli
ctd
specif
reach
step
ich
process
steer
committe
meet
juli
public
consult
step
achiev
confer
san
diego
california
novemb
septemb
washington
dc
meet
number
section
header
edit
consist
use
ectd
ctd
consist
five
modul
modul
region
specif
modul
intend
common
region
modul
includ
administr
inform
ie
applic
form
propos
prescrib
inform
modul
summar
data
includ
modul
organ
seven
subsect
ctd
ctd
defin
gener
ich
guidelin
three
specif
technic
guidelin
cover
qualiti
safeti
efficaci
part
ctd
respect
q
document
associ
four
guidelin
facilit
implement
ctd
ich
parti
agre
implement
harmon
format
three
region
juli
inde
use
today
three
ich
region
mandatori
eu
japan
highli
recommend
us
current
legisl
allow
us
fda
make
mandatori
moreov
format
also
use
countri
eg
australia
canada
turkey
etc
deriv
ctd
develop
region
eg
actd
develop
asean
countri
harmon
format
inde
one
great
success
ich
process
realiz
ctd
took
mani
year
common
format
regulatori
submiss
across
three
ich
region
europ
japan
us
beyond
facilit
pharmaceut
compani
make
simultan
file
ich
region
elimin
extens
work
previous
requir
convert
one
format
anoth
howev
ctd
global
dossier
remain
harmon
format
instead
harmon
content
initi
misunderstand
certainli
creat
desir
mani
peopl
acceler
harmon
technic
requir
led
lot
critic
new
format
howev
ctd
truli
global
ident
dossier
includ
informationdatalevel
detail
technic
requir
fulli
harmon
moreov
submiss
content
may
also
differ
sever
reason
differ
individu
regul
legal
statu
requir
differ
manufactur
situat
three
region
inde
although
ctd
provid
common
format
regulatori
applic
actual
content
must
still
meet
local
regul
law
statut
result
despit
present
order
requir
content
modul
may
vari
region
exampl
integr
summari
efficacyintegr
summari
safeti
ise
iss
request
us
fda
implement
ctd
still
need
integr
summari
uniqu
us
tabl
content
ctd
specif
includ
specif
us
fda
guidanc
releas
june
help
pharmaceut
compani
decid
place
usspecif
iseiss
document
within
structur
ctd
conclud
even
ctd
agreedupon
common
format
modular
present
summari
report
data
provid
obviou
advantag
ctd
allow
compani
dra
harmon
term
way
commun
languag
certainli
help
harmon
content
ultim
harmon
technic
requir
inde
regulatori
review
commun
applic
facilit
standard
document
common
element
addit
exchang
regulatori
inform
dra
simplifi
increas
commun
author
author
pharmaceut
compani
obvious
facilit
expertis
opinion
share
relat
safeti
efficaci
qualiti
develop
product
time
manner
ultim
provid
benefit
patient
provid
qualiti
medicin
quickli
market
like
meddra
object
project
inde
support
aspect
preand
postapprov
pharmacovigil
activ
well
commun
regulatori
inform
exampl
meddra
harmon
drug
dictionari
critic
transmiss
icsr
present
ich
guidelin
data
element
transmiss
individu
case
safeti
report
transmiss
structur
data
especi
electron
impli
use
control
vocabulari
ich
initi
harmon
standard
document
inform
data
medicin
product
regul
differ
region
establish
standard
differ
data
format
content
languag
appli
standard
terminolog
eg
terminolog
use
substanc
rout
administr
pharmaceut
form
etc
drug
dictionari
modifi
version
product
sometim
use
lack
intern
harmon
standard
relat
core
set
medicin
product
inform
medicin
product
terminolog
made
scientif
evalu
comparison
exchang
drug
data
especi
area
pharmacovigil
difficult
activ
guidelin
began
follow
exampl
success
meddra
ich
steer
committe
meet
novemb
agre
launch
new
harmon
initi
develop
new
tripartit
guidelin
defin
data
element
standard
drug
dictionari
ich
meet
tokyo
japan
februari
present
white
paper
regard
concept
global
drugcod
dictionari
meet
steer
committe
agre
conven
inform
discuss
group
brussel
belgium
ich
meet
juli
allow
discuss
propos
inform
work
group
establish
develop
concept
paper
prepar
busi
plan
guidelin
releas
consult
step
ich
process
may
along
control
vocabulari
list
rout
administr
unit
measur
guidelin
subsequ
submit
iso
develop
process
step
guidelin
updat
base
upon
feedback
receiv
consult
well
addit
consider
follow
submiss
iso
develop
intern
standard
key
part
updat
guidelin
incorpor
ich
implement
guid
identif
medicin
product
messag
specif
current
undergo
develop
iso
standard
achiev
far
two
decad
ich
process
achiev
much
success
benefit
dra
pharmaceut
industri
importantli
harmon
pursu
interest
patient
public
health
prevent
unnecessari
duplic
clinic
trial
human
minim
use
anim
test
without
compromis
regulatori
oblig
safeti
effect
achiev
object
goal
ich
promot
intern
harmon
bring
togeth
repres
eu
japan
us
discuss
establish
common
guidelin
standard
ich
process
consider
harmon
achiev
technic
requir
registr
pharmaceut
human
use
matur
harmon
initi
sinc
creation
harmon
guidelin
develop
area
qualiti
safeti
efficaci
order
elimin
duplic
develop
registr
process
moreov
common
harmon
tool
regulatori
commun
meddra
ctd
estri
also
made
avail
repres
extraordinari
contribut
global
harmon
pharmaceut
regul
guidelin
alreadi
form
solid
basi
harmon
applic
technic
requir
registr
process
technic
output
ich
process
posit
import
uniqu
way
ich
oper
also
note
inde
addit
practic
harmon
specif
technic
item
one
major
outcom
ich
creat
forum
allow
expert
differ
countri
differ
background
commun
exchang
discuss
share
experi
inform
structur
manner
cours
essenti
first
step
harmon
final
anoth
import
achiev
ich
well
recogn
worldwid
basi
ich
guidelin
adopt
follow
outsid
ich
region
eg
switzerland
canada
australia
also
mani
rhi
although
ich
initi
focu
develop
guidelin
use
ich
region
increas
global
drastic
modifi
intern
cooper
environ
respons
grow
interest
beyond
ich
region
use
ich
guidelin
ich
steer
committe
took
first
step
march
establish
ich
gcg
novemb
new
term
refer
rule
endors
gcg
aim
establish
partnership
beyond
ich
region
promot
better
understand
ich
guidelin
global
sinc
rhi
across
globe
also
repres
dra
depart
health
doh
either
major
sourc
api
clinic
trial
data
invit
particip
gcg
meet
listen
technic
topic
level
steer
committe
biannual
ich
meet
addit
per
decis
ich
steer
committe
novemb
invit
rhi
drasdoh
may
also
nomin
technic
expert
activ
member
ich
ewg
implement
ich
recommend
standard
outsid
three
ich
region
inde
import
allow
industri
better
develop
medicin
product
global
market
consequ
expans
nonich
region
train
capac
build
becom
key
focu
ich
gcg
gcg
implement
strategi
address
train
capac
need
help
ensur
effect
use
resourc
opportun
realiz
desir
outcom
past
year
gcg
respond
numer
request
train
provid
ich
expertis
develop
train
program
deliveri
train
today
gcg
ich
steer
committe
continu
implement
new
tool
promot
better
understand
use
ich
guidelin
recommend
one
driver
success
fact
harmon
process
base
scientif
consensu
develop
industri
dra
expert
ich
industri
regul
never
sat
tabl
intern
forum
discuss
scienc
drug
develop
order
develop
best
practic
across
differ
region
joint
effort
allow
involv
best
expert
author
pharmaceut
industri
specif
technic
discuss
also
ensur
discuss
take
account
region
legisl
practic
impact
develop
pharmaceut
product
inclus
industri
regul
increas
commit
common
goal
ie
implement
ich
tripartit
harmon
guidelin
recommend
obvious
key
factor
success
ich
result
survey
impact
ich
present
confer
osaka
japan
show
high
degre
satisfact
dra
industri
complet
ich
guidelin
continu
support
side
ich
activ
second
driver
ich
success
link
welldefin
structur
process
begin
year
ich
steer
committe
organ
structur
around
work
group
includ
worldrecogn
expert
decis
critic
allow
ich
robust
scientif
technic
recommend
time
accept
implement
without
fundament
critic
steer
committe
cours
also
key
govern
bodi
give
direct
select
topic
harmon
ensur
complet
project
time
manner
alway
easi
one
goal
consensu
addit
structur
steer
committe
also
abl
defin
process
support
incred
harmon
task
structur
organ
way
support
differ
player
ich
secretariat
coordin
inde
stepwis
approach
put
place
develop
guidelin
defin
fivestep
process
decis
point
step
step
import
approach
allow
creation
comprehens
draft
small
number
expert
best
environ
facilit
focus
discuss
develop
consensu
public
review
implement
promot
transpar
avoid
surpris
postapprov
issu
creation
concept
paper
busi
plan
steer
committe
put
place
later
stage
also
fundament
defin
clear
goal
help
monitor
progress
toward
predefin
goal
final
review
progress
regular
meet
also
ensur
commit
followup
therefor
serious
initi
final
extens
ich
beyond
ich
region
possibl
steer
committe
understood
earli
activ
could
restrict
ich
region
increas
global
drug
develop
manufactur
inde
research
manufactur
new
product
confin
three
ich
region
longer
clinic
trial
carri
throughout
world
mani
nonich
countri
involv
develop
manufactur
pharmaceut
product
increas
transpar
promot
collabor
outsid
ich
region
steer
committe
accept
observ
eg
canada
work
intern
organ
efta
involv
regionscountri
process
via
ich
gcg
evolv
time
action
allow
ich
work
expand
regionscountri
world
harmon
benefit
avail
worldwid
collabor
nonich
region
today
one
prioriti
ich
order
increas
commit
region
facilit
worldwid
implement
ich
recommend
limit
challeng
futur
mention
ich
incred
contributor
intern
harmon
pharmaceut
regul
ich
success
achiev
harmon
initi
technic
guidelin
format
content
registr
applic
posit
impact
global
develop
new
drug
parti
agre
need
maintain
harmon
interest
patient
public
health
process
network
place
seem
inde
obviou
ich
need
continu
activ
one
major
player
intern
harmon
pharmaceut
regul
harmon
activ
continu
focus
manner
howev
evolv
intern
environ
aspect
initi
need
review
new
approach
may
need
inde
aspect
initi
may
optim
order
better
handl
new
futur
challeng
first
challeng
ich
steer
committe
alreadi
acknowledg
implement
mainten
alreadi
develop
guidelin
current
magnitud
success
harmon
action
need
remain
current
rapidli
chang
environ
call
focus
effort
implement
monitor
ich
commit
develop
iwg
task
forc
manag
challeng
key
success
focu
implement
mainten
howev
impact
work
new
harmon
topic
still
need
discuss
new
topic
harmon
need
rigor
assess
need
ie
scientif
meritemerg
scienc
feasibl
ie
expect
outcom
timelin
resourc
requir
anoth
major
challeng
ich
confirm
worldwid
expans
continu
develop
strengthen
collabor
partnership
outsid
ich
region
order
better
integr
region
ich
process
time
ich
establish
agre
scope
would
confin
registr
new
drug
medicin
western
europ
japan
us
vast
major
new
drug
develop
manufactur
three
region
howev
sinc
strong
involv
part
world
canada
australia
key
market
pharmaceut
often
involv
global
clinic
studi
recent
emerg
countri
recogn
area
includ
pharmaceut
industri
alreadi
recogn
ich
steer
committe
success
ich
ich
region
relev
longer
modif
landscap
oblig
ich
review
broaden
object
current
organ
gcg
initi
respond
increas
global
may
appropri
solut
futur
stage
develop
ich
organ
system
need
review
revis
better
serv
broader
object
ich
steer
committe
review
structur
conclud
structur
continu
appropri
howev
order
increas
transpar
welcom
appropri
particip
interest
parti
flexibl
ad
hoc
manner
topic
also
affect
decad
later
new
evolv
environ
requir
bigger
revis
structur
process
ich
steer
committe
understand
urgent
need
declar
new
ich
organiz
structur
adopt
steer
committe
set
framework
new
rule
govern
decis
make
membership
final
ich
becom
proactiv
new
emerg
topic
prevent
futur
disharmoni
gene
therapi
topic
interest
exampl
demonstr
previou
lack
commit
ich
proactiv
harmon
septemb
ich
steer
committe
establish
gene
therapi
discuss
group
gtdg
recognit
rapidli
evolv
area
gene
therapi
medicin
gtdg
develop
sever
ich
consider
document
area
despit
first
posit
stepoutcom
develop
consider
paper
activ
toward
develop
new
multidisciplinari
guidelin
guidelin
discontinu
septemb
current
ich
region
resourc
support
develop
ich
consider
document
domain
recent
ich
steer
committe
start
defin
new
proactiv
approach
identifi
creativ
pursu
advanc
scienc
ich
succe
challeng
certainli
becom
real
intern
organizationforum
vs
multiregion
initi
proactiv
discuss
past
new
technic
requir
registr
pharmaceut
human
use
discuss
howev
challeng
new
ich
acknowledg
challeng
year
ago
alreadi
tri
resolv
without
succeed
eg
proactiv
confirm
difficulti
task
face
challeng
ich
need
revis
structur
engag
new
phase
order
address
evolut
regul
global
drug
develop
manufactur
promot
better
proactiv
harmon
ongo
ich
reform
obvious
import
mileston
toward
resolut
current
limit
europ
first
major
region
bloc
establish
world
war
ii
follow
mani
region
harmon
activ
throughout
world
especi
past
year
countri
differ
region
globe
organ
closer
econom
polit
entiti
movement
transform
world
econom
polit
creat
new
opportun
also
new
challeng
eg
manag
regul
standard
disharmoni
region
harmon
initi
includ
member
closer
interest
need
compar
global
initi
allow
harmon
cooper
level
harmon
also
essenti
develop
countri
may
access
global
harmon
discuss
due
spars
resourc
lack
expertis
region
cooper
repres
interest
challeng
allow
heard
global
level
ii
level
cooper
also
essenti
establish
regionwid
pool
procur
system
divers
initi
differ
scope
object
structur
work
model
establish
due
differ
cultur
histor
polit
context
rang
simpl
technic
scientif
intergovernment
cooper
model
advanc
integr
model
ii
although
countri
part
mani
countri
repres
ich
global
standard
develop
howev
major
region
harmon
initi
today
repres
via
ich
gcg
group
polit
econom
develop
region
sometim
subregion
inde
shape
level
harmon
pharmaceut
area
scenario
pharmaceut
harmon
context
econom
polit
integr
certain
region
econom
integr
among
countri
impli
integr
pharmaceut
regul
harmon
technic
standard
degre
integr
vari
one
region
anoth
sometim
one
subregioncountri
anoth
harmon
regul
polici
standard
import
creat
consist
region
legisl
framework
common
certif
system
product
across
region
europ
best
exampl
term
advanc
harmon
integr
develop
central
system
institut
procedur
registr
medicin
market
singl
market
jj
scenario
pharmaceut
harmon
context
gener
polit
agreement
initi
follow
gener
polit
agreement
mostli
sign
avoid
conflict
war
certain
area
world
facilit
econom
growth
trade
within
region
eg
asiapacif
econom
cooper
apec
without
integr
goal
output
harmon
initi
variabl
time
produc
deep
harmon
pharmaceut
regul
primari
object
agreement
therefor
resourc
effort
countri
pharmaceut
regul
harmon
variabl
scenario
pharmaceut
harmon
base
specif
intergovernment
agreement
region
simpl
technic
scientif
intergovernment
cooper
establish
focus
sole
harmon
pharmaceut
regul
case
pandhr
initi
america
region
integr
object
countri
continu
present
differ
system
degre
develop
polit
commit
creat
singl
market
countri
cooper
promot
harmon
without
creat
common
legisl
procedur
scenario
produc
good
harmon
pharmaceut
regul
focu
initi
compar
scenario
deriv
broader
polit
agreement
howev
risk
difficulti
scenario
implement
ultim
econom
polit
goal
eg
develop
singl
market
scenario
implement
agreedupon
recommend
nation
law
somewhat
difficult
success
clearli
depend
commit
countri
import
understand
scenario
discuss
also
consid
step
harmon
move
process
harmon
initi
evolv
time
exampl
jj
central
system
support
nation
dra
also
continu
oper
registr
system
product
limit
nation
market
european
model
initi
stop
war
countri
scenario
time
sinc
evolv
integr
model
creat
econom
polit
bond
scenario
asean
anoth
evolv
initi
may
follow
european
model
today
scenario
evolut
integr
model
obvious
easier
member
somewhat
limit
number
share
common
geograph
histor
cultur
root
inde
difficult
imagin
apec
pandrh
evolv
toward
integr
model
europ
asean
european
commun
creat
world
war
ii
order
develop
peac
europ
promot
cooper
project
sinc
rapidli
evolv
becom
uniqu
partnership
european
countri
main
goal
commun
progress
integr
member
state
econom
polit
system
establish
singl
european
market
base
free
movement
good
peopl
money
servic
european
union
eu
feder
like
unit
state
america
us
simpli
organ
cooper
govern
like
unit
nation
fact
uniqu
countri
make
eu
member
state
remain
independ
sovereign
nation
pool
sovereignti
order
gain
strength
world
influenc
none
could
kk
approxim
million
peopl
repres
world
popul
eu
today
world
third
largest
popul
china
india
repres
huge
singl
market
eu
gross
domest
product
gdp
bigger
us
world
biggest
export
import
divers
import
characterist
eu
symbol
motto
unit
divers
mani
differ
exist
among
member
state
divers
posit
attribut
union
howev
consid
offici
languag
major
histor
social
cultur
econom
differ
member
state
develop
easi
divers
also
influenc
organ
way
harmon
process
structur
therefor
import
understand
histori
organ
eu
order
understand
european
pharmaceut
regul
structur
time
effect
alon
cooper
action
commun
level
indispens
includ
major
health
threat
issu
cross
border
intern
impact
pandem
bioterror
well
issu
relat
free
movement
good
servic
peopl
acknowledg
countri
share
common
valu
ie
ensur
high
standard
public
health
equiti
access
qualiti
healthcar
therefor
logic
eu
develop
common
standard
medicin
moreov
implement
singl
market
requir
harmon
pharmaceut
market
abil
travel
freeli
live
work
anywher
eu
make
sens
eu
citizen
sure
obtain
level
healthcar
wherev
go
therefor
number
european
commun
rule
adopt
ensur
highest
possibl
degre
protect
public
health
promot
free
movement
medicin
intern
market
without
barrier
european
commiss
ec
role
mirror
duplic
nation
activ
coordin
work
healthcar
commun
level
add
valu
member
state
action
particularli
area
ill
prevent
includ
activ
safeti
efficaci
medicin
today
european
pharmaceut
system
well
develop
vast
major
requir
harmon
success
european
cooper
pharmaceut
also
recogn
worldwid
basi
due
major
contribut
global
harmon
pharmaceut
regul
via
activ
involv
intern
initi
ich
today
eu
compos
member
state
size
eu
chang
time
continu
expand
sinc
european
integr
first
began
six
countri
tabl
final
three
enlarg
expand
eu
member
state
root
collaps
commun
histor
advanc
offer
unexpect
unpreced
opportun
extend
union
central
eastern
europ
today
landmass
eu
cover
million
km
rightli
claim
repres
contin
plate
stretch
atlant
ocean
black
sea
reunit
western
eastern
europ
first
time
sinc
separ
cold
war
futur
eu
continu
grow
increas
number
countri
express
interest
membership
treati
european
union
set
condit
access
articl
european
countri
respect
principl
liberti
democraci
respect
human
right
fundament
freedom
rule
law
may
appli
becom
member
union
applic
countri
must
meet
core
criteria
eg
stabl
institut
function
market
economi
order
ensur
eu
principl
respect
eu
rule
procedur
effect
implement
long
rigor
process
start
countri
submit
applic
council
today
iceland
former
yugoslav
republ
macedonia
montenegro
turkey
albania
bosnia
herzegovina
kosovo
serbia
candid
join
eu
countri
advanc
stage
negoti
eu
other
membership
grant
necessari
requir
met
candid
countri
demonstr
abl
fulfil
part
member
eu
regulatori
network
exampl
ipa
program
support
particip
nomin
repres
concern
countri
select
meet
train
cours
observ
program
also
support
organ
confer
prepar
countri
integr
european
regulatori
network
medicin
activ
help
identifi
area
addit
action
might
need
ensur
smooth
transposit
eu
acqui
communautair
mm
nation
legisl
futur
eu
member
state
specif
case
iceland
liechtenstein
norway
juli
iceland
submit
applic
eu
membership
access
negoti
open
norway
despit
two
fail
attempt
referendum
enter
european
commun
eu
remain
undecid
whether
appli
eu
membership
present
howev
neither
norway
liechtenstein
candid
eu
membership
howev
even
three
countri
current
part
eu
import
note
specif
strong
relationship
union
european
econom
area
eea
agreement
enter
forc
januari
agreement
allow
three
eea
european
free
trade
associ
efta
state
nn
particip
eu
intern
market
basi
applic
intern
market
relev
acqui
oo
new
relev
commun
legisl
dynam
incorpor
agreement
thu
appli
throughout
eea
ensur
homogen
eu
intern
market
also
eea
agreement
allow
eeaefta
state
particip
intern
market
relev
commun
program
agenc
albeit
right
vote
pharmaceut
sector
norway
iceland
liechtenstein
adopt
complet
commun
acqui
medicin
consequ
parti
european
procedur
case
central
procedur
repres
three
countri
vote
posit
state
separ
opinion
relev
minut
committe
case
diverg
opinion
append
committe
opinion
posit
count
reach
committe
opinion
accord
decis
eea
joint
committe
enter
forc
januari
decis
approv
medicin
product
accept
commun
three
countri
accept
correspond
decis
basi
relev
act
liechtenstein
author
transpos
nation
legisl
provis
make
commiss
decis
automat
applic
territori
howev
legal
mm
acqui
communautair
french
term
refer
cumul
bodi
eu
law
compris
ec
object
substant
rule
polici
particular
primari
secondari
legisl
case
law
form
part
legal
order
eu
nn
european
free
trade
associ
efta
intergovernment
organ
set
promot
free
trade
econom
integr
benefit
four
member
state
iceland
liechtenstein
norway
switzerland
although
switzerland
mani
agreement
eu
today
part
eea
agreement
due
reject
access
swiss
peopl
oo
eea
agreement
concern
princip
four
fundament
pillar
intern
market
four
freedom
ie
freedom
movement
good
person
servic
capit
bind
act
commun
eg
commiss
decis
directli
confer
right
oblig
norway
iceland
first
transpos
legal
bind
act
state
sinc
end
world
war
ii
eu
steadili
becom
establish
organ
uniqu
european
model
feder
integr
simpl
cooper
govern
requir
complex
organ
protect
independ
sovereignti
member
state
also
allow
deleg
decisionmak
power
share
supran
institut
today
structur
place
specif
design
repres
interest
commun
member
state
european
citizen
within
overal
european
structur
context
mani
special
domain
harmon
organ
support
function
singl
market
number
institut
committe
technic
bodi
tabl
play
signific
role
european
pharmaceut
system
role
characterist
briefli
describ
follow
section
european
parliament
directli
elect
eu
institut
repres
interest
eu
citizen
member
elect
everi
five
year
origin
go
back
found
treati
lisbon
treati
significantli
increas
role
decisionmak
process
budget
approv
legisl
power
reinforc
extens
codecis
procedur
today
european
parliament
firmli
establish
colegisl
budgetari
power
exercis
democrat
control
european
institut
work
organ
system
special
committe
review
prepar
legisl
propos
report
present
plenari
assembl
committe
environ
public
health
food
safeti
respons
legisl
cover
pharmaceut
product
ema
european
parliament
three
work
locat
brussel
belgium
luxembourg
strasbourg
franc
luxembourg
home
administr
offic
gener
secretariat
meet
entir
parliament
known
plenari
session
take
place
strasbourg
sometim
brussel
committe
meet
also
held
brussel
council
european
union
repres
individu
member
state
meet
differ
configur
attend
one
minist
eu
nation
govern
depend
agenda
healthrel
discuss
handl
employ
social
polici
health
consum
affair
council
epsco
european
parliament
council
set
found
treati
key
decisionmak
bodi
among
respons
eg
coordin
eu
econom
polici
foreign
secur
polici
share
lawmak
budgetari
power
european
parliament
work
facilit
committe
perman
repres
corep
respons
prepar
work
council
european
union
issu
must
pass
corep
includ
agenda
eu
council
meet
committe
consist
member
state
ambassador
eu
perman
nation
repres
team
locat
brussel
belgium
protect
nation
interest
eu
level
european
commiss
ec
independ
nation
govern
repres
uphold
interest
eu
whole
act
guardian
treati
remain
polit
account
parliament
like
parliament
council
ec
set
eu
found
treati
new
commiss
form
presid
design
member
state
approv
parliament
commission
respons
specif
polici
area
appoint
everi
five
year
role
draft
propos
new
european
law
present
european
parliament
council
adopt
also
eu
execut
arm
respons
implement
decis
parliament
council
mean
manag
daytoday
busi
eu
implement
polici
run
program
alloc
fund
repres
eu
intern
negoti
daytoday
run
commiss
done
administr
offici
technic
expert
via
variou
committe
group
translat
interpret
secretari
staff
repres
peopl
staff
organ
depart
known
directoratesgener
dg
servic
legal
servic
overal
coordin
provid
secretariatgener
dg
respons
particular
polici
area
head
directorgener
answer
one
commission
regul
medicin
product
previous
dg
enterpris
industri
polici
area
transfer
dg
health
consum
sanco
march
commiss
base
brussel
belgium
also
offic
luxembourg
represent
eu
countri
deleg
mani
capit
citi
around
world
institut
triangl
produc
polici
law
european
pharmaceut
legisl
appli
throughout
eu
court
justic
uphold
rule
european
law
make
sure
eu
legisl
interpret
appli
way
eu
countri
institut
eu
european
council
court
auditor
critic
function
eu
directli
involv
develop
harmon
pharmaceut
legisl
eu
institut
support
number
bodi
eg
european
central
bank
european
ombudsman
etc
special
agenc
eg
ema
european
centr
diseas
prevent
control
execut
agenc
health
consum
also
establish
handl
certain
technic
scientif
manag
task
agenc
head
execut
director
legal
repres
respons
oper
staf
matter
staff
fulltim
member
manag
board
supervisori
bodi
respons
set
agenc
budget
approv
annual
work
program
ensur
agenc
work
effect
cooper
success
partner
organ
across
eu
beyond
addit
staff
ema
compos
seven
committe
conduct
main
scientif
work
agenc
committe
characterist
review
human
use
chmp
play
vital
role
eu
market
procedur
respons
conduct
initi
scientif
assess
issu
opinion
maa
medicin
regist
via
central
procedur
opinion
use
ec
basi
legal
bind
decis
coordin
postmarket
activ
medicin
regist
via
central
procedur
arbitr
disagr
member
state
mutual
recognit
decentr
procedur
arbitr
procedur
act
referr
case
initi
concern
relat
protect
public
health
commun
interest
stake
commun
referr
procedur
committe
work
parti
also
provid
assist
compani
develop
prepar
scientif
regulatori
guidelin
cooper
intern
partner
harmon
regulatori
requir
medicin
committe
orphan
medicin
product
comp
establish
regul
ec
charg
review
applic
compani
seek
orphan
medicin
product
design
product
intend
develop
diagnosi
prevent
treatment
rare
diseas
socal
orphan
drug
committe
also
respons
advis
european
commiss
establish
develop
polici
orphan
medicin
product
eu
assist
commiss
draw
detail
guidelin
liais
intern
matter
relat
orphan
medicin
product
submit
pharmaceut
compani
adopt
opinion
plan
includ
assess
applic
full
partial
waiver
assess
applic
deferr
pediatr
studi
committe
also
assess
data
gener
accord
agreedupon
pip
provid
opinion
qualiti
safeti
efficaci
medicin
use
pediatr
popul
request
chmp
member
state
support
develop
european
network
pediatr
research
european
medicin
agenc
enprema
ss
committe
advanc
therapi
cat
multidisciplinari
committe
establish
accord
regul
ec
respons
provid
scientif
opinion
advancedtherapi
medicin
product
atmp
scientif
question
relat
field
exampl
prepar
draft
opinion
atmp
applic
chmp
adopt
final
opinion
grant
variat
suspens
revoc
market
author
medicin
concern
committe
medicin
product
veterinari
use
cvmp
respons
prepar
agenc
opinion
question
concern
veterinari
medicin
product
pharmacovigil
risk
assess
committe
prac
last
committe
establish
ema
implement
new
eu
pharmacovigil
legisl
respons
assess
monitor
safeti
issu
human
medicin
includ
detect
assess
minim
commun
relat
risk
advers
reaction
take
therapeut
effect
medicin
account
also
respons
design
evalu
postauthor
safeti
studi
pharmacovigil
audit
recommend
consid
chmp
adopt
opinion
central
author
medicin
referr
procedur
cmdh
provid
recommend
use
medicin
member
state
ema
scientif
committe
compris
member
eu
eeaefta
state
iceland
liechtenstein
norway
committe
includ
patient
doctor
repres
support
number
work
parti
relat
group
expertis
particular
scientif
field
committe
consult
scientif
issu
relat
particular
field
expertis
deleg
certain
task
associ
scientif
evalu
maa
draft
revis
scientif
guidanc
document
particular
chmp
support
import
number
group
ie
biolog
work
parti
scientif
advic
work
parti
numer
scientif
advisori
group
special
therapeut
area
stand
parti
temporari
group
group
made
member
select
european
expert
list
maintain
ema
inde
worth
note
ema
evalu
system
work
network
european
expert
made
avail
agenc
nation
dra
eu
member
state
three
eeaefta
state
iceland
liechtenstein
norway
system
bring
togeth
scientif
resourc
expertis
countri
network
european
expert
serv
member
agenc
scientif
committe
work
parti
scientif
assess
team
ema
today
consid
model
fruit
cooper
nation
dra
work
togeth
within
commun
bodi
serv
commun
purpos
also
ensur
european
system
access
everyon
ema
launch
dedic
offic
provid
special
assist
smalland
mediums
enterpris
collect
prepar
storag
distribut
appropri
use
blood
compon
blood
transfus
transplant
organ
tissu
cell
role
edqm
essenti
europ
facilit
mutual
recognit
qualiti
control
test
carri
medicin
ensur
patient
receiv
qualiti
pharmaceut
product
throughout
europ
substanti
amount
interact
ema
edqm
exampl
edqm
repres
particip
observ
ema
qualiti
work
parti
qwp
biolog
work
parti
bwp
meet
gmp
inspect
servic
group
meet
well
hmpc
meet
ema
import
note
european
member
state
play
signific
role
european
pharmaceut
system
ema
work
close
eu
member
state
well
eeaefta
countri
norway
iceland
liechtenstein
member
state
repres
member
agenc
manag
board
agenc
scientif
committe
network
scientif
expert
nomin
member
state
without
support
expertis
ema
would
unabl
deliv
respons
mandat
laid
european
legisl
also
import
realiz
mani
medicin
avail
europ
author
ec
recommend
ema
mani
product
still
approv
supervis
nation
dra
via
mutual
recognit
procedur
decentr
procedur
nation
procedur
coordin
effort
member
state
establish
head
medicin
agenc
hma
group
network
head
nation
dra
hma
compris
nation
agenc
also
respons
veterinari
product
medic
devic
cosmet
also
price
reimburs
product
ema
also
member
hma
first
meet
hma
took
place
amsterdam
netherland
schiphol
airport
februari
hma
focus
eu
coordin
harmon
decis
make
consensu
strateg
issu
european
medicin
regulatori
network
aim
foster
effect
effici
european
medicin
regulatori
system
specif
work
toward
follow
key
object
address
key
strateg
issu
european
medicin
regulatori
network
exchang
inform
share
best
practic
collect
respons
area
medicin
regul
includ
mutual
recognit
decentr
procedur
focus
develop
coordin
consist
network
support
network
provid
highqual
profession
scientif
resourc
provid
focu
make
effect
use
scarc
resourc
across
network
develop
overse
arrang
work
share
fulfil
object
hma
work
gener
issu
ie
strategi
telemat
regulatori
scientif
train
technic
scientif
topic
ie
harmon
clinic
trial
coordin
product
test
european
risk
manag
strategi
support
european
medicin
regulatori
network
hma
websit
contain
mri
product
index
databas
includ
medicin
approv
member
state
accord
mutual
recognit
procedur
one
interest
program
develop
benchmark
european
medicin
agenc
bema
bema
program
assess
system
process
individu
agenc
set
agreedupon
indic
good
opportun
exchang
best
practic
ensur
harmon
practic
ie
assess
inspect
etc
regul
within
network
coordin
among
nation
compet
author
simpl
task
due
heterogen
nation
organ
inde
author
differ
size
histor
origin
role
resourc
expertis
fund
acknowledg
differ
also
legal
scientif
social
polit
financi
challeng
face
network
hma
adopt
strateg
paper
provid
plan
action
second
plan
first
one
cover
highlight
number
key
theme
area
focu
ie
pharmacovigil
clinic
trial
commun
also
need
intern
cooper
hma
support
head
medicin
agenc
manag
group
perman
secretariat
work
group
cover
specif
area
respons
iceland
liechtenstein
appoint
renew
period
three
year
observ
european
commiss
access
countri
also
particip
meet
also
mani
interact
ema
facilit
harmon
sever
area
ie
pediatr
regul
variat
regul
pharmacovigil
hold
monthli
meet
ema
also
provid
secretariat
cmdh
practic
approxim
half
time
cmdh
meet
dedic
discuss
procedur
regulatori
issu
develop
guidanc
document
oversight
activ
variou
cmdh
subgroup
work
group
half
devot
tri
reach
agreement
applic
refer
cmdh
case
disagr
member
state
gradual
harmon
pharmaceut
regul
eu
dictat
develop
expans
commun
repres
good
exampl
success
harmon
also
demonstr
influenc
polit
econom
decis
harmon
process
outcom
birth
european
union
histor
root
eu
lie
world
war
ii
follow
bloodi
horrif
war
sever
leader
europ
want
ensur
war
could
never
happen
goal
develop
peac
europ
stop
frequent
war
via
promot
cooper
project
initi
critic
easili
accomplish
due
postwar
geopolit
situat
begin
cold
war
split
europ
east
west
septemb
winston
churchil
call
kind
unit
state
europ
speech
given
zurich
univers
mani
attempt
cooper
made
follow
year
eg
custom
convent
belgium
luxembourg
netherland
organ
european
econom
cooper
west
european
nation
creat
council
europ
uu
first
step
toward
cooper
countri
want
go
ever
may
franc
foreign
minist
robert
schuman
present
plan
deeper
cooper
creation
organ
europ
would
prove
indispens
mainten
longterm
peac
relat
propos
known
schuman
declar
consid
begin
creation
eu
may
sinc
design
europ
day
celebr
event
idea
plan
inspir
jean
monnet
top
advisor
french
govern
promot
european
peac
elimin
ageold
opposit
franc
germani
creat
framework
organ
open
particip
countri
europ
propos
francogerman
product
coal
steel
place
common
high
author
new
product
unit
open
european
countri
will
particip
doubl
object
propos
set
common
foundat
econom
develop
first
step
feder
europ
make
war
materi
imposs
base
schuman
plan
six
countri
germani
franc
itali
netherland
belgium
luxembourg
sign
treati
pari
april
establish
european
coal
steel
commun
ecsc
order
run
coal
steel
industri
common
manag
import
note
independ
power
high
author
critic
differenti
eu
tradit
intergovernment
organ
inde
establish
ecsc
first
step
toward
supran
europ
first
time
six
member
state
organ
relinquish
part
sovereignti
albeit
limit
domain
favor
european
commun
build
success
first
treati
six
countri
decid
expand
cooper
econom
sector
march
belgian
minist
foreign
affair
paulhenri
spaak
sign
treati
rome
establish
european
econom
commun
eec
common
market
allow
person
good
servic
capit
move
freeli
across
border
day
also
sign
second
treati
creat
european
atom
energi
commun
euratom
despit
construct
berlin
wall
august
increas
divis
east
west
cooper
european
countri
continu
increas
differ
area
eg
food
agricultur
aerial
navig
environ
etc
juli
six
countri
creat
world
largest
trade
group
remov
custom
duti
good
import
six
countri
other
allow
free
crossbord
trade
first
time
also
appli
duti
import
outsid
countri
eu
intern
market
reinforc
adopt
singl
european
act
enter
forc
juli
remov
final
obstacl
singl
market
four
freedom
movement
good
servic
peopl
money
final
fulli
establish
addit
agreement
schengen
agreement
sinc
sign
facilit
movement
within
europ
today
singl
market
repres
core
eu
follow
collaps
commun
across
central
eastern
europ
dissolut
pact
de
varsovi
decad
began
would
critic
futur
europ
decemb
eu
leader
agre
start
process
membership
negoti
countri
central
eastern
europ
bulgaria
czech
republ
estonia
hungari
latvia
lithuania
poland
romania
slovakia
slovenia
mediterranean
island
cypru
malta
also
includ
decemb
treati
chang
agre
nice
franc
final
sign
februari
enter
forc
februari
open
way
enlarg
eu
reform
institut
vote
rule
enlarg
eastern
european
countri
becam
effect
may
januari
six
year
later
juli
access
croatia
brought
number
member
state
countri
singl
currenc
euro
introduc
januari
countri
join
greec
commerci
financi
transact
note
coin
introduc
januari
introduct
singl
currenc
follow
long
stepwis
process
start
creation
exchang
rate
mechan
maintain
monetari
stabil
next
import
step
integr
ie
develop
polit
union
fulli
function
institut
took
time
face
mani
challeng
debat
constitution
europ
start
european
parliament
adopt
altiero
spinelli
report
propos
draft
treati
european
union
fundament
reform
european
commun
two
import
treati
transform
commun
treati
european
union
sign
maastricht
netherland
februari
enter
forc
novemb
repres
new
stage
european
integr
open
way
polit
integr
major
eu
mileston
introduc
concept
european
citizenship
set
clear
rule
futur
singl
currenc
foreign
secur
polici
treati
name
european
union
offici
replac
european
commun
treati
amsterdam
sign
octob
enter
forc
may
built
achiev
treati
maastricht
laid
plan
reform
eu
institut
gave
europ
stronger
voic
world
concentr
resourc
employ
right
eu
citizen
build
transform
commun
adopt
european
constitut
major
institut
reform
becam
import
topic
discuss
two
reason
succeed
treati
spur
progress
build
reform
europ
institut
long
process
mark
everclos
integr
progress
transform
europ
econom
commun
polit
union
combin
variou
treati
protocol
sign
year
made
european
structur
legisl
complex
although
eu
certainli
continu
grow
difficult
predict
next
step
integr
due
current
geopolit
situat
instabl
caus
financi
crisi
evolut
pharmaceut
regul
harmon
cooper
europ
repres
excel
exampl
model
need
analyz
detail
show
differ
import
step
necessari
harmon
success
larg
bodi
legisl
develop
progress
harmon
requir
sinc
first
european
direct
relat
pharmaceut
product
direct
sign
januari
text
provid
european
definit
medicin
product
substanc
set
fundament
principl
creation
european
pharmaceut
system
medicin
may
place
market
member
state
unless
market
author
issu
compet
author
follow
review
applic
submit
person
respons
place
product
market
qualiti
safeti
efficaci
basi
evalu
applic
compet
author
inform
includ
applic
updat
regular
basi
follow
first
direct
mani
text
follow
year
detail
european
principl
requir
led
direct
organ
structur
european
system
add
new
requir
relat
specif
type
product
emerg
problem
major
text
import
step
develop
european
pharmaceut
system
discuss
howev
import
note
mani
legisl
text
guidelin
recommend
includ
harmon
qualiti
nonclin
clinic
requir
prepar
releas
year
support
major
legisl
text
list
section
direct
complement
two
addit
direct
direct
may
provid
detail
analyt
nonclin
clinic
standard
protocol
appli
develop
medicin
result
studi
present
maa
direct
also
establish
idea
expert
report
would
later
influenc
structur
ctd
cpmp
would
later
part
ema
first
multist
licens
procedur
would
evolv
progress
becom
current
mutual
recognit
procedur
mrp
clarif
requir
provid
direct
also
modifi
multist
licens
procedur
facilit
use
direct
eec
establish
notion
combin
product
creat
rout
abridg
applic
case
gener
literaturebas
applic
direct
establish
concert
procedur
provid
simpl
communitywid
licens
opinion
via
mandatori
referr
cpmp
new
biotechnolog
product
option
high
technolog
medicin
product
import
new
step
build
european
pharmaceut
system
new
procedur
forerunn
current
central
procedur
requir
cooper
nation
dra
compar
multist
licens
procedur
previous
establish
howev
procedur
still
base
voluntari
cooper
relev
nation
author
member
state
remain
sole
respons
grant
market
author
legisl
extend
scope
previou
direct
specif
type
product
vaccin
toxin
serum
allergen
direct
radiopharmaceut
direct
product
deriv
human
blood
human
plasma
direct
addit
april
direct
laid
first
common
measur
relat
genet
modifi
organ
gmo
sever
addit
text
sinc
releas
topic
year
final
extens
scope
harmon
homeopath
product
made
via
adopt
direct
direct
laid
principl
guidelin
gmp
adopt
four
new
direct
cover
distribut
medicin
adopt
establish
eu
intern
market
facilit
free
movement
product
especi
harmon
wholesal
distribut
direct
classif
product
subject
medic
prescript
direct
label
product
direct
advertis
principl
direct
despit
text
adopt
sinc
result
progress
complet
singl
market
pharmaceut
satisfactori
therefor
decid
fundament
improv
author
procedur
new
european
pharmaceut
system
creat
implement
januari
new
system
still
place
today
base
two
major
text
establish
first
time
european
decis
bind
member
state
follow
adopt
european
procedur
necessari
harmon
system
vari
term
market
author
done
via
adopt
two
regul
regul
mrp
regul
central
procedur
addit
acknowledg
increas
complex
european
pharmaceut
legisl
agre
assembl
previou
direct
one
singl
text
codifi
direct
direct
adopt
novemb
necessari
direct
adopt
sinc
frequent
substanti
amend
therefor
direct
regroup
legal
requir
agreedupon
sinc
except
requir
legal
provis
provid
regul
new
direct
alreadi
amend
sever
time
sinc
adopt
amend
result
major
gener
review
legisl
system
discuss
direct
regul
articl
commiss
conduct
major
review
oper
new
system
implement
goal
audit
contract
independ
auditor
review
extent
result
achiev
first
five
year
met
object
name
enhanc
creation
singl
market
medicin
product
ensur
protect
public
health
develop
pharmaceut
industri
audit
report
known
cameron
mckenna
andersen
report
includ
result
extens
consult
carri
involv
individu
compani
dra
respons
author
medicin
emea
patient
profession
associ
trade
associ
relev
ministri
audit
highlight
overal
satisfact
new
system
procedur
perceiv
contributor
qualit
quantit
way
creat
harmon
european
commun
pharmaceut
market
ninetytwo
percent
compani
dra
eu
satisfi
satisfi
central
procedur
also
gener
recognit
consider
contribut
made
emea
eu
telemat
strategi
success
oper
system
howev
report
also
identifi
sever
issu
list
sever
possibl
improv
system
critic
primarili
direct
toward
mpr
agre
lack
real
supervisori
manag
support
liaison
member
state
alter
applic
central
principl
mutual
recognit
concern
member
state
continu
assess
applic
regard
central
procedur
felt
open
broader
rang
product
decisionmak
process
commiss
postcpmp
opinion
reduc
improv
final
also
interest
note
european
procedur
yet
produc
real
dividend
term
cost
effici
economi
scale
also
need
reduc
administr
burden
public
health
implic
eg
relat
minor
variat
exist
approv
evalu
regulatori
process
time
emerg
technic
challeng
eg
gene
therapi
etc
also
polit
challeng
prepar
eu
expans
inde
littl
doubt
upcom
major
enlarg
eu
involv
addit
countri
would
accentu
weak
system
structur
process
issu
resolv
base
review
eu
pharmaceut
legisl
variou
public
hear
ec
conclud
whole
system
proven
appropri
suitabl
purpos
therefor
recommend
keep
main
principl
structur
howev
ec
also
propos
sever
adapt
system
legisl
order
better
achiev
four
major
object
assur
high
level
public
health
protect
notabl
increas
supervis
market
strengthen
inspect
procedur
pharmacovigil
complet
singl
market
pharmaceut
product
take
account
stake
global
establish
regulatori
legisl
framework
favor
competit
european
industri
respond
challeng
futur
enlarg
eu
ration
simplifi
system
improv
overal
coher
visibl
transpar
procedur
propos
open
central
procedur
broader
rang
product
establish
fast
track
procedur
condit
author
improv
transpar
system
strengthen
pharmacovigil
supervis
requir
abolit
renew
control
effect
use
market
author
sunset
claus
improv
decisionmak
process
cpmp
opinion
reorgan
increas
role
emea
committe
major
modif
mrp
creation
decentr
procedur
harmon
data
protect
period
debat
parliament
council
subsequ
year
final
implement
via
adopt
new
revis
legisl
andor
guidelin
one
major
legisl
impact
adopt
regul
final
addit
critic
text
creat
european
system
gener
requir
worth
mention
follow
addit
legisl
text
adopt
past
year
import
specif
subject
see
part
current
european
pharmaceut
system
progress
develop
year
via
adopt
agreedupon
polici
sinc
mani
text
adopt
aim
achiev
singl
market
pharmaceut
product
note
sever
european
institut
technic
bodi
togeth
eu
member
state
involv
harmon
european
pharmaceut
regul
european
harmon
process
lie
adopt
eu
law
categor
follow
primari
legisl
treati
bind
agreement
eu
member
countri
state
eu
object
rule
eu
institut
decis
made
relationship
eu
member
state
also
form
basi
ground
rule
eu
action
mean
everi
action
taken
eu
found
treati
approv
voluntarili
democrat
eu
member
countri
exampl
polici
area
cite
treati
law
propos
area
secondari
legisl
deriv
principl
object
set
treati
includ
follow
text
regul
direct
form
eu
law
soon
pass
bind
legal
forc
throughout
everi
member
state
must
appli
entireti
across
eu
nation
govern
take
action
implement
eu
regul
ie
regul
requir
transposit
nation
author
direct
legisl
act
set
goal
eu
countri
must
achiev
nation
author
adapt
law
meet
goal
free
decid
vv
direct
use
bring
differ
nation
law
line
particularli
common
matter
affect
oper
singl
market
eg
product
safeti
standard
may
concern
one
member
state
decis
individu
act
relat
specif
case
address
specif
parti
bind
address
eg
eu
countri
individu
compani
directli
applic
need
implement
nation
law
decis
come
eu
council
sometim
jointli
european
parliament
ec
vv
direct
specifi
date
nation
law
must
adapt
give
nation
author
room
maneuv
within
deadlin
necessari
take
account
differ
nation
situat
recommend
bind
allow
institut
make
view
known
suggest
line
action
without
impos
legal
oblig
address
opinion
bind
instrument
allow
institut
make
statement
nonbind
fashion
word
without
impos
legal
oblig
address
issu
main
eu
institut
commiss
council
parliament
committe
region
european
econom
social
committe
european
parliament
council
eu
share
legisl
power
mean
empow
adopt
european
law
direct
regul
principl
commiss
propos
new
legisl
text
ww
parliament
council
adopt
commiss
member
state
implement
commiss
ensur
law
correctli
appli
vast
major
european
law
adopt
jointli
european
parliament
council
use
procedur
known
codecis
xx
mean
directli
elect
european
parliament
approv
eu
legisl
togeth
council
govern
eu
countri
addit
ordinari
legisl
procedur
also
special
legisl
procedur
appli
specif
case
parliament
consult
role
requir
procedur
market
author
medicin
product
well
rule
variat
term
market
author
constant
supervis
product
author
primarili
laid
direct
regul
ec
subsequ
amend
text
addit
lay
harmon
provis
relat
area
manufactur
wholes
advertis
medicin
product
human
use
addit
variou
law
adopt
address
particular
certain
type
medicin
product
promot
research
specif
area
addit
legal
text
mani
addit
commun
intern
document
recommend
develop
support
harmon
cooper
eu
introduct
gener
principl
annex
direct
ww
european
commiss
institut
empow
initi
legisl
propos
new
text
assess
potenti
econom
social
environment
consequ
may
prepar
impact
assess
set
advantag
disadvantag
possibl
polici
option
consult
interest
parti
commiss
propos
action
eu
level
consid
problem
solv
effici
nation
region
local
action
principl
deal
thing
lowest
possibl
level
call
subsidiar
principl
reaffirm
lisbon
treati
xx
codecis
procedur
introduc
maastricht
treati
european
union
strengthen
made
effect
amsterdam
treati
lisbon
treati
took
effect
decemb
procedur
renam
ordinari
legisl
procedur
becom
main
legisl
procedur
eu
decisionmak
system
amend
acknowledg
scientif
technic
recommend
ie
rule
govern
medicin
product
european
commun
ich
guidelin
monograph
european
pharmacopoeia
commun
rule
area
medicin
product
human
veterinari
use
compil
rule
govern
medicin
product
european
union
eudralex
publish
ec
volum
public
contain
bodi
eu
pharmaceut
legisl
ie
regul
direct
decis
etc
subsequ
volum
includ
guidelin
yy
develop
support
basic
legisl
zz
volum
also
known
notic
applic
first
publish
contain
regulatori
guidelin
relat
procedur
regulatori
requir
ie
present
content
dossier
also
applic
form
prepar
regularli
updat
european
commiss
consult
compet
author
member
state
ema
notic
legal
power
case
doubt
therefor
refer
made
appropri
commun
direct
regul
also
juli
inform
contain
chapter
volum
concern
gener
inform
procedur
market
author
transfer
ema
cmdh
websit
volum
consist
scientif
guidelin
medicin
product
human
use
prepar
committe
medicin
product
human
use
chmp
consult
compet
author
eu
member
state
guidelin
intend
provid
basi
practic
harmon
manner
eu
member
state
ema
interpret
appli
detail
requir
demonstr
qualiti
safeti
efficaci
contain
commun
direct
updat
list
scientif
guidelin
access
ema
websit
volum
contain
guidanc
interpret
principl
gmp
medicin
product
human
veterinari
use
volum
contain
pharmacovigil
guidelin
medicin
product
human
use
volum
veterinari
use
volum
volum
replac
ema
guidelin
good
pharmacovigil
practic
gvp
volum
contain
guidanc
document
appli
clinic
trial
final
addit
publish
rule
list
lot
document
statu
law
guidelin
ie
question
answer
q
recommend
public
statement
posit
paper
reflect
paper
etc
releas
ema
provid
addit
guidanc
moreov
templat
eg
assess
templat
guidanc
intern
standard
oper
procedur
sop
work
instruct
win
polici
cover
gener
specif
topic
eg
pharmacovigil
inspect
etc
develop
ema
improv
consist
activ
evalu
help
eas
exchang
inform
mani
technic
requir
harmon
publish
europ
ensur
medicin
product
throughout
europ
equal
qualiti
safe
efficaci
three
basic
criteria
alway
evalu
taken
consider
establish
risk
benefit
ratio
criteria
evalu
qualiti
nonclin
clinic
inform
includ
applic
cours
level
qualitynonclinicalclin
document
vari
depend
upon
type
product
level
develop
alway
basi
approv
registr
clinic
trial
new
product
legal
provis
relat
technic
requir
includ
annex
direct
relev
regul
direct
addit
scientif
technic
guidelin
also
prepar
ema
committe
ie
chmp
comp
pdco
etc
work
parti
consult
compet
author
eu
member
state
guidelin
develop
technic
bodi
eg
european
pharmacopoeia
intern
bodi
also
use
europ
exampl
europ
founder
member
ich
therefor
ich
guidelin
also
applic
europ
qualiti
mani
european
requir
place
regard
qualiti
product
activ
substanc
excipi
finish
product
detail
scientif
guidelin
develop
adequ
cover
pharmaceut
develop
manufactur
packag
control
ie
specif
analyt
procedur
valid
impur
stabil
evalu
postapprov
chang
moreov
guidelin
certain
type
product
ie
biolog
radiopharmaceut
medicin
gase
herbal
medicin
product
specif
releas
take
account
specif
challeng
technic
scientif
guidelin
togeth
q
document
provid
common
interpret
european
legisl
ensur
harmon
qualiti
requir
also
addit
guidelin
worth
mention
two
public
critic
harmon
qualiti
aspect
medicin
product
avail
european
market
good
manufactur
practic
gmp
one
import
harmon
requir
issu
per
direct
direct
product
includ
investig
medicin
product
compli
principl
guidelin
gmp
gmp
principl
laid
direct
addit
ec
publish
detail
gmp
guidelin
line
principl
eudralex
volum
volum
cover
basic
requir
medicin
product
part
activ
substanc
use
start
materi
part
ii
particular
consider
condit
specif
product
biolog
product
radiopharmaceut
medicin
gase
product
deriv
human
blood
plasma
herbal
medicin
product
excipi
etc
also
place
discuss
eu
system
manufactur
import
medicin
locat
eea
subject
manufactur
author
come
supervis
compet
author
member
state
supervisori
author
respons
issu
author
activ
take
place
territori
european
pharmacopoeia
ep
establish
juli
eight
countri
aaa
collect
standard
specif
socal
monograph
defin
qualiti
refer
standard
medicin
today
convent
ratifi
european
countri
eu
european
direct
refer
mandatori
charact
ep
monograph
prepar
dossier
maa
eu
ep
also
applic
signatori
state
convent
elabor
ep
use
refer
mani
countri
observ
ep
publish
edqm
cover
activ
substanc
excipi
substanc
prepar
pharmaceut
use
chemic
anim
human
herbal
origin
homoeopath
prepar
stock
antibiot
well
dosag
form
contain
text
european
pharmacopoeia
also
appli
biolog
blood
plasma
deriv
vaccin
radiopharmaceut
prepar
nonclin
aspect
nonclin
test
program
cover
gener
guidelin
eg
glp
bbb
discuss
nonclin
strategi
identifi
mitig
risk
firstinhuman
clinic
trial
guidelin
specif
type
test
ie
pharmacolog
aaa
belgium
franc
germani
itali
luxembourg
netherland
switzerland
unit
kingdom
bbb
principl
good
laboratori
practic
defin
set
rule
criteria
qualiti
system
concern
organiz
process
condit
nonclin
health
environment
safeti
studi
plan
perform
monitor
record
report
archiv
pharmacokinet
singl
repeat
dose
toxic
genotox
carcinogen
reproduct
development
toxic
local
toler
guidelin
fact
develop
auspic
ich
qualiti
requir
specif
nonclin
guidelin
also
develop
certain
type
product
numer
clinic
guidelin
avail
cover
phase
clinic
develop
earli
ie
clinic
pharmacolog
pharmacokinet
studi
design
phase
studi
diseas
patient
characterist
advic
select
endpoint
durat
control
group
choic
compar
etc
due
specif
group
product
guidelin
organ
therapeut
area
focu
certain
type
product
herbal
medicin
product
radiopharmaceut
diagnost
agent
addit
gener
guidelin
also
releas
provid
advic
gener
consider
topic
drug
develop
diseasespecif
eg
guidelin
miss
data
confirmatori
clinic
trial
extrapol
result
clinic
studi
conduct
outsid
europ
eu
popul
clinic
trial
small
popul
data
monitor
committe
choic
noninferior
margin
excipi
label
packag
leaflet
medicin
product
human
use
addit
numer
scientif
guidelin
worth
mention
develop
implement
gcp
europ
investig
medicin
product
harmon
gcp
critic
recognit
data
european
countri
therefor
cooper
clinic
aspect
drug
develop
direct
framework
legisl
provid
addit
direct
accompani
guidelin
detail
guidanc
document
guidelin
guidanc
document
publish
eudralex
volum
final
import
note
lot
effort
put
forth
past
year
regard
harmon
european
pharmacovigil
system
system
coordin
ema
also
involv
nation
compet
author
ccc
european
commiss
includ
broad
rang
activ
review
risk
manag
plan
rmp
psur
develop
mainten
eu
report
data
warehous
system
case
report
eudravigil
signalidentif
activ
eu
coordin
eu
rapid
alert
incid
manag
system
time
adequ
respons
new
safeti
data
eu
legal
framework
pharmacovigil
provid
regul
ec
direct
addit
relev
ich
guidelin
implement
volum
eudralex
dedic
key
public
health
function
includ
number
detail
guidelin
definit
standard
inform
regard
precis
execut
pharmacovigilancerel
procedur
ccc
member
state
region
center
place
coordin
nation
compet
author
decemb
follow
public
consult
ec
decid
harmon
system
ensur
optim
effect
robust
transpar
via
adopt
two
addit
text
final
new
legisl
final
publish
decemb
offici
journal
european
union
june
commiss
implement
regul
eu
adopt
complement
pharmacovigil
legisl
start
appli
juli
final
pharmacovigil
incid
union
shown
need
improv
legisl
issu
address
direct
regul
start
appli
due
number
import
improv
need
implement
mani
observ
consid
new
pharmacovigil
legisl
biggest
chang
eu
legal
framework
sinc
creation
ema
implement
new
pharmacovigil
legisl
requir
lot
effort
ema
major
activ
sever
process
need
establish
amend
eg
establish
new
pharmacovigil
risk
assess
committe
prac
replac
chmp
pharmacovigil
work
parti
also
import
chang
new
legisl
increas
direct
involv
ema
pharmacovigil
nation
author
product
addit
central
author
product
exampl
ema
releas
guidelin
good
pharmacovigil
practic
gvp
replac
volum
eudralex
new
set
guidelin
appli
medicin
author
eu
whether
central
nation
author
ema
also
work
group
continu
improv
safeti
monitor
medicin
includ
central
coordin
role
protect
ddd
support
european
network
centr
pharmacoepidemiolog
pharmacovigil
encepp
eee
work
us
fda
ae
signal
detect
activ
notif
measur
taken
eu
medicin
may
bear
public
health
protect
thirdworld
countri
final
head
medicin
agenc
also
put
place
multiannu
program
call
european
risk
manag
strategi
erm
aim
strengthen
european
pharmacovigil
system
put
place
effici
measur
allow
earli
detect
assess
minim
commun
medicin
risk
throughout
lifecycl
guidelin
appli
one
specif
area
prepar
collabor
sever
work
parti
provid
advic
guidanc
specif
ddd
protect
project
innov
medicin
initi
imi
aim
strengthen
monitor
benefit
risk
medicin
europ
develop
innov
tool
method
enhanc
earli
detect
assess
advers
reaction
eee
encepp
network
support
independ
postauthor
studi
safeti
benefitrisk
aspect
specif
medicin
import
topic
ie
pediatr
cell
therapi
tissu
engin
vaccin
biosimilar
gene
therapi
pharmacogenom
eu
harmon
activ
relat
certain
topic
discuss
follow
section
also
import
note
cooper
area
inspect
eg
gmp
glp
gcp
phv
critic
although
respons
carri
inspect
rest
nation
compet
author
member
state
coordin
inspect
ema
agreement
common
standard
import
step
allow
increas
cooper
member
state
reduc
duplic
work
due
recognit
inspect
perform
member
state
ensur
level
qualiti
medicin
product
data
gener
develop
wherev
locat
manufactur
site
studi
european
system
author
medicin
product
creat
object
ensur
safe
effect
highqual
medicin
quickli
made
avail
citizen
across
eu
today
european
system
offer
sever
rout
author
medicin
product
central
procedur
laid
regul
ec
compulsori
certain
type
product
product
deriv
biotechnolog
process
advanc
therapi
medicin
orphan
medicin
product
intend
treatment
certain
specif
diseas
medicin
fall
within
categori
mandatori
scope
compani
also
submit
applic
medicin
product
constitut
signific
therapeut
scientif
technic
innov
respect
interest
public
health
applic
central
procedur
made
directli
ema
lead
european
market
author
author
bind
member
state
grant
ec
base
opinion
relev
ema
committe
valid
entir
commun
market
mean
medicin
may
put
market
member
state
ultim
integr
model
domain
singl
applic
singl
evalu
singl
author
allow
direct
access
singl
market
commun
mutual
recognit
procedur
mrp
laid
direct
applic
major
convent
medicin
product
base
principl
recognit
alreadi
exist
nation
market
author
one
member
state
member
state
refus
recogn
origin
nation
author
ground
potenti
seriou
risk
public
health
issu
refer
cmdh
find
consensu
case
cmdh
use
best
effort
reach
agreement
action
taken
within
time
period
foreseen
legisl
fail
matter
refer
emachmp
arbitr
see
detail
end
mrp
decentr
procedur
nation
market
author
grant
member
state
involv
wherea
central
procedur
result
singl
market
author
call
commun
market
author
valid
across
eu
well
eeaefta
state
iceland
liechtenstein
norway
pure
nation
author
still
avail
limit
medicin
product
market
one
member
state
addit
registr
procedur
anoth
european
procedur
call
referr
establish
commun
referr
procedur
use
resolv
disagr
eg
member
state
mrp
decentr
procedur
address
specif
concern
relat
safeti
efficaci
medicin
class
medicin
need
harmon
nation
decis
across
eu
referr
procedur
ema
request
conduct
behalf
european
commun
scientif
assess
particular
medicin
class
medicin
problem
refer
chmp
committe
make
recommend
harmon
posit
across
eu
referr
procedur
start
ec
member
state
pharmaceut
compani
end
referr
committe
make
recommend
european
commiss
issu
decis
member
state
reflect
measur
take
implement
chmp
recommend
final
import
note
addit
harmon
procedur
author
medicin
system
also
ensur
harmon
coordin
preand
postauthor
activ
preauthor
activ
compani
request
scientif
advic
protocol
assist
case
medicin
orphan
rare
diseas
ema
stage
medicin
develop
whether
medicin
elig
central
procedur
european
procedur
help
compani
make
sure
perform
appropri
test
studi
major
object
regard
design
test
like
rais
evalu
market
author
applic
postauthor
regulatori
activ
ie
variat
extens
transfer
market
author
renew
psur
notif
also
harmon
coordin
via
central
mrp
decentr
procedur
ensur
qualiti
safeti
efficaci
product
maintain
entir
lifecycl
manag
product
throughout
europ
eg
avail
new
formul
extens
indic
etc
year
extens
discuss
involv
ethic
aspect
european
commiss
adopt
propos
septemb
propos
led
new
legisl
regul
ec
enter
forc
eu
januari
today
amend
text
sever
associ
guidelin
publish
inform
set
system
requir
reward
incent
togeth
later
measur
ensur
medicin
research
develop
author
meet
therapeut
need
children
repres
total
european
popul
practic
new
regul
establish
expert
pediatr
committe
pdco
within
ema
respons
provid
opinion
develop
medicin
pediatr
use
key
object
regul
ensur
highqual
research
develop
medicin
children
age
year
age
ensur
time
major
medicin
use
children
specif
author
use
ensur
avail
highqual
inform
medicin
use
children
commun
ec
commun
provid
guidelin
format
content
applic
agreement
modif
pediatr
investig
plan
mani
addit
procedur
scientif
guidanc
document
also
releas
ema
facilit
implement
new
regul
eu
introduc
new
orphan
medicin
product
legisl
order
provid
incent
develop
medicin
product
rare
disord
harmon
requir
type
product
critic
allow
multin
clinic
studi
limit
develop
challeng
due
small
number
patient
prior
european
legisl
number
member
state
adopt
specif
measur
increas
knowledg
rare
diseas
improv
detect
diagnosi
prevent
treatment
howev
initi
lead
signific
progress
research
rare
diseas
procedur
design
orphan
medicin
technic
committe
orphan
medicin
product
comp
respons
scientif
examin
applic
design
orphan
medicin
assess
central
european
level
chmp
rather
member
state
separ
regul
also
put
place
incent
research
market
develop
product
eg
fee
waiver
market
exclus
period
postauthor
scientif
assist
market
author
follow
entri
forc
associ
rule
guidelin
number
orphan
medicin
author
increas
significantli
direct
aim
protect
public
health
secur
free
movement
herbal
medicin
within
commun
individu
herbal
medicin
continu
licens
nation
member
state
process
licens
inform
herbal
substanc
prepar
increasingli
harmon
across
eu
exampl
order
integr
special
medicin
european
regulatori
framework
committe
herbal
medicin
product
hmpc
establish
ema
septemb
replac
cpmp
work
parti
herbal
medicin
product
major
task
scientif
committe
establish
commun
monograph
tradit
herbal
medicin
prepar
maintain
list
herbal
substanc
medicin
use
suffici
period
time
consid
harm
normal
condit
use
procedur
clinic
trial
europ
use
vari
one
countri
anoth
differ
nation
approach
regard
approv
notif
system
document
requir
timelin
octob
order
coordin
implement
new
harmon
requir
across
member
state
hma
establish
clinic
trial
facilit
group
ctfg
ctfg
attend
repres
nation
dra
ec
ema
act
forum
discuss
agreement
common
principl
process
appli
throughout
europ
also
promot
harmon
clinic
trial
assess
decis
administr
process
across
nation
dra
group
establish
voluntari
harmon
procedur
vhp
assess
multin
cta
threephas
procedur
dra
member
state
involv
assess
applic
though
member
state
remain
ultim
respons
approv
cta
countri
howev
coordin
valid
phase
phase
voluntari
cooper
member
state
assess
phase
phase
usual
formal
nation
process
phase
phase
procedur
coordin
vhp
coordin
accept
statement
obtain
vhp
procedur
includ
subsequ
nation
cta
applic
march
april
applic
evalu
pilot
vhp
procedur
applic
receiv
posit
opinion
averag
procedur
time
day
significantli
less
averag
time
standard
nation
procedur
overal
feedback
sponsor
posit
except
direct
associ
text
guidelin
import
step
harmon
procedur
registr
conduct
clinic
trial
europ
implement
clinic
trial
direct
nation
legisl
eu
member
state
complet
principl
like
clinic
trial
author
nation
dra
within
defin
maximum
timelin
led
signific
harmon
clinic
trial
approv
process
howev
agre
new
system
need
harmon
order
achiev
ultim
object
inde
actual
assess
request
author
clinic
trial
done
independ
member
state
concern
legisl
provid
mechan
wherebi
member
state
oblig
reach
common
conclus
regard
clinic
trial
involv
differ
member
state
lack
oblig
detail
direct
impli
differ
interpret
member
state
therefor
creat
implement
issu
consequ
sponsor
respond
variou
requir
chang
adapt
protocol
view
diverg
assess
dra
situat
requir
addit
time
effort
pharmaceut
industri
without
ad
valu
patient
follow
public
consult
long
thorough
impact
assess
propos
submit
european
parliament
council
engag
ordinari
legisl
procedur
propos
adopt
eulegisl
go
replac
clinic
trial
direct
expect
come
effect
provid
major
revis
current
system
eg
singl
assess
outcom
simplifi
report
procedur
etc
final
must
note
import
topic
relat
regul
medicin
also
coordin
commun
level
ec
ema
order
harmon
regulatori
action
enforc
complet
singl
pharmaceut
market
harmon
initi
differ
stage
develop
support
cooper
harmon
activ
eu
need
system
knowledg
manag
support
implement
telemat
integr
use
telecommun
informat
strategi
coordin
ema
critic
increas
effici
transpar
across
european
medicin
regulatori
network
addit
standard
electron
submiss
esubmiss
develop
publish
central
set
pan
european
system
databas
creat
system
databas
exchang
inform
system
extern
stakehold
dra
stay
separ
also
help
provid
highqual
inform
medicin
product
gener
public
support
monitor
postauthor
risk
benefit
balanc
medicin
eu
follow
critic
project
tool
develop
program
still
develop
eudract
commun
electron
databas
clinic
trial
contain
inform
submit
sponsor
inform
dra
ongo
clinic
trial
member
state
eea
countri
enabl
overview
multist
trial
system
also
alert
dra
case
earli
interrupt
termin
eudragmp
commun
databas
manufactur
import
author
gmp
certif
ema
launch
first
releas
april
system
use
eu
gmp
inspector
share
inform
ie
gmp
author
noncompli
gmp
inform
result
inspect
activ
plan
inspect
activ
rapid
alert
aris
faulti
manufactur
eudranet
privat
electron
network
link
member
european
medicin
regulatori
network
ema
ensur
electron
mail
member
network
access
eu
telemat
system
secur
eudralink
european
medicin
regulatori
network
secur
file
transfer
system
use
exchang
inform
regulatori
purpos
oper
independ
eudranet
use
applic
market
author
holder
well
regulatori
organ
within
network
transfer
file
eudrapharm
commun
databas
author
medicin
product
function
databas
still
develop
eudravigil
system
monitor
postauthor
safeti
medicin
safeti
report
ie
suspect
advers
reaction
report
design
receiv
process
store
make
avail
inform
one
object
system
earli
detect
possibl
safeti
signal
facilit
regulatori
decisionmak
process
base
broader
knowledg
advers
reaction
profil
medicin
ema
receiv
valid
store
make
avail
inform
review
market
author
applic
system
key
benefit
abil
take
advantag
lifecycl
manag
function
built
ectd
easili
allow
full
extent
current
valid
document
well
submiss
histori
eu
telemat
control
term
eutct
central
repositori
public
system
control
term
list
use
european
medicin
regulatori
network
establish
eu
easi
repres
desir
end
conflict
europ
sinc
creation
eu
success
deliv
peac
member
state
reunit
fractur
contin
via
promot
cooper
project
ie
econom
social
cooper
initi
went
beyond
initi
object
founder
ever
deeper
integr
pursu
embrac
new
member
membership
eu
grown
nation
bring
eu
popul
half
billion
peopl
creat
stabl
institut
singl
market
singl
currenc
despit
numer
challeng
ggg
eu
surviv
today
major
econom
commerci
power
although
improv
still
need
certain
area
eu
repres
uniqu
model
success
cooper
harmon
integr
countri
differ
languag
cultur
histori
level
develop
pharmaceut
sector
much
achiev
toward
consolid
european
system
evalu
supervis
medicin
sever
challeng
alreadi
overcom
outstand
issu
still
need
resolv
support
improv
public
health
europ
free
movement
access
medicin
commun
competit
union
take
consider
success
challeng
section
provid
balanc
evalu
current
situat
demonstr
harmon
pharmaceut
regul
europ
consid
real
quick
success
gener
consid
major
chang
requir
acknowledg
specif
area
work
still
need
reason
develop
eu
european
pharmaceut
regul
system
great
exampl
need
evalu
discuss
although
model
harmon
integr
may
fulli
applic
case
experi
certainli
help
region
global
harmon
initi
sinc
adopt
first
pharmaceut
direct
mani
topic
harmon
past
year
seen
gradual
converg
pharmaceut
legisl
europ
today
consider
packag
harmon
legisl
form
pharmaceut
acqui
communautair
place
support
two
object
protect
public
health
free
movement
product
provisionstext
applic
medicin
product
includ
eudralex
includ
bind
legisl
ie
regul
direct
also
numer
technic
guidelin
recommend
facilit
implement
common
principl
wellstructur
european
pharmaceut
system
also
establish
addit
european
institut
necessari
harmon
creat
european
pharmaceut
legisl
technic
european
bodi
also
establish
today
evalu
supervis
medicin
europ
share
european
nation
bodi
form
complex
wellorgan
network
approxim
technic
regulatori
expert
word
like
network
work
share
harmon
becam
common
remain
crucial
futur
establish
ema
key
coordin
system
import
decis
integr
harmon
practic
standard
support
promot
singl
european
pharmaceut
market
primari
aim
central
system
creat
condit
singl
scientif
evalu
highest
possibl
standard
would
lead
rapid
access
integr
market
innov
good
costeffect
treatment
object
larg
measur
achiev
ema
compris
expert
provid
nation
dra
today
establish
lead
world
agenc
evalu
medicin
contribut
effect
effici
eu
system
therefor
protect
public
health
achiev
oper
intern
market
well
recogn
stakehold
effect
system
maintain
despit
grow
complex
inde
increas
number
central
applic
hhh
procedur
eu
enlarg
new
regul
led
increas
workload
enlarg
scope
respons
ema
past
year
chang
led
creation
new
committe
comp
pdco
cat
hmpc
prac
requir
implement
addit
procedur
new
tool
structur
chang
increas
respons
monitor
close
futur
avoid
risk
inconsist
overlap
bureaucraci
rigid
also
critic
continu
monitor
financi
compens
nation
dra
regularli
assess
involv
member
state
eu
pharmaceut
system
ensur
avail
appropri
resourc
expertis
within
legal
framework
european
pharmaceut
system
commun
author
procedur
central
mrp
decentr
place
sinc
central
coordin
task
includ
assess
led
rapporteur
corapporteur
inspect
pharmacovigil
medicin
lifecycl
although
nation
dra
prime
respons
effici
oper
mrp
decentr
procedur
nation
market
author
clinic
trial
author
human
medicin
ema
import
role
support
noncentr
function
exampl
ema
maintain
eudravigil
databas
eudract
databas
support
rang
scientif
committe
coordin
group
mrp
decentr
procedur
criteria
approv
medicin
technic
topic
extens
harmon
within
eu
mani
technic
regulatori
guidelin
releas
area
qualiti
nonclin
clinic
specif
focu
recent
year
improv
european
pharmacovigil
system
simplifi
variat
system
harmon
requir
clinic
trial
implement
advanc
therapi
regul
establish
european
pharmacopoeia
also
import
ensur
standard
specif
qualiti
medicin
eu
measur
action
describ
led
improv
market
author
procedur
harmon
data
protect
eu
better
access
medicin
children
orphan
drug
develop
clinic
trial
new
regulatori
framework
advanc
therapi
lifecycl
manag
product
also
improv
ie
revis
legisl
variat
reduc
administr
burden
streamlin
circumst
oblig
industri
file
applic
next
review
european
system
noteworthi
evalu
new
measur
develop
follow
last
review
improv
system
produc
real
dividend
term
cost
effici
economi
scale
via
reduct
administr
burden
public
health
implic
also
worth
mention
european
system
solid
enough
stand
challeng
new
therapeut
current
structur
forum
process
allow
proactiv
harmon
inde
harmon
initi
creat
discuss
exist
disharmoni
specif
topic
begin
european
harmon
effort
relat
pharmaceut
regul
focus
disharmoni
countri
today
even
disharmoni
still
exist
specif
subject
mani
topic
success
harmon
process
structur
form
year
allow
system
cover
new
subject
nation
regul
requir
develop
yet
develop
new
regul
eu
level
automat
creat
harmon
requir
call
proactiv
harmon
group
includ
ema
staff
member
chmp
work
parti
gener
recommend
ema
tackl
new
emerg
topic
cover
exist
nation
region
global
regul
standard
ema
innov
task
forc
itf
order
provid
support
medicin
innov
eu
ema
establish
intern
horizont
crosssectori
group
focu
emerg
therapi
technolog
itf
bring
togeth
compet
area
qualiti
safeti
efficaci
pharmacovigil
scientif
advic
orphan
drug
good
practic
complianc
well
legal
regulatori
affair
one
object
itf
address
impact
emerg
therapi
technolog
current
scientif
regulatori
requir
scope
also
encompass
area
establish
scientif
legal
regulatori
experi
one
task
identifi
area
legal
regulatori
technic
guidanc
prepar
propos
consider
ema
committe
work
parti
contribut
relev
ec
initi
legisl
eu
today
recogn
major
player
intern
harmon
pharmaceut
regul
develop
privileg
relationship
initi
cooper
project
countri
outsid
european
commun
major
develop
countri
emerg
market
exampl
ema
cooper
mani
world
largest
regulatori
bodi
outsid
eu
iii
area
inspect
safeti
medicin
exchang
inform
issu
mutual
concern
establish
intern
european
cooper
sector
form
februari
respons
develop
coordin
implement
agenc
intern
strategi
activ
includ
confidenti
arrang
countri
outsid
eu
demonstr
ema
commit
intern
cooper
also
collabor
initi
china
india
russia
pharmaceut
partner
intern
organ
ie
ich
pic
work
continu
also
extend
inde
import
support
develop
global
harmon
standard
requir
order
ensur
fair
competit
part
world
develop
medicin
avoid
delay
avail
essenti
medicin
european
patient
ensur
falsifi
medicin
resolut
pandem
issu
product
develop
emerg
market
reliabl
clinic
data
produc
outsid
europ
good
exampl
intern
cooper
necessari
ensur
adequ
protect
public
health
europ
spite
abovement
major
progress
regular
improv
legisl
european
commiss
still
room
improv
eu
pharmaceut
system
regulatori
side
issu
deal
implement
interpret
commun
legisl
member
state
continu
creat
obstacl
free
movement
medicin
stakehold
continu
rais
concern
regard
market
fragment
link
dispar
nation
price
reimburs
scheme
despit
adopt
direct
earli
day
european
pharmaceut
system
unnecessari
regulatori
burden
caus
diverg
implement
commun
legisl
eg
clinic
trial
requir
lack
commerci
interest
nation
market
econom
less
attract
european
patient
still
suffer
inequ
avail
afford
medicin
situat
could
worsen
creat
signific
inequ
patient
access
medicin
resolv
addit
europ
lose
ground
come
innov
competit
pharmaceut
market
commun
decemb
ec
recogn
harmon
necessari
resolv
shortcom
eu
pharmaceut
market
further
increas
global
sector
improv
issu
ec
confirm
object
continu
progress
toward
singl
sustain
pharmaceut
market
support
improv
public
health
europ
free
movement
medicin
within
commun
maintain
competit
eu
need
harmon
sever
area
novel
medicin
patient
mainli
due
increas
pressur
cut
healthcar
budget
certain
countri
medicin
made
avail
due
administr
requir
poor
econom
reward
lack
transpar
harmon
regard
price
reimburs
rel
effect
remain
challeng
contrast
benefitrisk
assess
carri
regul
nation
hta
bodi
compar
rel
effect
medicin
take
financi
cost
account
postmarket
nation
hta
evalu
lead
nation
differ
due
differ
countri
need
addit
differ
request
ie
differ
type
studi
regul
hta
bodi
also
delay
avail
new
product
resolv
major
issu
european
network
health
technolog
assess
eunethta
establish
support
effect
collabor
nation
hta
also
ec
gave
polit
mandat
ema
begin
interact
hta
bodi
publish
conclus
pharmaceut
forum
octob
kkk
sinc
ema
begun
collabor
nation
hta
bodi
eunethta
interact
focus
central
approv
product
aim
facilit
commun
ema
hta
bodi
earli
medicin
develop
throughout
medicin
lifecycl
mention
harmon
price
reimburs
evalu
critic
support
european
pharmaceut
market
howev
difficult
long
process
implement
due
polit
budgetari
aspect
differ
pharmaceut
market
healthcar
budget
exist
member
state
european
clinic
trial
direct
direct
import
necessari
step
harmon
european
pharmaceut
regul
principl
defin
declar
helsinki
ich
gcp
guidelin
allow
harmon
clinic
practic
protect
clinic
patient
direct
came
forc
rule
perform
clinic
trial
ie
regulatori
procedur
requir
vari
significantli
european
commun
base
differ
regulatori
approach
member
state
new
legisl
promot
harmon
clinic
trial
practic
allow
import
improv
relat
protect
patient
ie
safeti
ethic
concern
reliabl
data
facilit
exchang
inform
dra
howev
despit
progress
import
neg
effect
new
legisl
report
eg
increas
bureaucraci
administr
cost
number
clinic
trial
carri
eu
fallen
recent
year
administr
kkk
pharmaceut
forum
set
european
commiss
threeyear
process
order
find
relev
solut
public
health
consider
regard
pharmaceut
ensur
competit
industri
sustain
nation
health
care
system
specif
forum
analyz
three
key
theme
inform
patient
pharmaceut
price
reimburs
polici
rel
effect
cost
delay
doubl
still
labor
intens
costli
duplic
larg
ident
administr
procedur
multin
clinic
trial
addit
sponsor
spend
great
deal
time
retriev
relev
nation
inform
requir
prepar
custom
applic
without
ad
valu
patient
regul
core
scientif
inform
format
administr
inform
form
differ
inde
problem
larg
pharmaceut
compani
usual
requir
addit
dedic
depart
necessari
resourc
track
differ
nation
requir
follow
mani
parallel
procedur
even
problemat
sme
academ
sponsor
cost
reach
prohibit
level
multipl
parallel
procedur
also
import
impact
dra
inde
avail
resourc
use
multipl
assess
core
inform
differ
member
state
clearli
delay
start
clinic
studi
import
note
duplic
assess
necessarili
increas
qualiti
assess
necessari
specif
expertis
might
alway
readili
avail
member
state
concern
noneffici
use
nation
resourc
without
ad
valu
patient
scienc
implement
problem
partli
due
legal
framework
chosen
harmon
area
direct
clinic
trial
direct
transpos
nation
law
unfortun
case
object
direct
transpos
diverg
nation
legisl
somewhat
miss
harmon
goal
make
multin
trial
difficult
perform
consult
paper
ec
propos
option
improv
situat
one
best
option
continu
harmon
process
would
mean
creat
real
european
system
author
clinic
trial
avoid
duplic
assess
would
avoid
inconsist
assess
conclus
request
encourag
appropri
use
resourc
expertis
sponsor
dra
ensur
common
implement
principl
laid
clinic
trial
direct
vhp
initi
seem
good
first
step
allow
better
implement
eu
clinic
trial
direct
principl
harmon
conduct
clinic
trial
europ
howev
procedur
consid
ultim
solut
resolv
issu
specif
still
parallel
cta
assess
multipl
dra
still
major
differ
countri
regard
time
take
issu
approv
voluntari
cooper
differ
level
interest
respons
countri
current
procedur
remov
specif
nation
requir
differ
nation
assess
cooper
effort
harmon
requir
process
acceler
first
patient
enrol
fpe
europ
resolv
outstand
issu
current
vhp
procedur
revis
becom
real
mrp
assess
conduct
one
refer
member
state
content
dossier
also
fulli
harmon
countri
establish
central
procedur
new
regul
deliv
paneu
approv
would
also
help
certain
type
product
requir
specif
expertis
avail
eu
countri
eg
advanc
therapi
orphan
drug
andor
pediatr
medicin
central
process
cta
would
good
bridg
ema
scientif
advic
process
central
registr
procedur
system
registr
clinic
trial
would
mimic
system
alreadi
place
registr
medicin
product
combin
three
type
procedur
central
procedur
specif
product
biotechnolog
advanc
therapi
mutual
recognit
procedur
multin
clinic
trial
nation
procedur
clinic
trial
involv
one
member
state
reorgan
system
procedur
support
ec
sharehold
involv
clinic
trial
would
util
current
structur
expertis
europ
would
build
experi
acquir
registr
process
would
facilit
patient
access
clinic
trial
new
technolog
within
commun
would
allow
necessari
flexibl
differ
level
review
intervent
trial
eg
small
nation
studi
wellknown
entiti
need
type
evalu
organ
bureaucraci
phase
studi
new
fusion
protein
larg
multin
phase
studi
measur
put
place
ensur
reorgan
would
allow
flexibl
avoid
increas
delay
administr
cost
burden
exampl
recognit
assess
focu
nonrecognit
limit
major
issu
clearli
defin
nonrecognit
assess
anoth
countri
rare
avoid
regular
arbitr
appeal
would
delay
start
clinic
studi
select
refer
member
state
rm
also
defin
mani
paramet
involv
select
ie
expertis
resourc
balanc
workload
countri
etc
final
new
cooper
system
result
simpl
addit
nation
requir
harmon
scientif
assess
would
implement
equal
member
state
next
step
harmon
clinic
trial
europ
would
certainli
benefici
patient
sponsor
clinic
trial
pharmaceut
compani
also
small
entiti
academ
center
dra
propos
alreadi
recommend
european
commiss
recent
adopt
propos
regul
european
parliament
council
clinic
trial
medicin
product
human
use
repeal
direct
commiss
repres
import
step
improv
current
system
howev
process
take
time
implement
nation
interest
need
overcom
final
assess
ethic
committe
also
need
review
improv
clinic
trial
direct
base
concept
one
ethic
committe
opinion
per
member
state
concern
howev
sever
member
state
maintain
decentr
system
singl
ethic
committe
opinion
base
opinion
sever
local
committe
consequ
eu
approxim
ethic
committe
involv
assess
clinic
trial
also
better
harmon
respons
dra
ethic
committe
must
happen
across
europ
agre
ethic
issu
fall
within
respons
member
state
howev
current
practic
need
review
order
smoothli
integr
improv
harmon
system
protect
european
clinic
trial
subject
program
import
make
new
therapi
avail
patient
soon
possibl
handl
european
basi
order
ensur
everi
european
person
wherev
locat
equal
right
access
new
medicin
time
today
differ
access
within
europ
clearli
contrari
overal
european
object
ensur
patient
within
commun
access
qualiti
product
throughout
europ
cours
harmon
requir
procedur
care
implement
avoid
creation
delay
compar
current
situat
pharmacovigil
eu
pharmacovigil
system
demonstr
cooper
harmon
regul
practic
europ
benefici
patient
inde
merg
eu
nation
pharmacovigil
system
one
network
increas
quantiti
datareport
inform
facilit
earli
detect
possibl
safeti
signal
therefor
monitor
product
safeti
unfortun
mediat
issu
franc
shown
eu
pharmacovigil
system
need
improv
fulli
function
topic
one
prioriti
european
network
ongo
implement
new
legisl
ema
member
state
critic
although
mutual
recognit
decentr
procedur
improv
time
challeng
still
exist
principl
procedur
ie
recognit
anoth
countri
assess
alway
respect
procedur
member
state
refus
recogn
countri
assess
feel
recognit
could
potenti
seriou
risk
public
health
unfortun
reason
disagr
vagu
enough
allow
flexibl
member
state
guidelin
releas
clarifi
risk
defin
howev
nation
dra
continu
broad
interpret
potenti
seriou
risk
public
health
trigger
ema
arbitr
ground
fall
specif
categori
addit
specif
issu
discuss
gener
challeng
also
impact
harmon
european
pharmaceut
regul
although
gener
consider
specif
pharmaceut
sector
influenc
establish
implement
pharmaceut
regul
therefor
need
understood
integr
develop
implement
plan
timelin
major
differ
workload
countri
demonstr
big
gap
work
share
certainli
highlight
differ
nation
dra
expertis
resourc
pharmaceut
compani
interest
nation
market
one
complex
difficulti
eu
system
divis
activ
undertaken
nation
level
eg
clinic
trial
respons
scientif
advic
handl
etc
eu
level
eg
equal
scientif
advic
handl
assess
pediatr
investig
plan
etc
requir
mani
commun
infrastructur
eu
nation
player
extern
econom
polit
factor
could
also
influenc
harmon
european
pharmaceut
regul
exampl
modif
european
border
via
new
enlarg
eu
even
eu
leader
agre
mark
paus
discuss
access
countri
turkey
iceland
serbia
still
ongo
addit
possibl
creation
mediterranean
union
desir
past
french
presid
sarkozi
could
also
impact
scope
timelin
next
step
harmon
integr
final
import
see
two
new
function
creat
treati
lisbon
presid
eu
council
high
repres
union
foreign
affair
secur
polici
benefit
eu
first
import
dossier
creation
two
function
global
financi
crisi
global
secur
support
greec
inde
still
handl
polit
leader
major
member
state
ie
franc
germani
clear
european
system
integr
link
histori
model
fulli
fit
everi
harmon
initi
world
everi
situat
need
differ
howev
worth
review
lesson
learn
plu
year
old
initi
first
region
harmon
initi
rhi
overcam
lot
challeng
sinc
develop
strong
region
harmon
pharmaceut
regul
system
success
demonstr
organ
cooper
harmon
facilit
develop
high
standard
practic
specif
european
initi
clearli
demonstr
structur
stepwis
approach
necessari
first
necessari
set
major
principl
direct
second
critic
provid
specif
detail
requir
detail
agre
principl
direct
etc
third
structur
organ
system
need
implement
principl
requir
technic
bodi
need
establish
control
medicin
manag
establish
common
procedur
especi
central
type
europ
key
nation
dra
provid
expertis
resourc
european
bodi
ensur
appropri
avail
resourc
also
ensur
full
adhes
countri
system
adequ
commun
player
system
nation
european
basic
principl
system
place
addit
specif
requir
discuss
system
take
account
particular
need
ie
specif
requir
specif
product
popul
etc
order
coher
system
final
import
monitor
system
regularli
review
extent
system
measur
support
harmon
goal
meet
predefin
object
evolut
environment
impact
ie
global
chang
membership
chang
polit
commit
need
new
requir
due
emerg
problem
etc
also
taken
consider
regul
system
need
care
adjust
ensur
longev
anoth
lesson
learn
europ
import
cooper
success
ensur
effect
function
system
cooper
differ
entiti
system
ema
hma
nation
dra
ec
remain
critic
even
european
pharmaceut
system
complex
well
organ
provis
member
state
highqual
scientif
resourc
evalu
supervis
medicin
critic
factor
success
eu
system
inde
scientif
excel
result
euwid
pool
expertis
data
key
strength
respect
stress
excel
progress
highli
depend
close
collabor
ema
nation
dra
within
context
eu
regulatori
network
particular
valuabl
input
highqual
specialist
expertis
provid
member
state
provis
nation
resourc
coordin
ema
one
featur
eu
regulatori
network
success
also
reli
polit
support
european
harmon
initi
order
support
creation
singl
market
without
polit
commit
therefor
associ
fund
resourc
would
certainli
much
difficult
taken
time
creat
system
recogn
harmon
initi
world
certainli
suffer
lack
polit
commit
especi
harmon
driven
willing
creat
singl
market
ie
integr
model
final
eu
also
clearli
demonstr
better
organ
region
level
extrem
critic
ensur
success
global
harmon
cooper
even
region
work
toward
integr
like
europ
exampl
better
coordin
represent
follow
discuss
region
world
inde
exampl
demonstr
wellorgan
coordin
region
structur
benefici
stakehold
individu
countri
via
better
represent
better
access
intern
activitiesagreementsdecis
region
structur
especi
true
small
countri
less
expertis
resourc
individu
countri
also
benefit
infrastructur
ie
databas
train
program
good
practic
develop
region
level
region
allow
better
represent
interest
europ
power
combin
small
countri
voic
impress
network
expert
intern
cooper
harmon
initi
facilit
commun
reduc
number
contact
seat
intern
level
provid
structur
dissemin
inform
exampl
eu
countri
repres
ich
would
possibl
region
coordin
import
futur
global
initi
ich
project
even
import
manag
worldwid
health
crisi
eg
pandem
influenza
european
coordin
system
implement
region
world
coordin
rapid
effici
commun
inform
action
crisi
help
overal
coordin
situat
exampl
recent
case
pandem
influenza
critic
central
coordin
global
region
ema
use
crisi
manag
plan
allow
europ
respond
rapidli
effici
challeng
outbreak
pandem
influenza
fasttrack
review
vaccin
use
best
expert
monitor
safeti
central
author
pandemicinfluenza
vaccin
antivir
medicin
liais
coordin
activ
critic
partner
includ
ec
eu
member
state
european
agenc
european
centr
diseas
prevent
control
intern
partner
regulatori
bodi
noneu
countri
ensur
time
exchang
inform
coordin
activ
relat
pandem
coordin
commun
relev
inform
public
healthcar
profession
media
activ
would
less
effici
perform
individu
countri
polit
econom
develop
panamerican
region
result
interest
region
econom
integr
sever
subregion
integr
group
emerg
area
sinc
harmon
pharmaceut
regul
technic
standard
compon
econom
integr
degre
progress
area
vari
lot
one
subregion
anoth
even
one
countri
anoth
light
variou
econom
integr
initi
need
becam
evid
entiti
differ
countri
region
could
share
experi
expertis
panamerican
network
drug
regulatori
harmon
pandrh
creat
novemb
region
initi
establish
promot
drug
regulatori
harmon
throughout
panamerican
region
within
framework
nation
subregion
health
polici
continent
forum
supran
entiti
decis
repres
recommend
assimil
subregion
integr
initi
mission
network
promot
harmon
pharmaceut
regul
cover
aspect
qualiti
safeti
efficaci
ration
use
pharmaceut
product
strengthen
nation
regulatori
author
nra
capac
within
region
america
base
right
popul
access
qualiti
medicin
recogn
advanc
scienc
technolog
within
context
nation
subregion
realiti
object
initi
facilit
region
harmon
medicin
drug
requir
guidelin
specif
regulatori
issu
object
achiev
adopt
recommend
implement
nation
region
level
also
support
develop
train
specif
import
topic
howev
initi
also
broader
object
promot
maintain
construct
dialogu
among
dra
pharmaceut
industri
sector
strengthen
dra
region
encourag
converg
drug
regulatori
system
panamerican
region
facilit
technic
cooper
among
countri
collabor
subregion
integr
group
sinc
pandrh
member
ich
global
cooper
group
gcg
membership
broaden
pandrh
role
region
harmon
initi
also
involv
global
harmon
pandrh
provid
way
dissemin
recommend
drug
regulatori
harmon
global
initi
also
ensur
region
specif
challeng
consid
new
global
recommend
discuss
dra
pan
american
health
organ
paho
member
state
region
pharmaceut
industri
associ
latin
american
associ
pharmaceut
industri
alifar
latin
american
feder
pharmaceut
industri
fifarma
academia
consum
group
profession
associ
also
includ
repres
five
subregion
trade
integr
group
within
america
plate
multin
cooper
initi
work
broader
integr
emphasi
polit
andor
financi
interest
andean
commun
commun
establish
cartagena
agreement
current
regroup
four
countri
bolivia
colombia
ecuador
peru
chile
venezuela
also
part
initi
past
other
countri
observ
countri
decid
voluntarili
join
togeth
purpos
achiev
rapid
betterbalanc
autonom
develop
andean
south
american
latin
american
integr
also
creat
free
trade
area
includ
four
current
member
plu
venezuela
integr
initi
broad
regroup
sever
area
one
health
integr
health
govern
andean
health
bodi
coordin
action
aim
improv
healthcar
member
countri
give
prioriti
cooper
mechan
promot
develop
subregion
supran
system
methodolog
action
also
coordin
subregion
region
intern
organ
discuss
includ
mani
topic
develop
pharmaceut
polici
model
evalu
medicin
product
surveil
network
sica
central
american
integr
system
institut
framework
subregion
integr
central
america
latest
step
long
integr
process
region
creat
decemb
sign
tegucigalpa
protocol
state
beliz
costa
rica
el
salvador
guatemala
hondura
nicaragua
panama
initi
also
involv
dominican
republ
associ
state
region
extraregion
observ
mexico
chile
brazil
china
spain
germani
headquart
gener
secretariat
locat
el
salvador
first
object
integr
process
central
america
transform
area
region
peac
liberti
democraci
develop
base
firmli
respect
tutelag
promot
human
right
follow
histori
polit
crisi
conflict
dictatori
rule
region
health
topic
cover
execut
secretariat
council
minist
health
central
america
secomisca
sever
project
discuss
subregion
basi
qualiti
assur
drug
pharmacovigil
system
mercosur
common
market
south
creat
signatur
treati
asuncion
encompass
five
latin
american
countri
argentina
brazil
paraguay
current
suspend
uruguay
venezuela
purpos
agreement
set
common
market
elimin
trade
barrier
among
signatori
parti
mercosur
involv
sever
health
project
implement
gmp
train
joint
inspect
develop
program
vaccin
regul
control
promot
cooper
member
harmon
specif
pharmaceut
regul
subregion
date
mutual
recognit
system
nafta
north
american
free
trade
agreement
implement
januari
remov
barrier
trade
invest
among
us
canada
mexico
object
agreement
establish
procedur
facilit
trade
invest
north
american
contin
trade
liber
posit
impact
creat
one
largest
trade
bloc
world
downsid
also
report
economist
shown
nafta
abl
produc
econom
converg
nafta
minor
impact
harmon
pharmaceut
regul
region
abl
resolv
problem
parallel
import
pharmaceut
product
canada
us
one
major
compon
initi
panamerican
confer
drug
regulatori
harmon
held
everi
two
three
year
confer
highest
instanc
pandrh
network
serv
defin
prioriti
area
harmon
endors
standard
guidelin
recommend
includ
norm
procedur
steer
committe
membership
also
provid
forum
discuss
issu
common
interest
drug
regul
particip
includ
interest
parti
dra
paho
member
state
repres
region
pharmaceut
industri
associ
academia
consum
group
profession
associ
repres
five
subregion
trade
integr
group
within
america
pandrh
confer
took
place
novemb
washington
dc
us
pandrh
offici
creat
pandrh
confer
novemb
also
washington
dc
follow
first
two
confer
subsequ
confer
took
place
review
ongo
activ
work
group
pandrh
mimic
ich
structur
organ
around
three
major
bodi
steer
committe
sc
ensur
oper
manag
initi
confer
compos
seven
member
five
nation
dra
one
subregion
econom
group
two
industri
repres
fifarma
alifar
seven
altern
member
five
differ
nation
dra
one
subregion
econom
group
two
industri
repres
fifarma
lifar
regul
countri
repres
sc
repres
nongovernment
organ
ngo
recogn
pahowho
stakehold
invit
sc
may
also
particip
sc
meet
observ
member
committe
serv
period
four
year
stagger
rotat
maintain
continu
sc
meet
least
twice
everi
year
primari
role
establish
agenda
biennial
panamerican
confer
follow
confer
recommend
establish
monitor
progress
work
group
respons
group
promot
progress
confer
coordin
promot
facilit
monitor
harmon
activ
technic
work
group
specif
form
work
topic
area
identifi
harmon
member
expert
specif
subject
matter
work
group
may
includ
follow
categori
member
main
member
repres
nation
dra
countri
five
subregion
bloc
region
industri
associ
alifar
fifarma
design
secretariat
altern
member
design
attend
meet
instead
princip
member
observ
countri
gener
nomin
particip
nation
dra
observ
retain
vote
right
expert
resourc
need
support
specif
activ
group
expert
resourc
vote
right
nation
dra
countri
repres
work
group
design
focal
point
follow
activ
group
work
group
coordin
altern
chair
coordin
meet
lead
develop
document
report
period
sc
progress
group
gener
first
task
new
work
group
conduct
survey
identifi
differ
regulatori
requir
among
countri
order
prepar
work
plan
group
review
intern
region
andor
nation
recommend
guidelin
prepar
harmon
propos
harmon
standard
develop
work
group
charg
design
train
help
implement
standard
assist
countri
dissemin
educ
concern
new
rule
technic
work
group
meet
conjunct
sc
meet
separ
determin
work
plan
resourc
secretariat
provid
paho
support
initi
technic
administr
monitor
pandrh
websit
serv
focal
point
coordin
dissemin
inform
coordin
activ
aris
recommend
confer
sc
act
liaison
repres
network
global
interregion
harmon
organ
icdra
ich
etc
region
world
need
promot
harmon
pharmaceut
regul
facilit
avail
safe
effect
goodqual
product
therebi
protect
public
health
paho
initi
commun
among
differ
member
pharmaceut
sector
america
order
facilit
commun
among
differ
subregion
bloc
also
countri
alreadi
cover
bloc
organ
region
harmon
first
panamerican
confer
took
place
novemb
washington
dc
us
confer
consid
first
step
toward
establish
pandrh
first
confer
scope
term
harmon
defin
search
common
ground
within
framework
recogn
standard
take
account
exist
differ
polit
health
legisl
realiti
among
countri
region
structur
financi
support
pandrh
also
discuss
first
confer
howev
pandrh
offici
creat
confer
novemb
washington
dc
follow
consult
caraca
venezuela
januari
also
sever
ad
hoc
discuss
meet
meet
america
regul
washington
dc
novemb
region
work
group
bioequival
caraca
januari
region
work
group
gcp
bueno
air
may
second
confer
mission
statement
object
sc
agre
upon
initi
offici
recogn
direct
council
paho
septemb
resolut
approv
council
provid
strong
support
minist
health
member
state
region
pandrh
process
drug
regulatori
harmon
pandrh
confer
v
bueno
air
novemb
regul
govern
pandrh
mission
structur
procedur
origin
creat
confer
slightli
modifi
incorpor
lesson
learn
first
year
establish
harmon
propos
develop
technic
work
group
group
primarili
use
document
basi
develop
region
guidelin
intern
guidelin
includ
ich
select
region
eg
eu
american
subregion
nation
technic
document
also
use
basi
harmon
propos
refer
materi
work
group
agre
draft
harmon
document
post
websit
extern
comment
comment
review
work
group
prepar
final
version
document
present
adopt
confer
sc
conclus
recommend
confer
adopt
consensu
consensu
reach
differ
point
view
record
seventh
meet
june
washington
dc
us
sc
establish
system
phase
stage
harmon
process
system
mimic
ich
process
compos
five
phase
substag
final
technic
document
intend
use
nation
level
subregion
integr
group
implement
discret
countri
member
sc
respons
monitor
implement
subregion
pandrh
also
discuss
strategi
follow
implement
recommend
nation
subregion
level
addit
biennial
pan
american
confer
drug
regulatori
harmon
allow
commun
exchang
pandrh
also
commit
train
interest
parti
includ
regul
industri
train
cover
major
topic
gmp
inspect
gcp
glp
bioequival
etc
initi
prioriti
pandrh
defin
first
confer
gmp
facilit
implement
gmp
region
ultim
develop
mechan
mutual
recognit
inspect
bioequival
gcp
addit
topic
ad
consid
critic
develop
network
protect
public
health
concern
countri
current
area
prioriti
select
pandrh
work
group
establish
sever
recommend
develop
far
base
recommend
exampl
report
basi
discuss
gmp
ich
guidelin
use
build
consensu
gcp
select
topic
technic
chosen
order
ensur
qualiti
safeti
efficaci
product
approv
product
adequ
promot
maintain
work
drug
classif
also
key
ensur
common
languag
facilit
subsequ
harmon
discuss
combat
drug
counterfeit
also
select
major
issu
region
directli
affect
public
health
countri
requir
multidisciplinari
multisectori
crossbord
perspect
final
activ
drug
registr
broader
project
import
ensur
implement
pandrh
recommend
reach
full
harmon
pharmaceut
regul
critic
ultim
develop
collabor
region
subregion
registr
process
system
share
expertis
resourc
countri
group
draft
propos
list
harmon
requir
drug
registr
america
current
list
select
topic
certainli
amend
futur
new
emerg
topic
creat
potenti
health
public
issu
sever
countri
region
need
discuss
resolv
region
level
exampl
work
group
biotechnolog
product
establish
follow
roundtabl
session
pandrh
confer
roundtabl
session
organ
discuss
biotechnolog
product
also
specif
issu
biosimilar
biosimilar
present
clear
risk
patient
well
control
also
major
opportun
increas
access
cheaper
essenti
medicin
well
regul
biotechnologicalbiolog
product
uniqu
technic
challeng
requir
technic
specif
expertis
pandrh
work
topic
collabor
alreadi
releas
recommend
topic
pandrh
scope
harmon
cooper
includ
technic
guidelin
regulatori
process
strengthen
nation
dra
harmon
process
standard
improv
assur
drug
qualiti
adopt
recommend
standard
countri
region
clearli
improv
qualiti
regulatori
system
provid
access
qualiti
safe
effect
drug
moreov
pandrh
play
import
role
global
harmon
pharmaceut
regul
import
link
global
organizationsforum
region
involv
ich
gcg
increas
integr
region
challengesprioritiesvis
develop
intern
standard
implement
intern
standard
region
region
initi
one
difficult
oper
includ
differ
regulatori
system
structur
develop
system
us
fda
undevelop
countri
world
initi
also
take
account
exist
differ
polit
health
legisl
realiti
among
countri
correspond
differ
prioriti
interest
resourc
realiti
creat
difficulti
manag
project
establish
consensu
howev
disadvantag
also
provid
opportun
benefit
develop
dra
help
mentor
less
develop
one
recogn
preexist
asymmetri
region
pandrh
becom
forum
discuss
common
issu
drug
regul
share
knowledg
expertis
countri
involv
actual
develop
propos
particip
decis
adopt
via
confer
promot
collabor
expert
differ
countriessubregion
also
public
sector
author
academia
privat
sector
industri
pandrh
develop
qualiti
recommend
frequent
base
intern
report
recommend
must
note
pandrh
clearli
depend
pahowho
without
support
invest
pandrh
would
certainli
viabl
inde
financi
technic
administr
support
pahowho
repres
import
recognit
outsid
region
critic
follow
reason
multin
initi
one
challeng
pandrh
fund
pandrh
budget
primarili
support
paho
addit
fund
also
come
govern
pharmaceut
industri
intern
organ
registr
fee
train
cours
resourc
involv
countri
limit
paho
provid
secretariat
structur
initi
allow
practic
develop
harmon
project
provid
critic
technic
help
prepar
pandrh
recommend
pandrh
guidelin
document
inde
base
report
confer
pandrh
held
juli
includ
particip
countri
focus
discuss
theme
strengthen
nation
health
regulatori
author
sever
work
group
present
conclus
work
recommend
action
topic
also
address
confer
includ
role
pandrh
coordin
intern
cooper
paho
recognit
nation
regulatori
refer
author
anmatargentina
anvisabrazil
invimacolombia
cecmedcuba
implement
pandrh
guidelin
subregion
innov
activ
nation
dra
surveil
treatment
complianc
confer
conclud
approv
strateg
orient
document
main
recommend
aim
develop
effect
cooper
among
countri
guarante
inter
alia
adopt
implement
differ
technic
document
produc
major
challeng
futur
pandrh
assess
implement
ich
recommend
determin
initi
deliv
promis
countri
form
initi
commit
harmon
dra
countri
region
particip
confer
expect
recommend
guidelin
adopt
implement
individu
countri
incorpor
discuss
subregion
econom
group
howev
may
alway
straightforwardautomat
implement
recommend
may
becom
one
major
challeng
region
initi
member
oblig
implement
harmon
standard
decis
develop
pandrh
strateg
plan
guid
futur
develop
network
ensur
flexibl
scientif
rigor
represent
stakehold
network
certainli
strengthen
initi
gulf
cooper
council
gcc
also
known
cooper
council
arab
state
gulf
ccasg
polit
econom
union
establish
trade
bloc
compris
six
arab
state
arab
gulf
repres
one
wealthiest
countri
group
world
due
extens
oil
ga
reserv
popul
approxim
million
gross
domest
product
gdp
estim
approxim
us
billion
gcc
activ
polit
affair
outsid
territori
due
instabl
middl
east
region
gcc
heavili
involv
diplomat
discuss
solv
differ
conflict
problem
region
ie
iraqiran
war
iraqi
invas
kuwait
iraqi
situat
breakdown
former
regim
israelipalestinian
war
etc
object
avoid
expans
war
elimin
violenc
terror
region
order
support
region
develop
modern
order
achiev
uniti
gcc
promot
coordin
integr
interconnect
member
state
variou
field
one
first
object
gcc
formul
similar
regul
differ
area
includ
health
cooper
coordin
health
respons
council
gcc
health
minist
chm
oversight
gulf
central
committe
drug
registr
gccdr
establish
provid
gulf
state
safe
effect
medicin
reason
cost
committe
work
toward
object
promot
cooper
harmon
among
member
state
initi
cover
prescript
nonprescript
gener
biolog
intern
side
gcc
repres
region
ich
global
cooper
group
gcg
current
gcc
member
six
arab
state
arab
gulf
plate
bahrain
kuwait
oman
qatar
saudi
arabia
unit
arab
emir
uae
iran
iraq
current
exclud
although
nation
coastlin
persian
gulf
yemen
current
part
union
countri
howev
involv
gcc
initi
ie
activ
relat
health
sector
view
futur
access
exampl
yemen
member
council
gcc
health
minist
chm
suprem
council
highest
author
gcc
form
head
member
state
presid
gcc
suprem
council
rotat
conven
annual
regular
session
though
addit
extraordinari
session
may
also
schedul
suprem
council
support
ministeri
council
compos
minist
foreign
affair
member
state
minist
act
behalf
ministeri
council
propos
polici
lay
recommend
coordin
exist
activ
field
resolut
adopt
ministeri
committe
refer
ministeri
council
turn
refer
relev
matter
suprem
council
approv
chm
highest
region
level
author
area
health
consist
health
minist
gcc
member
state
plu
yemen
though
present
member
meet
two
three
day
twice
year
meet
open
regul
gcc
member
state
yemen
via
region
offic
eastern
mediterranean
emro
also
attend
observ
chm
support
execut
board
execut
offic
gener
director
report
execut
offic
locat
riyadh
saudi
arabia
work
level
gccdr
establish
overse
differ
activ
pharmaceut
sector
steer
committe
gccdr
compos
two
member
member
state
includ
yemen
meet
least
four
time
per
year
membership
limit
govern
agenc
dra
execut
offic
also
appoint
two
affili
advisor
nonvot
member
steer
committe
committe
respons
registr
pharmaceut
compani
product
well
prepar
technic
regul
guidelin
develop
new
guidelin
gccdr
steer
committe
use
resourc
member
state
assign
draft
specif
guidelin
either
singl
member
state
sever
member
state
technic
work
group
also
set
help
develop
guidelin
within
execut
offic
perman
gccdr
secretariat
also
creat
support
organ
role
secretariat
facilit
harmon
activ
administr
coordin
commun
also
respons
receiv
review
registr
file
complet
prepar
steer
committe
meet
agenda
gcc
creat
may
unifi
econom
agreement
sign
member
state
novemb
riyadh
saudi
arabia
primari
object
achiev
coordin
integr
interconnect
member
state
field
order
achiev
uniti
integr
plan
develop
detail
first
year
follow
establish
gcc
decemb
gcc
suprem
council
adopt
session
muscat
oman
revis
econom
agreement
acceler
integr
revis
agreement
enhanc
strengthen
econom
tie
increas
harmon
among
member
state
chapter
ii
agreement
defin
specif
area
need
harmon
order
support
gcc
common
market
health
one
area
articl
also
promot
joint
project
adopt
integr
polici
member
state
final
complet
requir
gcc
common
market
declar
decemb
came
forc
januari
launch
common
market
remov
barrier
crosscountri
invest
servic
trade
gcc
cooper
health
sector
began
gcc
health
minist
held
inform
meet
one
held
geneva
may
gener
assembl
cooper
formal
establish
confer
health
minist
arab
countri
gulf
held
first
meet
februari
sinc
call
chm
mention
previous
chm
gccdr
establish
provid
gulf
state
safe
effect
medicin
scope
gccdr
harmon
cooper
effort
pharmaceut
sector
cover
technic
guidelin
regulatori
process
includ
registr
pharmaceut
compani
product
well
good
manufactur
practic
gmp
inspect
oversight
chm
gccdr
steer
committe
respons
select
priorit
topic
assign
develop
guidelin
polici
subsequ
review
approv
result
recommend
new
topic
select
harmon
gccdr
steer
committe
assign
develop
guidelinepolici
either
singl
member
state
sever
member
state
technic
work
group
establish
membership
work
group
discret
assign
member
state
may
includ
regulatori
industri
academ
expert
technic
work
group
meet
regularli
independ
steer
committe
meet
annual
meet
also
held
steer
committe
relev
invit
expert
discuss
polici
regul
ich
guidelin
often
use
refer
materi
develop
gccdr
guidelin
intern
guidelin
includ
recommend
avail
nation
technic
document
guidelin
region
eg
eu
also
use
develop
work
group
draft
guidelin
post
gcc
saudi
food
drug
author
sfda
websit
http
wwwsghorgsa
http
wwwsfdagovsa
enpagesdefaultaspx
also
circul
member
state
comment
end
consult
period
work
group
review
comment
receiv
final
document
propos
adopt
gccdr
steer
committe
follow
adopt
gener
director
execut
offic
submit
guidelin
chm
final
approv
gccdr
steer
committe
member
respons
monitor
implement
adopt
guidelin
countri
countri
report
whether
encount
problem
implement
guidelin
annual
meet
gccdr
activ
evalu
standard
practic
oper
procedur
develop
govern
step
harmon
process
ie
select
priorit
topic
solicit
comment
approv
implement
guidelin
respons
differ
bodi
well
fund
addit
procedur
also
cover
process
place
registr
product
compani
gccdr
financ
member
state
use
establish
quota
contribut
registr
fee
statu
activ
commun
websit
also
present
nation
intern
meet
workshop
confer
although
execut
offic
organ
gmp
train
current
offici
structur
train
program
within
initi
member
state
respons
provid
train
regul
gccdr
initi
work
sever
gener
topic
relat
develop
registr
medicin
product
gmp
gmp
inspect
bioequival
studi
stabil
good
laboratori
practic
glp
clinic
trial
group
also
decid
harmon
practic
postmarket
activ
via
develop
guidelin
postmarket
surveil
cover
counterfeit
problem
pharmacovigil
final
recommend
specif
type
product
biosimilar
sera
antivenom
vaccin
blood
product
also
discuss
guidelin
list
differ
stage
develop
discuss
draft
progress
approv
implement
base
ich
us
fda
andor
ema
recommend
addit
guidelin
gccdr
also
establish
common
central
procedur
registr
pharmaceut
compani
pharmaceut
product
establish
common
system
registr
control
medicin
discuss
first
meet
chm
subject
recurr
topic
discuss
actual
implement
procedur
sinc
implement
registr
medicin
pharmaceut
compani
slowli
transit
nation
gcc
registr
procedur
shown
tabl
procedur
dossier
includ
fee
submit
gccdr
secretariat
countri
review
dossier
forward
recommend
gccdr
steer
committe
committe
resolut
adopt
major
attend
member
vote
four
countri
minimum
must
repres
gmp
inspect
analysi
sampl
accredit
laboratori
also
part
central
procedur
central
approv
countri
must
adopt
central
approv
nation
mention
gccdr
respons
gmp
inspect
also
approv
qualiti
control
laboratori
review
technic
postmarket
surveil
report
central
activ
increas
harmon
integr
pharmaceut
sector
sinc
creation
sign
initi
unifi
econom
agreement
gcc
cooper
mani
differ
field
ie
polit
militari
secur
legal
econom
environ
health
develop
common
polici
support
achiev
full
integr
integr
goal
reemphas
gcc
suprem
council
adopt
revis
econom
agreement
januari
launch
gcc
common
market
mark
import
step
gcc
integr
health
sector
cooper
began
earlier
signatur
unifi
econom
agreement
health
minist
decid
cooper
area
health
sinc
initi
discuss
health
minist
mani
object
fulfil
develop
common
guidelin
cooper
domain
gmp
establish
central
registr
procedur
compani
product
certainli
major
achiev
group
unifi
purchas
drug
ie
common
tender
concept
also
one
import
achiev
chm
ensur
purchas
highqual
regist
product
regist
compani
nation
intern
afford
price
increas
amount
product
purchas
also
ensur
use
product
member
state
inde
import
step
integr
process
creation
common
market
cooper
allow
member
countri
implement
common
drug
polici
adopt
effici
drug
qualiti
surveil
report
system
monitor
efficaci
safeti
regist
drug
recogn
achiev
despit
clear
increas
cooper
gcc
howev
yet
fulli
achiev
goal
uniti
pharmaceut
sector
inde
group
select
integr
model
requir
stronger
tie
countri
exampl
central
registr
procedur
still
involv
nation
review
longer
nation
registr
moreov
approv
deliv
via
central
procedur
still
adopt
member
countri
integr
process
advanc
europ
rapporteur
conduct
review
applic
behalf
group
ec
approv
drug
behalf
european
countri
harmon
regul
via
region
integr
intern
cooper
critic
region
follow
two
reason
first
region
highli
depend
medicin
develop
manufactur
countri
region
even
pharmaceut
compani
intern
region
increas
invest
middl
east
region
region
still
primarili
importori
market
gcc
countri
share
characterist
high
import
pharmaceut
product
pharmaceut
consum
oman
saudi
arabia
respect
import
critic
region
ensur
product
countri
develop
manufactur
follow
accept
standard
requir
second
seen
gccdr
recommend
guidelin
base
intern
work
ie
ich
etc
gcc
therefor
depend
resourc
expertis
intern
organ
develop
stateoftheart
requir
standard
next
step
integr
process
gcc
region
certainli
better
bigger
share
resourc
expertis
challeng
next
step
develop
organ
infrastructur
support
evolut
today
regulatori
expertis
differ
countri
vari
saudi
arabia
leader
region
countri
repres
biggest
pharmaceut
market
region
approxim
pharmaceut
sale
gcc
regulatori
system
recogn
develop
region
regulatori
agenc
saudi
arabia
sfda
employ
peopl
drug
sector
approxim
review
compar
less
gcc
countri
ongo
develop
common
central
system
need
ensur
less
develop
countri
region
benefit
cooper
without
impact
develop
countri
sector
anoth
challeng
group
like
harmon
initi
implement
agreedupon
standard
gcc
need
work
measur
includ
develop
structur
train
program
facilit
implement
followup
recommend
today
southern
african
develop
commun
sadc
compris
southern
africa
state
headquart
locat
gaboron
botswana
sadc
member
state
vari
stage
socioeconom
develop
predominantli
underdevelop
aggreg
gross
domest
product
gdp
approxim
us
billion
south
africa
repres
signific
portion
amount
estim
total
popul
approxim
million
averag
popul
growth
rate
averag
fertil
rate
birth
per
woman
childbear
age
approxim
popul
lack
sustain
access
afford
qualiti
essenti
medicin
averag
life
expect
year
lowest
world
sadc
object
list
articl
sadc
treati
support
region
integr
increas
econom
social
polit
cooper
order
promot
peac
secur
econom
growth
well
popul
protect
environ
natur
resourc
region
achiev
major
broad
object
sadc
launch
project
defin
specif
action
eg
harmon
polici
creation
appropri
institut
mechan
addit
sadc
major
mileston
format
sadc
free
trade
area
fta
set
futur
goal
includ
establish
common
market
creation
singl
currenc
first
achiev
relat
format
sadc
fta
took
place
august
sandton
south
africa
summit
sadc
head
state
govern
acknowledg
region
cooper
critic
address
health
problem
region
sadc
decid
includ
health
program
action
need
harmon
registr
control
medicin
justifi
dispar
legal
system
level
develop
affect
implement
region
bulk
purchas
initi
involv
five
medicin
use
treat
tuberculosi
sadc
health
program
develop
take
account
global
region
health
declar
target
enhanc
region
health
integr
within
legal
enforc
framework
protocol
health
matter
develop
sadc
also
access
intern
network
part
ich
global
cooper
group
gcg
summit
compris
head
andor
govern
sadc
member
state
highest
region
author
therefor
suprem
policymak
institut
sadc
respons
overal
direct
control
commun
structur
function
enumer
articl
sadc
treati
summit
usual
meet
member
state
hold
deputi
chairpersonship
sadc
time
addit
meet
also
held
necessari
main
object
organ
polit
defens
secur
oversight
summit
promot
peac
secur
region
structur
oper
function
organ
regul
protocol
polit
defens
secur
cooper
approv
sign
summit
meet
august
blantyr
malawi
sinc
sadc
leadership
base
troika
system
includ
chair
incom
chair
outgo
chair
sadc
member
state
may
coopt
troika
necessari
troika
repres
summit
annual
meet
make
quick
decis
behalf
sadc
ordinarili
made
summit
meet
system
allow
organ
execut
task
implement
decis
expediti
also
allow
provis
polici
direct
sadc
program
oper
regular
sadc
meet
troika
system
appli
summit
level
also
applic
organ
polit
defens
secur
council
integr
committe
minist
stand
committe
offici
support
sadc
activ
central
secretariat
form
bodi
defin
princip
execut
institut
sadc
respons
coordin
harmon
polici
strategi
acceler
region
integr
respons
manag
sadc
meet
financi
gener
administr
also
involv
strateg
plan
manag
sadc
program
implement
decis
sadc
polici
organ
institut
one
characterist
sadc
emphasi
decentr
institut
arrang
figur
follow
previou
neg
experi
failur
region
discuss
founder
state
agre
member
state
princip
player
formul
implement
polici
decis
therefor
addit
central
sadc
institut
sadc
nation
committe
establish
sadc
treati
sadc
institut
nation
level
present
member
state
includ
key
stakehold
govern
privat
sector
civil
societi
function
provid
nation
feedback
input
region
strategi
plan
ensur
proper
implement
agreedupon
region
strategi
protocol
program
nation
level
southern
african
union
creat
nine
found
member
state
angola
botswana
lesotho
malawi
mozambiqu
swaziland
unit
republ
tanzania
zambia
zimbabw
adopt
lusaka
declar
april
lusaka
zambia
time
allianc
call
southern
african
develop
coordin
confer
main
object
coordin
develop
project
order
lessen
econom
depend
south
africa
apartheid
format
allianc
culmin
long
process
consult
begun
becam
clear
leader
founder
countri
improv
live
standard
would
requir
region
cooper
cooper
direct
initi
toward
polit
liber
region
follow
decolon
polit
independ
southern
african
countri
acknowledg
poverti
econom
problem
region
leader
countri
saw
promot
econom
social
develop
cooperationintegr
next
logic
step
august
windhoek
namibia
new
declar
treati
sign
summit
head
state
govern
articl
treati
gave
legal
basi
organ
promot
coordin
confer
develop
commun
sadc
establish
spearhead
econom
integr
southern
africa
strengthen
integr
process
southern
africa
align
overal
african
continent
effort
promot
closer
econom
relat
defin
treati
sign
establish
african
econom
commun
march
sadc
countri
head
state
govern
met
windhoek
namibia
extraordinari
summit
mani
import
decis
made
trigger
amend
sadc
treati
first
summit
decid
restructur
sadc
institut
establish
sadc
nation
committe
order
facilit
implement
coher
bettercoordin
strategi
extraordinari
summit
also
approv
prepar
risdp
secretariat
purpos
plan
adopt
august
launch
march
clearli
deepen
region
integr
provid
sadc
member
state
consist
comprehens
program
longterm
econom
social
polici
plan
reemphas
major
object
organ
review
socioeconom
indic
challeng
region
analyz
import
domain
integr
process
includ
health
also
provid
object
specif
target
prioriti
intervent
area
specifi
plan
timefram
implement
monitor
import
measur
exampl
health
domain
plan
propos
coordin
harmon
monitor
implement
region
polici
standard
qualif
accredit
system
cooper
health
domain
start
develop
sadc
health
program
three
key
polici
document
import
implement
sadc
health
program
defin
articl
sadc
treati
protocol
establish
area
cooper
protocol
spell
object
scope
institut
mechan
cooper
integr
protocol
approv
summit
regist
secretariat
unit
nation
organ
commiss
african
union
bind
member
state
parti
protocol
protocol
develop
domain
integr
protocol
health
cover
aspect
relat
health
control
major
communic
noncommunic
diseas
health
laboratori
servic
institut
mechan
articl
state
member
state
cooper
harmon
procedur
pharmaceut
qualiti
assur
registr
also
product
procur
distribut
afford
essenti
drug
implement
plan
protocol
defin
priorit
action
facilit
implement
protocol
fix
integr
region
regulatori
process
establish
mutual
recognit
past
present
futur
mileston
line
sadc
health
protocol
pharmaceut
program
develop
address
issu
relat
access
qualiti
medicin
member
state
program
approv
june
sadc
pharmaceut
harmon
initi
cooper
activ
includ
develop
technic
guidelin
polici
relat
registr
control
medicin
across
sadc
member
state
initi
aim
improv
qualiti
safeti
efficaci
medicin
circul
within
region
establish
maintain
region
share
network
system
dra
ich
guidelin
well
guidelin
form
basi
refer
materi
develop
region
guidelin
agreement
adopt
intern
guidelin
whenev
possibl
potenti
topic
harmon
identifi
level
subcommitte
minist
health
often
input
senior
ministeri
health
offici
mra
forum
expert
process
harmon
initi
sadc
secretariat
prepar
submit
decis
agenda
minist
health
within
context
sadc
pharmaceut
busi
plan
releas
june
plan
identifi
prioriti
area
object
major
activ
need
implement
region
nation
level
improv
access
qualiti
afford
essenti
medicin
includ
african
tradit
medicin
exampl
strengthen
regulatori
capac
ensur
fulli
function
dra
place
adequ
enforc
infrastructur
facilit
trade
pharmaceut
within
region
key
strategi
develop
plan
monitor
ongo
evalu
plan
implement
estim
us
million
also
describ
see
figur
explain
relationship
differ
player
plan
oversight
minist
health
group
design
senior
offici
monitor
implement
plan
via
establish
technic
subcommitte
task
team
group
senior
offici
health
depart
member
state
also
support
secretariat
sector
secretariat
respons
support
oper
pharmaceut
harmon
initi
take
place
director
shd
sp
nation
health
ministri
also
play
signific
role
coordin
lead
implement
program
nation
level
report
progress
sadc
nation
committe
final
stakehold
eg
profession
associ
research
institut
dra
etc
also
involv
request
provid
expertis
feedback
specif
action
plan
medicin
regulatori
forum
creat
technic
subcommitte
promot
harmon
enhanc
pharmaceut
regul
region
standalon
committe
made
head
nation
regulatori
bodi
sadc
releas
guidelin
sever
topic
guidelin
regul
follow
gener
area
conduct
clinic
trial
guidelin
provid
framework
inform
submit
review
process
etc
refer
entir
ich
gcp
replac
subimplement
ich
gcp
registr
medicin
guidelin
submit
applic
registr
medicin
releas
applic
form
also
avail
good
manufactur
practic
pharmacovigil
basic
rule
provid
advertis
recal
registr
nutrit
supplement
vaccin
tradit
medicin
bioavail
bioequival
stabil
studi
importexport
emphas
gmp
guidelin
base
crossrefer
ich
guidelin
recommend
intern
bodi
provid
much
technic
assist
sadc
initi
exist
nation
rule
requir
also
use
eg
gcp
requir
south
africa
guidelin
also
develop
cover
follow
topic
specif
interest
region
pharmaceut
wholesal
hiv
vaccin
clinic
trial
donat
pharmaceut
product
note
sadc
effort
pharmaceut
area
includ
african
tradit
medicin
product
import
part
healthcar
environ
countri
one
cooper
project
establish
region
databank
tradit
medicin
medicin
plant
develop
region
polici
legal
framework
practic
tradit
medicin
final
sadc
tri
establish
joint
procur
system
harmon
standard
treatment
guidelineslist
among
countri
two
action
facilit
use
medicin
within
region
therefor
allow
harmon
pharmaceut
environ
sinc
incept
april
sadc
demonstr
region
cooper
integr
possibl
use
southern
africa
one
foremost
achiev
sadc
put
place
region
program
sadc
programm
action
numer
project
cover
cooper
variou
econom
sector
format
sadc
fta
august
import
first
step
ongo
integr
process
overal
ultim
goal
sadc
integr
ambiti
plan
present
level
cooper
vari
area
area
cooper
aim
coordin
nation
activ
polici
other
cooper
goe
toward
real
integr
exampl
foreign
polici
main
object
coordin
cooper
term
trade
econom
polici
tighter
coordin
progress
view
one
day
establish
common
market
common
regulatori
institut
health
pharmaceut
domain
mani
harmon
project
establish
despit
challeng
inde
recogn
sadc
pharmaceut
busi
plan
region
mani
weak
weak
regulatori
system
lead
mani
unregist
product
lack
adequ
capac
train
personnel
outdat
medicin
intellectu
properti
law
noncompli
gmp
lead
inadequ
avail
medicin
poor
inconsist
qualiti
medicin
member
state
even
polit
difficult
author
region
resolv
situat
confront
two
major
problem
manag
major
diseas
hivaid
tuberculosi
malaria
etc
lack
adequ
resourc
financ
support
health
initi
combin
two
problem
common
develop
countri
slow
develop
health
activ
effort
resourc
domain
health
right
dedic
prevent
treatment
major
public
health
concern
activ
develop
adequ
regulatori
function
framework
develop
harmon
pharmaceut
requir
therefor
neg
impact
even
sadc
member
state
nation
medicin
polici
legisl
regul
place
polici
draft
document
mani
year
year
number
law
date
back
even
clear
polici
legisl
need
revis
includ
recent
develop
meet
current
standard
public
health
medicin
revis
updat
would
help
implement
sadc
harmon
recommend
guidelin
howev
despit
numer
weak
problem
region
face
sadc
abl
promot
cooper
member
state
order
improv
access
qualiti
medicin
sever
major
accomplish
develop
harmon
pharmaceut
requir
develop
pharmaceut
guidelin
registr
control
medicin
establish
pharmaceut
busi
plan
establish
medicin
regulatori
forum
moreov
sadc
analyz
pharmaceut
busi
plan
weak
opportun
overal
prioriti
pharmaceut
domain
ie
regul
control
medicin
road
map
includ
assess
strengthen
dra
work
perform
collabor
combat
spread
counterfeit
medicin
develop
region
train
program
establish
accredit
qualiti
control
qc
laboratori
support
road
map
area
harmon
structur
sadc
institut
certainli
modifi
done
past
order
success
sadc
also
need
continu
work
extern
organ
support
technic
assist
ich
continu
critic
commun
cooper
group
region
eg
new
partnership
africa
develop
nepad
also
necessari
coordin
effort
entir
contin
share
avail
resourc
financi
support
expertis
especi
import
sadc
member
also
part
african
subregion
initi
final
next
import
phase
sadc
implement
agreedupon
standard
recommend
plan
eg
propos
action
strengthen
nation
dra
capac
implement
harmon
sadc
guidelin
manag
implement
challeng
harmon
initi
especi
true
region
due
weak
carri
countri
lack
resourc
financ
howev
lack
appropri
regul
countri
may
paradox
becom
opportun
coordin
develop
regul
base
ich
recommend
view
priori
harmon
moreov
interest
note
sadc
structur
present
specif
found
harmon
initi
addit
standard
central
bodi
ie
summit
council
minist
committe
senior
offici
central
secretariat
etc
sadc
establish
nation
committe
nation
sadc
contact
point
could
becom
critic
implement
phase
unusu
model
may
also
use
worldwid
initi
associ
southeast
asian
nation
asean
establish
broad
object
aim
purpos
associ
state
declar
includ
acceler
econom
growth
social
progress
cultur
develop
region
joint
endeavor
spirit
equal
partnership
order
strengthen
foundat
prosper
peac
commun
southeast
asian
nation
promot
region
peac
stabil
abid
respect
justic
rule
law
relationship
among
countri
region
promot
activ
collabor
mutual
assist
matter
common
interest
econom
social
cultur
technic
scientif
administr
field
provid
assist
form
train
research
facil
educ
profession
technic
administr
sphere
maintain
close
benefici
cooper
exist
intern
region
organ
similar
aim
purpos
explor
avenu
even
closer
cooper
among
asean
region
popul
approxim
million
total
area
million
squar
kilomet
combin
gross
domest
product
gdp
us
billion
total
trade
us
billion
estim
annual
pharmaceut
import
export
us
billion
among
three
pillar
asean
commun
politicalsecur
econom
sociocultur
agre
upon
asean
leader
declar
asean
concord
ii
sign
octob
bali
indonesia
establish
singl
market
import
goal
object
allow
creation
stabl
prosper
asean
econom
region
free
flow
good
servic
invest
order
reduc
poverti
socioeconom
dispar
asean
summit
januari
leader
affirm
strong
commit
acceler
establish
asean
econom
commun
aec
sign
cebu
declar
acceler
establish
asean
commun
move
toward
ultim
goal
asean
launch
asean
free
trade
area
afta
defin
prioriti
eg
healthcar
region
integr
acceler
one
basic
criteria
support
afta
ultim
singl
market
harmon
standard
regul
therefor
recogn
import
harmon
standard
facilit
liber
trade
invest
region
asean
establish
asean
consult
committe
standard
qualiti
accsq
harmon
nation
standard
intern
standard
implement
mutual
recognit
arrang
conform
assess
achiev
end
goal
one
standard
one
test
accept
everywher
accsq
monitor
harmon
standard
regul
mani
differ
area
ie
pharmaceut
product
also
cosmet
medic
devic
food
electr
electron
equip
automot
product
woodbas
product
etc
harmon
pharmaceut
area
coordin
pharmaceut
product
work
group
ppwg
object
group
harmon
technic
procedur
requir
applic
asean
pharmaceut
industri
region
take
account
region
intern
develop
pharmaceut
sinc
asean
member
ich
global
cooper
group
gcg
membership
help
asean
becom
import
compon
global
harmon
process
constitut
way
dissemin
ich
recommend
drug
regulatori
harmon
also
ensur
asean
specif
challeng
consid
new
global
recommend
discuss
highest
decisionmak
bodi
asean
meet
asean
head
state
govern
asean
summit
conven
annual
addit
ministeri
meet
also
held
regularli
committe
senior
offici
technic
work
group
task
forc
creat
support
asean
summit
ministeri
meet
conduct
agre
asean
activ
accsq
establish
coordin
harmon
nation
standard
intern
standard
committe
report
asean
senior
econom
offici
meet
seom
supervis
asean
econom
minist
aem
ppwg
supervis
accsq
creat
coordin
harmon
activ
relat
pharmaceut
area
scope
activ
ppwg
includ
follow
exchang
inform
exist
pharmaceut
requir
regul
implement
asean
member
countri
review
prepar
compar
studi
requir
regul
review
harmon
procedur
regulatori
system
current
implement
other
region
order
develop
harmon
standard
regul
procedur
region
specif
topic
select
harmon
ppwg
set
ad
hoc
committe
assign
one
member
state
project
leader
membership
ad
hoc
committe
voluntari
basi
core
member
ppwg
chair
cochair
repres
dra
asean
member
state
repres
asean
secretariat
well
repres
pharmaceut
industri
associ
deleg
addit
member
state
also
particip
ppwg
meet
observ
addit
accsq
member
invit
expert
may
attend
annual
ppwg
meet
ad
hoc
committe
meet
prior
ppwg
meet
addit
ppwg
oper
selfsponsorship
ie
member
state
respons
fund
travel
host
meet
also
contribut
process
past
ppwg
activ
support
asean
secretariat
establish
feburari
coordin
asean
branch
implement
asean
project
activ
mandat
asean
secretarygener
enlarg
initi
advis
coordin
implement
agreedupon
asean
activ
final
note
anoth
work
group
asean
work
group
pharmaceut
develop
awgpd
supervis
asean
health
minist
meet
also
particip
region
harmon
pharmaceut
regul
activ
tradit
medicin
good
manufactur
practic
gmp
good
clinic
practic
gcp
counterfeit
drug
pharmacovigil
asean
offici
establish
signatur
declar
bangkok
declar
august
bangkok
thailand
five
origin
member
countri
ie
indonesia
malaysia
philippin
singapor
thailand
brunei
darussalam
join
januari
vietnam
juli
lao
myanmar
juli
cambodia
april
accsq
form
facilit
complement
afta
effort
toward
specif
harmon
pharmaceut
regul
initi
accsq
sinc
pharmaceut
product
work
group
establish
septemb
kuala
lumpur
malaysia
follow
decis
accsq
meet
march
manila
inaugur
meet
septemb
ppwg
formul
term
refer
set
work
plan
ie
goal
strategi
activ
expect
output
statu
subsequ
meet
focus
statu
review
ongo
harmon
activ
discuss
adopt
final
recommend
asean
also
decid
develop
relationship
countri
develop
bilater
agreement
number
countri
canada
india
us
russian
feder
pakistan
etc
region
europ
gcc
sadc
andean
group
mercosur
intern
organ
unit
nation
unesco
one
import
develop
creation
asean
plu
three
cooper
promot
east
asia
region
cooper
began
decemb
conven
inform
summit
among
asean
leader
counterpart
east
asia
name
china
japan
republ
korea
formal
issuanc
joint
statement
east
asia
cooper
asean
plu
three
summit
manila
philippin
asean
plu
three
leader
express
confid
strengthen
deepen
east
asia
cooper
variou
level
area
particularli
econom
social
polit
field
public
health
harmon
standard
topic
discuss
among
other
sever
bilater
econom
arrang
alreadi
sign
may
basi
possibl
establish
east
asia
free
trade
area
futur
novemb
two
import
document
ratifi
first
asean
charter
spell
principl
member
state
adher
sign
legal
framework
enter
forc
decemb
serv
firm
foundat
formul
asean
commun
provid
legal
statu
institut
framework
asean
also
codifi
asean
norm
rule
valu
set
clear
target
asean
present
account
complianc
second
asean
leader
also
sign
declar
asean
econom
commun
aec
blueprint
provid
elimin
form
nontariff
measur
market
access
limit
order
transform
asean
singl
market
draft
guidelin
develop
ad
hoc
committe
review
discuss
adopt
consensu
ppwg
meet
standard
endors
accsq
ppwg
harmon
process
includ
follow
step
exchang
review
inform
exist
pharmaceut
requir
regul
member
state
compar
requir
regul
identifi
key
area
harmon
creat
ad
hoc
committe
assign
lead
countri
prepar
draft
harmon
product
time
base
guidelin
recommend
alreadi
avail
one
asean
countri
intern
anoth
region
circul
draft
member
state
comment
consolid
comment
revis
draft
discuss
adopt
consensu
agreement
draft
ppwg
endors
document
recommend
accsq
dissemin
adopt
document
via
asean
websit
seminar
meet
compulsori
implement
recommend
member
state
order
organ
coordin
monitor
implement
agreedupon
recommend
guidelin
ppwg
set
specif
task
forc
work
group
focu
mutual
recognit
arrang
mra
implement
develop
standard
oper
procedur
sop
plan
action
also
assess
statu
implement
requir
ie
adopt
nation
system
order
develop
appropri
train
govern
industri
increas
understand
asean
guidelin
fill
gap
among
member
state
first
project
asean
ppwg
compar
exist
product
registr
requir
pharmaceut
asean
member
countri
order
help
defin
key
area
harmon
report
final
follow
assess
group
develop
asean
common
technic
requir
actr
pharmaceut
product
registr
asean
region
requir
sometim
base
exist
nation
requir
guidelin
recommend
region
eg
asean
guidelin
conduct
bioavail
bioequival
studi
creat
emacpmp
note
guidanc
asean
actr
develop
via
adopt
modif
ich
guidelin
cover
qualiti
nonclin
clinic
aspect
alreadi
develop
ich
label
requir
administr
data
ie
certif
pharmaceut
product
cpp
letter
author
applic
form
etc
glossari
also
discuss
final
actr
endors
accsq
meet
march
guidelin
actr
eg
process
valid
stabil
also
develop
group
also
develop
asean
common
technic
dossier
actd
pharmaceut
product
registr
like
ich
ctd
initi
reduc
time
resourc
need
compil
applic
registr
differ
countri
regulatori
review
commun
applic
also
facilit
standard
document
common
element
actd
base
ich
ctd
organ
four
part
overview
summari
includ
begin
relev
part
ii
iii
instead
group
separ
section
modul
ich
ctd
part
activ
also
conduct
area
gmp
april
asean
econom
minist
asean
summit
relat
summit
pattaya
thailand
sign
asean
mra
gmp
inspect
manufactur
medicin
arrang
establish
mutual
recognit
gmp
certif
andor
inspect
report
issu
inspect
bodi
use
basi
regulatori
action
grant
licens
support
postmarket
assess
conform
product
ppwg
also
work
bioavailabilitybioequival
studi
report
format
postmarket
alert
system
object
asean
postmarket
alert
system
share
inform
relat
defect
unsaf
medicin
also
cosmet
health
supplement
tradit
medicin
pilot
project
launch
april
adopt
ppwg
februari
two
major
accomplish
ppwg
actd
atcr
actd
common
format
market
author
applic
dossier
atcr
set
written
materi
intend
guid
applic
prepar
applic
dossier
manner
consist
expect
asean
dra
seri
guidelin
implement
atcr
final
asean
recommend
strictli
follow
ich
guidelin
recommend
inde
asean
good
exampl
influenc
ich
outsid
ich
region
integr
implement
ich
standard
outsid
ich
frontier
beyond
harmon
technic
aspect
pharmaceut
product
registr
need
continu
ultim
goal
asean
ppwg
clearli
implement
system
countri
fulli
cooper
enhanc
mutual
regulatori
capac
resourc
ongo
challeng
pose
global
economi
particular
huge
econom
growth
china
india
may
specif
impact
region
associ
countri
clearli
commit
full
integr
goal
establish
asean
econom
commun
move
toward
european
commun
model
ultim
step
pharmaceut
harmon
process
certainli
develop
asean
pharmaceut
direct
develop
panasean
registr
process
central
procedur
establish
asean
regulatori
agenc
full
implement
supran
system
take
time
possibl
asean
develop
common
legisl
structur
ie
commiss
parliament
etc
europ
harmon
pharmaceut
regul
howev
continu
organ
place
next
logic
step
creation
mra
procedur
inde
type
procedur
bind
countri
therefor
requir
common
legisl
request
facilit
bodi
supran
evalu
agenc
procedur
would
similar
old
multist
procedur
europ
establish
first
step
toward
creation
system
know
today
asean
also
commit
increas
relat
extern
partner
creation
asean
plu
three
cooper
may
inde
promot
harmon
pharmaceut
regul
much
broader
asia
region
outsid
region
asean
ppwg
clearli
want
increas
relationship
cooper
region
organ
also
intern
bodi
ie
un
ich
develop
outsid
current
framework
could
inde
strengthen
initi
increas
exposur
intern
basi
therefor
allow
organ
play
pivot
role
intern
commun
asiapacif
econom
cooper
apec
forum
establish
facilit
econom
growth
cooper
trade
invest
asiapacif
region
region
account
approxim
world
popul
approxim
world
gross
domest
product
gdp
world
trade
sinc
creation
intergovernment
group
work
reduc
tariff
trade
barrier
across
asiapacif
region
order
liber
trade
invest
facilit
busi
within
region
apec
also
work
creat
environ
safe
effici
movement
good
servic
peopl
across
border
region
polici
align
econom
technic
cooper
support
three
pillar
ie
trade
invest
liber
busi
facilit
econom
technic
cooper
apec
activ
broad
rang
topic
fisheri
agricultur
tourism
terror
financ
intellectu
properti
broad
rang
topic
hundr
specif
project
develop
reflect
complex
factor
issu
relat
econom
develop
growth
pursuit
open
trade
invest
region
sever
topic
influenc
health
pharmaceut
sector
intellectu
properti
scienc
technolog
two
specif
focu
area
health
topic
manag
health
work
group
focus
mainli
prevent
manag
infecti
diseas
natur
occur
due
bioterror
region
work
group
involv
discuss
relat
pharmaceut
regul
life
scienc
topic
manag
life
scienc
innov
forum
lsif
address
key
challeng
health
pharmaceut
sector
order
creat
right
polici
environ
life
scienc
innov
harmon
standard
region
intern
cooper
two
tool
use
achiev
object
member
ich
global
cooper
group
gcg
sinc
apec
lsif
promot
implement
ich
guidelin
workshop
also
keep
ich
inform
statu
differ
ongo
initi
region
apec
member
economi
broad
asiapacif
region
span
four
contin
plate
member
apec
recogn
strong
economi
harmon
initi
built
govern
alon
partnership
govern
key
stakehold
includ
industri
academia
research
institut
interest
group
within
commun
therefor
apec
activ
involv
key
stakehold
work
forum
work
level
repres
privat
sector
invit
join
mani
apec
work
expert
group
process
provid
import
opportun
industri
provid
direct
input
apec
ongo
work
apec
offici
observ
associ
southeast
asian
nation
asean
secretariat
one
observ
particip
apec
meet
full
access
document
inform
apec
oper
cooper
multilater
econom
trade
forum
apec
polici
direct
provid
apec
leader
member
economi
life
scienc
innov
forum
lsif
committe
trade
invest
tripartit
forum
involv
repres
govern
academia
also
industri
bring
togeth
scientif
health
trade
econom
financi
consider
creat
right
polici
environ
life
scienc
innov
apec
activ
support
apec
secretariat
base
singapor
oper
core
support
mechan
apec
process
provid
coordin
technic
advisori
support
well
inform
manag
commun
public
outreach
servic
idea
apec
cooper
enhanc
econom
growth
prosper
strengthen
asiapacif
commun
first
publicli
mention
former
prime
minist
australia
bob
hawk
speech
seoul
south
korea
januari
later
year
asiapacif
economi
met
canberra
australia
establish
apec
novemb
apec
vision
reiter
apec
econom
leader
meet
bogor
indonesia
meet
econom
leader
adopt
refer
bogor
goal
goal
free
open
trade
invest
asiapacif
later
base
recognit
grow
interdepend
econom
divers
region
compris
develop
newli
industri
develop
economi
due
heterogen
region
agre
pace
implement
would
take
account
differ
level
econom
develop
among
apec
economi
framework
meet
bogor
goal
refer
osaka
action
agenda
adopt
action
plan
focus
three
key
area
trade
invest
liber
busi
facilit
econom
technic
cooper
follow
first
action
plan
sever
plan
adopt
year
support
implement
bogor
goal
specif
topic
climat
chang
sever
acut
respiratori
syndrom
sar
also
discuss
recogn
global
financi
crisi
one
seriou
econom
challeng
ever
face
leader
highlight
import
reduc
gap
develop
develop
member
meet
includ
discuss
relat
region
econom
challeng
implement
structur
reform
food
suppli
price
social
dimens
global
enhanc
human
secur
region
problem
climat
chang
lsif
health
work
group
held
first
joint
meet
march
washington
dc
us
explor
possibl
area
cooper
meet
follow
recommend
apec
senior
offici
endors
new
term
refer
steer
committe
econom
technic
cooper
agre
role
oper
health
work
group
would
review
view
merg
disband
reorient
bodi
lsif
lead
activ
relat
regulatori
converg
pharmaceut
area
within
asiapacif
region
apec
lsif
recogn
benefit
converg
relat
pharmaceut
standard
within
region
achiev
goal
two
group
reli
region
global
harmon
initi
inde
lsif
work
toward
adopt
implement
exist
harmon
intern
guidanc
regulatori
best
practic
also
provid
abil
access
fund
advanc
project
unlik
asean
object
proactiv
develop
specif
region
harmon
guidanc
practic
line
overal
apec
goal
facilit
cooper
trade
region
oper
basi
nonbind
commit
open
dialogu
alreadi
mention
apec
treati
oblig
requir
particip
plan
integr
unlik
asean
follow
integr
model
like
europ
recogn
specif
context
object
lsif
regulatori
converg
gradual
align
time
member
economi
distinct
regulatori
harmon
regulatori
converg
typic
involv
requir
activ
harmon
regul
would
unrealist
within
apec
environ
object
prioriti
lsif
list
strateg
plan
approv
apec
minist
broad
plan
includ
recommend
four
differ
sector
research
develop
manufactur
market
health
servic
goal
develop
recommend
would
contribut
effici
effect
coordin
polici
approach
support
innov
health
region
recommend
applic
mani
differ
area
legal
financ
scientif
regulatori
infrastructur
etc
one
recommend
strateg
plan
follow
harmon
standard
life
scienc
product
servic
mechan
collabor
exchang
inform
among
economi
recogn
critic
element
principl
review
polici
standard
regulatori
mechan
intern
best
practic
order
move
toward
region
converg
object
also
achiev
close
collabor
facilit
use
intern
standard
global
best
practic
collabor
outsid
bodi
ich
gcg
lsif
activ
sponsor
seri
workshop
anticounterfeit
ich
qualiti
guidanc
clinic
trial
good
clinic
practic
gcp
inspect
howev
recogn
lsif
use
full
potenti
promot
regulatori
converg
cooper
compar
rhi
miss
engag
regul
appropri
industri
peopl
equat
togeth
lack
focus
strateg
framework
multiyear
plan
medic
product
acknowledg
lack
strateg
effect
approach
lsif
decid
react
strengthen
organ
june
lsif
took
import
step
toward
harmon
establish
seoul
south
korea
apec
harmon
center
ahc
follow
propos
south
korea
august
apec
lsif
vi
lima
peru
endors
apec
leader
novemb
joint
ministeri
statement
lsif
organ
center
structur
includ
director
secretariat
advisori
board
lsif
expert
also
websit
wwwapecahcorg
organ
includ
repres
govern
industri
academia
mandat
provid
platform
address
solv
prioriti
concern
apec
member
regulatori
converg
follow
establish
ahc
sever
workshop
took
place
gener
focus
region
regulatori
converg
also
discuss
specif
problem
multiregion
clinic
trial
biosimilar
concept
purpos
workshop
allow
govern
regul
academ
pharmaceut
compani
discuss
exchang
inform
view
harmon
standard
fund
support
ahc
allow
deliveri
dozen
workshop
sinc
june
addit
ahc
apec
also
decid
establish
regulatori
harmon
steer
committe
rhsc
within
lsif
structur
strateg
coordin
regulatori
converg
region
rhsc
brought
togeth
senior
offici
regulatori
author
repres
industri
coalit
committe
provid
leadership
direct
regulatori
prioriti
inaugur
meet
seoul
south
korea
june
rhsc
discuss
final
term
refer
start
identifi
prioriti
project
sinc
rhsc
initi
sever
project
develop
strateg
framework
regulatori
converg
medic
product
coordin
activ
sinc
creation
apec
ahc
rhsc
consider
progress
made
design
develop
implement
strateg
coordin
sustain
approach
includ
strateg
framework
creation
prioriti
work
area
pwa
associ
roadmap
defin
overal
strategi
achiev
ultim
goal
greater
regulatori
converg
area
medic
product
project
activ
undertaken
must
support
roadmap
turn
move
apec
closer
goal
betterstructur
organ
move
away
individu
uncoordin
activ
workshop
direct
coordin
approach
parti
individu
posit
effect
chang
commit
resourc
workshop
organ
fund
ahc
led
rhsc
membership
tie
direct
roadmap
strateg
framework
repres
collect
effort
commit
mani
economi
workshop
serv
diagnost
issu
challeng
opportun
associ
particular
area
focu
recommend
come
back
rhsc
consider
workshop
champion
regul
variou
apec
economi
exampl
us
medic
product
qualiti
suppli
chain
integr
korea
biotechnolog
product
pharmacovigil
singapor
cellularand
tissuebas
therapi
chines
taipei
good
review
practic
combin
product
thailand
gcp
inspect
final
organ
partner
region
intern
player
effort
promot
synergi
effect
use
resourc
good
exampl
suppli
chain
roadmap
global
issu
requir
global
coordin
approach
rhsc
roadmap
implement
direct
oversight
committe
includ
ema
edqm
dra
nigeria
apec
take
account
complement
like
initi
serv
catalyst
global
action
apec
proactiv
develop
guidanc
harmon
standard
requir
object
promot
converg
via
dissemin
intern
harmon
inform
recommend
ie
ich
guidelin
achiev
goal
group
develop
fund
sever
project
lsif
releas
enabl
invest
checklist
voluntari
guidanc
tool
member
economi
assess
improv
innov
life
scienc
sector
invest
opportun
one
six
principl
cover
checklist
effici
intern
harmon
regulatori
system
principl
lsif
promot
develop
implement
focus
effort
harmon
toward
intern
standard
recogn
intern
organ
ie
ich
moreov
support
object
lsif
also
propos
develop
follow
regulatori
framework
transpar
predict
sciencebas
allow
quick
introduct
new
innov
product
effici
clinic
trial
regulatori
system
focus
safeti
efficaci
ethic
standard
adequ
number
level
train
program
regulatori
personnel
public
propos
regul
stakehold
comment
taken
account
law
provid
stakehold
consult
throughout
regulatori
draft
review
process
particip
intern
joint
clinic
trial
perform
metric
also
defin
assess
implement
recommend
final
principl
checklist
also
support
cooper
converg
assess
resourc
exchang
program
intellectu
properti
right
interag
coordin
life
scienc
polici
regul
addit
enabl
invest
checklist
lsif
also
develop
project
focus
specif
topic
interest
clinic
trial
area
clinic
trial
select
one
lsif
prioriti
strateg
plan
assess
improv
clinic
trial
system
regul
countri
also
recommend
lsif
enabl
invest
checklist
goal
put
place
effect
regul
infrastructur
harmon
regulatori
practic
polici
accord
intern
best
practic
standard
activ
includ
work
regulatori
process
framework
incorpor
interag
review
new
polici
guidanc
regul
implement
promot
good
clinic
practic
gcp
good
manufactur
practic
gmp
protect
enforc
intellectu
properti
establish
clinic
trial
registri
implement
ich
recommend
implement
goal
strengthen
dra
capac
harmon
practic
first
workshop
review
drug
develop
clinic
trial
held
march
sever
addit
workshop
concern
clinic
trial
gcp
includ
clinic
research
inspect
sinc
set
subject
first
workshop
organ
ahc
focus
opportun
challeng
multiregion
clinic
trial
workshop
serv
refin
recommend
showcas
chinajapankorea
tripartit
research
initi
explor
possibl
ethnic
differ
three
countri
result
workshop
two
roadmap
develop
one
gcp
inspect
leadership
thailand
one
multiregion
clinic
trial
leadership
japan
focu
address
gap
need
address
institut
regulatori
author
date
counterfeit
medicin
anoth
area
interest
lsif
increas
counterfeit
medicin
region
seri
seminar
workshop
organ
sinc
januari
examin
way
combat
problem
lsif
also
develop
anticounterfeit
medic
product
action
plan
object
plan
share
best
practic
detect
prevent
counterfeit
dra
industri
profession
organ
system
reduc
threat
occurr
counterfeit
medicin
final
import
note
apec
also
promot
capac
build
member
object
met
organ
workshop
train
cours
seminar
enabl
peopl
busi
govern
depart
improv
skill
knowledg
primari
focu
apec
clearli
economi
object
center
facilit
trade
busi
member
economi
integr
plan
asiapacif
region
consist
one
econom
dynam
region
world
sinc
establish
apec
total
amount
trade
grown
significantli
apec
work
three
main
pillar
activ
help
drive
econom
growth
apec
conduct
assess
determin
progress
made
bogor
goal
free
open
trade
invest
result
posit
show
member
economi
taken
concert
action
progress
wide
array
econom
trade
invest
social
area
averag
tariff
region
reduc
approxim
nontariff
barrier
also
reduc
thank
apec
work
trade
facilit
progress
apec
toward
bogor
goal
contribut
fivefold
increas
member
total
trade
good
servic
us
trillion
us
trillion
final
activ
contribut
real
benefit
peopl
across
entir
asiapacif
region
span
year
poverti
reduc
poverti
level
measur
calcul
popul
live
less
us
day
apec
repres
larg
region
approxim
world
popul
obvious
advantag
face
challeng
global
howev
size
magnitud
also
disadvantag
term
manag
inde
region
heterogen
countri
two
extrem
develop
spectrum
ie
develop
undevelop
countri
due
disadvantag
heterogen
larg
region
difficult
adopt
treati
impos
oblig
member
reason
apec
oper
basi
nonbind
commit
countri
choic
implement
decis
implement
econom
measur
ie
reduct
tax
trade
barrier
increas
trade
member
possibl
sinc
quickli
benefit
member
howev
lack
treati
oblig
member
sometim
challeng
drastic
longterm
reform
ie
harmon
standard
member
economi
differ
prioriti
divers
apec
region
mean
member
economi
gradual
move
closer
togeth
requir
approach
everyon
implement
measur
time
capac
local
realiti
must
taken
account
though
technic
cooper
part
apec
object
ie
apec
involv
specif
topic
climat
chang
second
prioriti
behind
econom
develop
health
topic
manag
health
work
group
life
scienc
innov
forum
clearli
fund
topic
impact
economi
state
apec
websit
life
scienc
innov
critic
growth
socioeconom
develop
healthi
peopl
produc
healthi
economi
effici
effect
deliveri
patient
focus
product
servic
improv
popul
longev
well
product
econom
potenti
howev
even
challeng
import
posit
outcom
note
term
regulatori
converg
pharmaceut
area
inde
organ
support
converg
via
fund
project
workshop
lsif
abl
focu
effort
project
impact
member
economi
develop
develop
coordin
multicountri
clinic
trial
implement
gcp
qualiti
medicin
counterfeit
medicin
problem
emerg
biosimilar
lsif
also
creat
forum
allow
exchang
inform
differ
countri
player
regul
industri
academia
commun
dissemin
harmon
standard
import
essenti
develop
standard
acknowledg
lack
strateg
coordin
apec
lsif
decid
better
organ
activ
first
establish
ahc
facilit
exchang
inform
creation
network
second
creat
rhsc
strateg
coordin
region
converg
sinc
revis
lsif
structur
creation
two
support
bodi
signific
progress
made
apec
sinc
declar
harmon
achiev
converg
regulatori
approv
procedur
target
support
goal
mani
import
project
initi
critic
topic
product
qualiti
suppli
chain
integr
good
review
practic
gcp
inspect
pharmacovigil
biotechnolog
product
etc
chang
project
today
repres
great
promis
region
tool
develop
could
also
support
global
cooper
converg
challeng
implement
plan
continu
coordin
project
order
achiev
desir
object
recent
establish
rhsc
regulatori
network
includ
dra
current
part
rhsc
certainli
support
implement
agreedupon
measur
mani
differ
type
bilater
cooper
establish
year
lll
would
difficult
list
discuss
sever
dozen
exist
howev
type
bilater
cooper
agreement
group
three
categori
base
scope
object
cooper
two
develop
countri
object
cooper
exchang
good
practic
harmon
standard
avoid
duplic
effort
eg
orphan
drug
exampl
eu
us
develop
privileg
relationship
exchang
offici
staff
us
fda
eu
author
allow
closer
collabor
exchang
therefor
better
understand
cooper
one
develop
countri
one
develop
countri
type
cooper
focus
train
mentor
support
develop
countri
develop
countri
object
inde
build
expertis
capac
develop
countri
base
experi
develop
countri
exampl
us
fda
establish
sever
agreement
develop
countri
eg
brazil
mexico
south
africa
taiwan
etc
cooper
two
develop
countri
pool
experi
resourc
two
countri
better
tackl
issu
common
interest
type
cooper
allow
better
alloc
spars
resourc
also
increas
interest
pharmaceut
compani
two
small
market
differ
requir
would
less
attract
industri
exampl
brazil
cooper
project
cuba
dominican
republ
mozambiqu
sever
countri
one
advanc
bilater
collabor
australia
new
zealand
repres
good
exampl
bilater
cooper
harmon
model
work
toward
full
integr
system
inde
sever
year
converg
harmon
australia
new
zealand
agre
establish
joint
australia
new
zealand
lll
bilater
cooper
involv
two
countri
also
mean
collabor
region
entiti
anoth
parti
exampl
european
union
collabor
australia
canada
us
japan
also
gcc
group
therapeut
product
agenc
anztpa
new
agenc
ultim
replac
australia
therapeut
good
administr
tga
new
zealand
medicin
medic
devic
safeti
author
medsaf
first
meet
anztpa
implement
ministeri
council
melbourn
januari
minist
countri
agre
key
element
establish
joint
transtasman
agenc
also
joint
regulatori
scheme
organ
fiveyear
period
sinc
framework
anztpa
discuss
cooperationharmon
initi
begun
object
share
expertis
resourc
order
provid
health
benefit
consum
creat
worldclass
scheme
also
expect
singl
approv
process
countri
increas
effici
improv
standard
medicin
produc
two
countri
reduc
regulatori
cost
industri
facilit
econom
integr
initi
great
exampl
success
bilater
harmon
cooper
emphas
import
stage
approach
type
project
also
show
ultim
integr
system
challeng
inde
agreement
joint
regulatori
scheme
first
reach
project
abl
proceed
new
zealand
unabl
pass
enabl
legisl
negoti
countri
also
suspend
juli
increas
collabor
europ
us
pharmaceut
domain
anoth
interest
exampl
bilater
cooper
though
cooper
follow
integr
model
welldevelop
bilater
initi
stepwis
structur
program
interest
provid
clear
exampl
bilater
collabor
achiev
nonintegr
process
also
outlin
limit
also
provid
exampl
measur
organ
necessari
support
bilater
work
european
union
eu
unit
state
america
us
addit
collabor
within
scope
multilater
framework
intern
confer
harmon
technic
requir
registr
pharmaceut
human
use
ich
also
establish
strong
regulatori
scientif
bilater
cooper
pharmaceut
sector
bilater
cooper
promot
public
health
safer
trade
product
harmon
regul
year
scope
transatlant
collabor
increas
today
repres
good
exampl
bilater
cooper
achiev
collabor
mainli
involv
european
commiss
ec
european
medicin
agenc
ema
unit
state
food
drug
administr
us
fda
howev
import
note
us
fda
also
maintain
activ
relationship
nation
dra
throughout
europ
confidenti
arrang
us
sign
european
level
ec
ema
also
nation
level
austria
belgium
denmark
franc
germani
ireland
itali
netherland
sweden
unit
kingdom
particularli
import
collabor
area
inspect
also
allow
us
fda
exchang
inform
product
approv
via
central
procedur
exchang
done
relev
refer
member
state
rmss
leader
eu
us
agre
framework
advanc
transatlant
econom
integr
establish
transatlant
econom
council
tec
overse
effort
outlin
framework
goal
acceler
progress
guid
work
euu
summit
moreov
confidenti
agreement
establish
creat
framework
allow
exchang
confidenti
inform
eu
us
fda
part
regulatori
scientif
process
includ
inform
advanc
draft
legisl
regulatori
guidanc
document
well
nonpubl
inform
relat
ensur
qualiti
safeti
efficaci
medicin
product
human
veterinari
use
implement
plan
also
agre
upon
parti
allow
success
exchang
inform
document
eu
us
fda
accord
term
confidenti
agreement
object
implement
plan
describ
process
parti
undertak
inform
document
exchang
envis
confidenti
agreement
also
facilit
transatlant
pharmaceut
cooper
us
fda
ema
establish
liaison
offici
liaison
offici
remain
employ
home
organ
physic
locat
partner
agenc
design
facilit
collabor
role
facilit
regulatori
scientif
cooper
us
fda
ema
coordin
inform
exchang
also
increas
awar
interact
opportun
ema
us
fda
potenti
new
area
common
interest
scope
bilater
cooper
intensifi
establish
confidenti
arrang
parti
agreement
sign
septemb
extend
septemb
septemb
confidenti
agreement
extend
effect
indefinit
period
without
need
renew
two
offici
statement
author
confidenti
commit
restat
agreement
pursu
indepth
collabor
exchang
confidenti
nonpubl
inform
us
fda
ema
interest
note
statement
reiter
share
inform
includ
confidenti
commerci
trade
secret
inform
us
fda
requir
current
legisl
ask
pharmaceut
compani
share
trade
secret
inform
counterpart
dra
euu
summit
april
momentum
given
regulatori
collabor
signatur
framework
advanc
transatlant
econom
integr
european
union
unit
state
america
ec
presid
manuel
barroso
german
chancellor
angela
merkel
us
presid
georg
w
bush
document
call
effect
systemat
transpar
regulatori
cooper
remov
unnecessari
differ
regul
also
specif
request
promot
administr
simplif
applic
regul
medicin
product
object
bilater
process
toward
cooper
harmon
per
se
exchang
inform
parti
allow
better
understand
system
requir
therefor
build
confid
recognit
facilit
converg
euu
cooper
also
tri
avoid
futur
disharmoni
upstream
regulatori
cooper
new
medicin
legisl
exchang
inform
practic
well
structur
occur
regular
basi
exchang
also
done
ad
hoc
basi
necessari
regular
exchang
ema
us
fda
exchang
list
specif
inform
applic
preauthor
new
molecul
postauthor
market
product
includ
decis
made
applic
quarterli
basi
also
exchang
inform
list
good
clinic
practic
gcp
inspect
pharmacovigil
topic
either
productor
nonproductrel
issu
ad
hoc
exchang
addit
exchang
new
draft
final
legisl
guidelin
prior
public
eu
us
fda
also
exchang
inform
relat
scientif
advic
difficulti
relat
evalu
applic
urgent
drug
safeti
issu
issu
impact
public
health
type
inform
exchang
prior
releas
public
domain
meet
workshop
regulatori
issu
mutual
concern
also
organ
ad
hoc
basi
final
ema
us
fda
publish
annual
report
summar
interact
confidenti
arrang
arrang
also
provid
annual
meet
us
fda
ema
ec
monitor
oper
activ
within
scope
agreedupon
implement
plan
howev
note
share
productrel
inform
limit
medicin
product
evalu
author
accord
eu
central
procedur
well
medicin
product
author
nation
level
eu
member
state
subject
arbitr
referr
accord
european
commun
procedur
initi
relat
gener
topic
report
addit
initi
cooper
also
establish
certain
specif
scientif
area
specif
type
product
ie
oncolog
pharmacogenom
nanotechnolog
advanc
therapi
medicin
product
atmp
blood
product
vaccin
auspic
transatlant
econom
council
novemb
ec
host
transatlant
administr
simplif
workshop
brussel
belgium
cochair
ec
us
fda
organ
collabor
ema
head
eu
nation
medicin
agenc
hma
key
object
identifi
opportun
administr
simplif
transatlant
cooper
remov
unnecessari
burden
administr
practic
guidelin
would
allow
human
fiscal
resourc
focus
greater
innov
effici
develop
qualiti
product
agre
project
requir
chang
legisl
cours
simplif
maintain
increas
current
level
public
health
protect
follow
transatlant
administr
simplif
workshop
medicin
regul
transatlant
administr
simplif
action
plan
publish
june
outlin
administr
simplif
project
taken
forward
document
promot
cooper
pilot
collabor
program
major
area
inspect
biomark
counterfeit
medicin
risk
manag
content
format
scientif
advic
biosimilar
pediatr
advanc
therapi
annual
ecemau
fda
bilater
meet
septemb
agre
major
project
origin
plan
success
complet
pilot
project
extend
becam
standard
cooper
ongo
develop
new
initi
transatlant
administr
simplif
includ
annual
report
interact
us
fda
ema
sever
project
initi
increas
collabor
gmp
gcp
inspect
ad
hoc
exchang
specif
product
qualiti
defect
product
shortag
draft
guidelin
also
took
place
gmp
inspect
sever
pilot
project
first
initi
context
transatlant
administr
simplif
workshop
deliver
initi
project
establish
cooper
european
director
qualiti
medicin
australian
therapeut
good
agenc
conduct
decemb
decemb
relat
gmp
inspect
activ
pharmaceut
ingredi
api
manufactur
project
object
determin
whether
greater
intern
collabor
inform
share
could
help
better
distribut
inspect
capac
thu
allow
site
monitor
reduc
unnecessari
duplic
second
project
relat
finish
product
allow
euu
fda
joint
inspect
aim
develop
way
work
togeth
joint
inspect
routin
schedul
site
territori
us
eu
reduc
duplic
inspect
result
burden
pharmaceut
industri
dra
pilot
phase
conduct
confidenti
agreement
allow
develop
new
tool
work
share
exchang
inform
order
share
inspect
report
organ
joint
inspect
increas
transpar
visibl
inspect
perform
particip
author
allow
success
collabor
author
manufactur
site
common
interest
also
increas
number
inspect
perform
valu
one
author
pilot
phase
confirm
collabor
area
gmp
inspect
led
reduct
duplic
inspect
effici
use
combin
inspect
resourc
wider
global
inspect
coverag
follow
success
conclus
pilot
agre
maintain
cooper
establish
decemb
us
fda
ema
decid
enhanc
gmp
inspect
cooper
move
confid
build
relianc
upon
initi
launch
januari
allow
ema
us
fda
share
inspect
manufactur
site
territori
import
step
follow
posit
experi
acquir
pilot
joint
inspect
program
inform
share
project
occur
sever
year
strategi
allow
inspect
territori
defer
waiv
complet
base
number
consider
riskbas
approach
strategi
applic
gmp
inspect
relat
manufactur
site
locat
us
european
econom
area
eea
mainli
focus
routin
postauthor
surveil
inspect
first
step
result
arrang
could
free
inspect
resourc
would
becom
avail
inspect
region
ongo
emau
fda
joint
inspect
pilot
project
continu
accord
agreedupon
procedur
remain
import
maintain
mutual
confid
build
mutual
understand
gmp
inspect
approach
success
pilot
program
also
expand
new
partner
ongo
collabor
gmp
inspect
activ
substanc
manufactur
due
increas
global
pharmaceut
product
clinic
develop
base
previou
posit
experi
gmp
field
ema
us
fda
agre
launch
pilot
emau
fda
gcp
initi
object
gcp
initi
conduct
septemb
march
reinforc
systemat
period
inform
exchang
gcprelat
activ
us
fda
ema
includ
exchang
gcp
inspect
plan
improv
inspect
coverag
exchang
inform
applic
help
identifi
candid
collabor
inspect
exchang
inspect
outcom
report
neg
posit
potenti
impact
conduct
collabor
gcp
inspect
share
inform
interpret
gcp
draft
guidelin
polici
also
part
project
pilot
initi
product
consider
amount
inform
exchang
mani
product
commun
includ
teleconfer
four
facetofac
meet
facilit
improv
inspect
coverag
decisionmak
process
agenc
collabor
inspect
conduct
initi
contribut
greatli
agenc
understand
inspect
procedur
also
led
identif
potenti
improv
procedur
agenc
learn
sever
gener
lesson
process
addit
exchang
view
interpret
gcp
document
also
organ
pilot
initi
ema
us
fda
share
differ
piec
gcprelat
guidanc
document
posit
paper
polici
order
harmon
agenc
understand
gcp
standard
requir
industri
wherev
converg
would
benefici
clinic
research
process
end
program
parti
consid
pilot
initi
success
agre
continu
collabor
incorpor
lesson
learn
broader
aim
move
confid
build
mutual
accept
inspect
find
agenc
also
expand
scope
initi
site
outsid
us
eu
although
defin
cluster
interact
area
safeti
continu
play
import
part
ongo
collabor
us
fda
ema
videoconfer
take
place
bimonthli
basi
includ
productrel
issu
issu
relat
risk
manag
usual
five
six
product
discuss
teleconfer
regular
inform
teleconfer
order
exchang
inform
emerg
safeti
strateg
issu
ema
share
earli
notif
system
monthli
basi
us
fda
send
advanc
notic
public
quarterli
updat
report
potenti
safeti
signal
joint
project
also
establish
collabor
project
progress
multifoc
leukoencephalopathi
research
agenda
stimul
research
import
safeti
issu
affect
biolog
agent
object
program
allow
interact
ema
us
fda
assessor
sponsor
product
develop
dialogu
two
agenc
assessor
sponsor
scientif
issu
aim
optim
product
develop
avoid
unnecessari
test
replic
unnecessari
divers
test
methodolog
procedur
valuabl
product
develop
indic
develop
guidelin
exist
guidelin
exist
ema
us
fda
recommend
differ
significantli
expert
ema
us
fda
exchang
view
discuss
draft
respons
question
applic
clinic
develop
program
new
biomark
gener
principl
voluntari
parallel
scientif
advic
publish
ema
us
fda
import
understand
parallel
procedur
unfortun
joint
advic
goal
ema
us
fda
primarili
share
inform
perspect
rather
specif
harmon
studi
regulatori
requir
although
recogn
harmon
benefici
outcom
procedur
two
agenc
conduct
individu
regulatori
decisionmak
process
regard
drug
develop
issu
market
applic
agenc
provid
independ
advic
sponsor
regard
question
pose
accord
usual
procedur
timelin
advic
agenc
may
therefor
still
differ
joint
discuss
howev
mani
case
discuss
regul
achiev
high
degre
align
help
industri
move
closer
global
develop
plan
follow
rather
slow
accept
previou
year
due
hesit
industri
use
procedur
commit
two
agenc
issu
common
advic
ema
us
fda
discuss
seven
new
parallel
scientif
advic
procedur
expert
involv
two
procedur
due
therapeut
area
cover
request
addit
formal
parallel
scientif
advic
exchang
us
fda
ema
ad
hoc
inform
scientif
advic
teleconfer
agenc
took
place
five
product
cluster
specif
area
mutual
interest
identifi
structur
work
relationship
establish
cluster
ie
oncolog
pediatr
orphan
medicin
pharmacogenom
blood
product
biosimilar
vaccin
facilit
exchang
inform
teleconfer
relat
applic
market
author
extens
indic
includ
risk
manag
plan
latest
cluster
establish
focu
biosimilar
significantli
increas
cooper
agenc
recent
announc
ema
state
agenc
accept
data
refer
product
batch
sourc
outsid
eu
biosimilar
product
applic
certainli
boost
euu
cooper
domain
global
develop
biosimilar
product
decis
follow
us
fda
propos
also
accept
compar
data
referenc
product
approv
us
euu
fda
collabor
orphan
drug
develop
import
discuss
ema
us
fda
usual
includ
share
inform
applic
submit
order
approach
discuss
criteria
design
common
applic
form
design
agre
sponsor
appli
orphan
design
medicin
product
use
jurisdict
use
common
form
facilit
exchang
inform
sinc
discuss
also
includ
analysi
differ
opinion
februari
us
fda
ema
announc
agre
accept
submiss
singl
annual
report
mmm
sponsor
orphan
product
design
us
eu
regulatori
bodi
continu
conduct
review
annual
report
assur
inform
meet
requir
use
one
singl
report
benefit
sponsor
two
regulatori
agenc
sponsor
benefit
elimin
duplic
effort
develop
two
separ
report
regul
better
identifi
share
inform
throughout
develop
process
orphan
product
collabor
pediatr
govern
principl
agre
framework
includ
inform
exchang
productspecif
gener
issu
invit
parti
relev
pediatr
meet
two
main
object
avoid
expos
mmm
report
provid
inform
statu
develop
orphan
medic
product
includ
review
statu
ongo
clinic
studi
descript
investig
plan
come
year
anticip
current
problem
process
difficulti
test
potenti
chang
may
impact
product
design
orphan
product
children
unnecessari
trial
facilit
develop
global
pediatr
develop
plan
base
scientif
ground
compat
agenc
practic
cluster
pediatr
organ
monthli
teleconfer
ema
pediatr
team
us
fda
pediatr
investig
plan
pip
discuss
detail
inform
two
agenc
exchang
addit
gener
question
also
address
extrapol
choic
endpoint
patientpar
report
outcom
septemb
septemb
product
four
gener
topic
discuss
sinc
end
us
fda
repres
abl
particip
certain
ema
pdco
discuss
vice
versa
ema
also
provid
us
fda
access
intern
databas
includ
scientif
detail
pip
sever
guidelin
develop
ich
level
ich
order
facilit
implement
qualiti
design
take
account
global
perspect
pharmaceut
manufactur
ema
us
fda
agre
would
benefici
earli
stage
implement
assessor
us
eu
could
exchang
view
implement
ich
concept
relev
regulatori
requir
use
actual
applic
threeyear
pilot
program
oper
useu
confidenti
arrang
start
april
program
allow
parallel
evalu
qualiti
design
aspect
applic
submit
ema
us
fda
time
august
ema
us
fda
publish
lesson
learn
q
result
first
parallel
assess
agenc
found
pilot
program
extrem
use
share
knowledg
facilit
consist
implement
ich
guidelin
harmon
regulatori
decis
greatest
extent
possibl
bilater
collabor
eu
us
extrem
product
today
recogn
success
initi
scope
increas
year
basic
exchang
inform
harmon
format
close
collabor
discuss
diverg
posit
liaison
placement
organ
also
import
decis
facilit
cooper
increas
interact
rel
short
period
time
driven
part
reaction
crise
part
proactiv
measur
enhanc
emau
fda
commun
collabor
establish
transatlant
administr
simplif
project
also
benefici
initi
sever
pilot
project
demonstr
need
benefit
collabor
gener
activ
cluster
increas
time
overal
increas
number
ad
hoc
request
teleconfer
specif
product
topic
follow
signific
increas
total
number
monthli
us
fda
ema
interact
ie
teleconfer
document
exchang
etc
averag
per
month
exclud
document
exchang
relat
cluster
pilot
activ
signific
achiev
also
made
sever
critic
area
public
health
orphan
medicin
product
agreement
singl
annual
report
drug
develop
establish
parallel
scientif
advic
procedur
collabor
pediatr
develop
gcp
gmp
inspect
sever
success
pilot
project
increas
collabor
safeti
product
close
collabor
regular
exchang
safeti
inform
risk
manag
safeti
alert
exchang
draft
regul
releas
public
domain
also
facilit
harmon
practic
exchang
opinion
final
tool
effect
track
also
develop
achiev
confirm
collabor
countri
posit
impact
public
health
particularli
evid
certain
area
orphan
drug
develop
diseas
affect
small
popul
exchang
inform
relat
urgent
drug
safeti
issu
better
assess
understand
risk
also
import
note
success
collabor
allow
converg
practic
importantli
exchang
inform
commun
build
confid
system
practic
evalu
allow
share
activ
certain
area
alreadi
case
area
inspect
decemb
ema
spokesperson
monika
benstett
state
agenc
reli
partner
drug
manufactur
facil
inspect
data
success
transatlant
cooper
partli
due
fact
well
structur
organ
year
establish
cluster
creation
liaison
offici
posit
nnn
strengthen
regulatori
cooper
agenc
decis
extrem
benefici
perspect
educ
time
commun
larg
number
staff
visit
exchang
also
took
place
routin
involv
scientif
work
agenc
us
fda
repres
take
part
observ
committe
medicin
product
human
use
chmp
discuss
ema
repres
provid
access
webcast
us
fda
advisori
committe
howev
paramet
list
also
critic
success
clearli
demonstr
import
type
cooper
harmon
initi
first
clear
polit
commit
increas
cooper
import
inde
closer
collabor
evid
sign
framework
advanc
transatlant
econom
integr
european
union
unit
state
america
ec
presid
manuel
barroso
german
chancellor
angela
merkel
us
presid
georg
w
bush
second
establish
confidenti
agreement
sinc
effect
indefinit
period
allow
parti
exchang
inspect
report
nonpubl
productrel
inform
critic
establish
collabor
commun
specif
practic
case
allow
parti
nnn
sinc
fda
second
perman
repres
ema
offic
london
sinc
earli
ema
second
repres
fda
offic
discuss
similar
differ
opinion
assess
product
applic
document
although
necessari
share
public
inform
ie
new
regul
guidelin
provid
opportun
third
bilater
collabor
benefit
fact
parti
level
matur
develop
system
regul
similar
public
health
need
challeng
even
alway
ident
lastli
stepbystep
approach
establish
help
provid
clear
prioriti
cluster
allow
progress
exchang
inform
ad
hoc
request
regular
teleconfer
nonpubl
product
inform
exchang
time
parti
evalu
partner
agenc
system
practic
sever
specif
pilot
project
visitsexchang
staff
although
took
time
lot
effort
differ
step
benefici
facilit
transpar
confid
build
clear
understand
similar
differ
practic
prerequisit
foster
cultur
converg
agenc
assess
evalu
conclud
bilater
collabor
develop
move
confid
build
exchang
inform
recognit
inform
data
decis
make
success
far
support
continu
collabor
even
extens
confid
system
continu
increas
although
recogn
parti
remain
ultim
respons
public
health
territori
closer
cooper
converg
obvious
possibl
mani
domain
final
would
benefici
continu
expand
success
project
addit
partner
case
gmp
inspect
activ
substanc
manufactur
order
foster
greater
intern
collabor
inform
share
addit
bilater
region
global
regulatori
initi
describ
previou
section
technic
scientif
harmon
project
also
initi
although
project
enter
scope
research
specif
relat
regulatori
harmon
import
mention
standard
develop
often
use
regulatori
harmon
initi
follow
organ
project
ooo
inde
support
harmon
standard
pharmaceut
domain
pharmacopoei
discuss
group
pdg
involv
sinc
european
pharmacopoeia
ep
japanes
pharmacopoeia
jp
us
pharmacopeia
usp
harmon
pharmacopoei
standard
ie
excipi
monograph
select
gener
chapter
work
collabor
ich
becam
observ
may
ooo
list
organizationsproject
provid
exampl
repres
exhaust
list
intern
organ
standard
iso
world
largest
develop
publish
intern
standard
network
nation
standard
institut
countri
central
secretariat
geneva
switzerland
nongovernment
organ
today
intern
standard
type
norm
document
cover
mani
technic
area
pharmaceut
inspect
cooper
scheme
pic
facilit
sinc
ppp
cooper
network
field
good
manufactur
practic
gmp
order
lead
intern
develop
implement
mainten
harmon
gmp
standard
qualiti
system
inspector
field
medicin
product
pic
activ
includ
develop
promot
harmon
gmp
standard
guidanc
document
train
inspector
assess
inspector
initi
current
includ
worldwid
pharmaceut
inspect
author
council
intern
organ
medic
scienc
ciom
intern
nongovernment
nonprofit
organ
establish
jointli
unit
nation
educ
scientif
cultur
organ
unesco
includ
intern
nation
associ
member
organ
repres
mani
biomed
disciplin
nation
academi
scienc
medic
research
council
one
object
ciom
facilit
promot
intern
activ
field
biomed
scienc
activ
includ
program
drug
develop
intern
nomenclatur
diseas
world
medic
associ
wma
intern
organ
found
repres
physician
today
includ
nation
medic
associ
goal
achiev
consensu
highest
intern
standard
medic
ethic
profession
compet
declar
helsinki
develop
wma
bestknown
polici
statement
final
group
expert
also
work
releas
recommend
specif
topic
relat
harmon
pharmaceut
regul
eg
phrma
pharmaceut
research
manufactur
america
simultan
global
develop
project
nonprofit
transceler
biopharma
project
project
contribut
global
converg
harmon
pharmaceut
regul
mani
harmon
initi
establish
past
sever
decad
regul
understand
cooper
help
resolv
new
challeng
brought
global
understand
import
advantag
cooper
ppp
pharmaceut
inspect
convent
pic
oper
sinc
harmon
support
mandat
promot
protect
public
health
mani
countri
region
strongli
enhanc
collabor
countri
bilater
multilater
region
global
level
global
pharmaceut
market
highlight
sever
problem
associ
data
gener
foreign
countri
import
product
exampl
death
associ
heparin
import
china
us
due
contamin
pharmaceut
ingredi
chines
plant
panama
diethylen
glycol
found
cold
fever
medicin
kill
mani
peopl
problem
wakeup
call
increas
recognit
benefit
deriv
leverag
activ
resourc
foreign
counterpart
dra
exampl
us
strongli
increas
intern
collabor
pharmaceut
domain
us
legisl
decid
intern
cooper
harmon
activ
integr
part
us
fda
mission
inde
food
drug
administr
modern
act
state
one
mission
fda
particip
appropri
process
repres
countri
reduc
burden
regul
harmon
regulatori
requir
achiev
appropri
reciproc
arrang
sinc
us
fda
intern
work
grown
exponenti
especi
past
decad
respond
adapt
new
global
societi
increas
commun
qqq
develop
regulatori
cooper
countri
bilater
multilater
us
fda
role
harmon
multilater
relat
coordin
collabor
activ
variou
intern
organ
ie
ich
pandrh
apec
individu
countri
intern
standard
harmon
regulatori
requir
pursuit
appropri
intern
collabor
us
fda
util
wide
varieti
intern
arrang
includ
confidenti
commit
rrr
memoranda
understand
cooper
arrang
sss
ema
one
us
fda
closest
regulatori
partner
china
uuu
us
fda
must
increas
capac
inspect
analyz
chines
product
ship
us
order
accomplish
us
fda
establish
offic
beij
china
novemb
employ
peopl
addit
employe
hire
plan
follow
year
allow
solid
relationship
chines
regul
export
train
manufactur
regul
us
safeti
standard
two
year
final
increas
recognit
within
us
fda
need
strengthen
regulatori
capac
provid
technic
scientif
expertis
develop
countri
ensur
product
export
us
meet
us
fda
standard
adequ
level
patient
protect
mani
cooper
initi
establish
meet
goal
countri
region
includ
us
eu
australia
canada
singapor
china
bilater
collabor
base
confidenti
agreement
vvv
includ
inform
share
proactiv
exchang
staff
also
agre
upon
dra
japan
pmda
also
develop
privileg
relationship
china
south
korea
follow
pandem
influenza
crisi
sinc
tripartit
initi
specif
cooper
clinic
research
promot
region
clinic
trial
februari
advisori
council
approv
pmda
intern
strateg
plan
framework
intern
activ
plan
outlin
strategi
bilater
region
global
cooper
establish
intern
offic
charg
intern
affair
line
intern
strateg
plan
goal
attain
publish
novemb
final
roadmap
pmda
intern
vision
releas
april
roadmap
pmda
defin
specif
action
support
intern
vision
primari
object
increas
intern
collabor
urgent
resolv
drug
lag
www
impact
japanes
pharmaceut
market
past
year
mani
measur
taken
improv
clinic
test
environ
includ
promot
global
clinic
trial
expedit
drug
approv
decis
via
among
measur
increas
collabor
worldwid
dra
global
simultan
drug
develop
approach
also
strongli
recommend
mani
action
includ
releas
guidelin
taken
facilit
global
develop
addit
us
japan
major
dra
develop
countri
health
canada
australian
tga
also
recogn
import
ad
valu
global
cooper
therefor
increas
involv
intern
activ
eu
base
prior
experi
harmon
cooper
establish
system
also
develop
extern
bilater
multilater
collabor
today
import
intern
partner
although
divers
coexist
bilater
region
global
initi
creat
complex
import
note
complementari
global
harmon
preclud
region
harmon
region
harmon
preclud
bilater
agreement
fact
three
level
harmon
cooper
bring
differ
ad
valu
bilater
agreement
allow
bigger
exchang
inform
includ
productspecif
data
confidenti
agreement
develop
privileg
relationship
trust
regul
allow
assess
one
anoth
vvv
case
china
cooper
agreement
establish
www
drug
lag
defin
differ
avail
new
medicin
us
japan
system
practic
xxx
assess
inde
critic
confid
build
ultim
support
sign
agreement
allow
recognit
inspect
exchang
nonpubl
inform
eg
euu
collabor
confidenti
agreement
bilater
collabor
also
help
strengthen
relationship
would
difficult
context
multilater
initi
facilit
train
mentor
activ
develop
develop
countri
region
harmon
allow
harmon
polici
countri
usual
closer
term
system
cultur
level
develop
inde
easier
harmon
close
system
polici
countri
similar
cultur
environ
exampl
difficult
harmon
system
polici
asia
north
america
differ
medic
practic
cultur
level
essenti
global
harmon
provid
structur
achiev
global
harmon
without
support
region
organ
structur
imposs
region
level
allow
inclus
region
realiti
difficulti
global
discuss
eas
diffus
implement
global
recommend
global
harmon
highest
level
harmon
compar
region
harmon
global
harmon
initi
driven
econom
object
goal
creat
free
trade
area
singl
market
develop
global
consensu
standard
order
allow
world
popul
access
medicin
innov
therapi
conclud
bilater
region
global
cooper
activ
benefici
support
harmon
requir
global
therefor
facilit
avail
safe
efficaci
medicin
critic
promot
global
public
health
worldwid
basi
mani
topic
standard
alreadi
partli
fulli
harmon
bilater
region
global
level
exampl
requir
regard
conduct
nonclin
studi
also
gmp
good
clinic
practic
gcp
principl
agre
allow
joint
inspect
project
common
format
applic
develop
mani
technic
aspect
harmon
ich
work
collabor
also
increas
resolv
major
topic
requir
global
interact
orphan
drug
evalu
yyy
develop
medicin
pediatr
popul
zzz
confid
trust
built
develop
countri
pilot
project
xxx
exampl
bilater
collabor
allow
two
countri
assess
respect
inspect
system
system
control
critic
inform
trade
secret
assess
system
could
possibl
case
multilater
collabor
would
complex
yyy
small
number
popul
affect
lifethreaten
diseas
seriou
condit
critic
global
requir
order
facilit
global
clinic
studi
moreov
pharmaceut
industri
reluct
invest
research
develop
medicin
product
treat
condit
develop
global
requir
allow
quick
access
global
market
therefor
allow
better
return
invest
zzz
critic
countri
cooper
area
avoid
expos
children
unnecessari
trial
also
locat
offici
liaison
dra
facilit
collabor
posit
new
type
interact
promis
increas
relationship
allow
better
exchang
experi
inform
aaaa
establish
liaison
countri
also
allow
proactiv
measur
risk
analysi
area
qualiti
system
inspect
exchang
inform
dra
also
dramat
increas
regular
commun
regul
facilit
evalu
risk
eg
via
exchang
safeti
alert
assess
new
medicin
final
system
put
place
help
develop
countri
eg
cpp
scheme
prequalif
medicin
articl
european
regul
ec
etc
howev
without
underestim
import
posit
outcom
clear
differ
still
exist
effort
requir
support
ongo
harmon
process
still
differ
countri
term
standard
strategi
assess
complianc
standard
conduct
global
clinic
studi
continu
present
mani
challeng
ie
relat
registr
conduct
studi
also
use
data
still
sever
clinic
trial
registri
databas
use
safeti
medicin
one
main
focus
dra
past
due
major
problem
event
real
effort
toward
worldwid
harmon
regard
riskmitig
strategi
addit
new
standard
continu
develop
differ
bodi
ie
ich
vs
region
organ
parallel
duplic
effort
also
creat
disharmoni
eg
biosimilar
requir
first
develop
individu
countri
also
also
signific
differ
level
implement
harmon
standard
ie
ich
recommendationsguidelin
countri
ctd
format
still
implement
countri
also
report
differ
develop
develop
countri
fact
continu
increas
past
sever
year
due
increas
complex
technolog
associ
develop
new
therapi
even
two
close
partner
like
us
eu
develop
privileg
partnership
strong
cooper
still
import
differ
standard
exampl
us
still
requir
two
placebocontrol
studi
determin
efficaci
new
medicin
eu
interest
compar
studi
use
activ
compar
differ
due
differ
legal
requir
scientif
opinion
regard
valu
compar
data
situat
may
chang
futur
grow
interest
us
compar
effect
promot
obama
administr
final
complex
worldwid
harmon
context
increas
commun
exchang
experi
inform
good
practic
requir
good
commun
coordin
ongo
initi
even
commun
initi
ich
gcg
group
improv
would
still
need
enhanc
coordin
intern
cooper
would
inde
benefici
would
provid
necessari
transpar
regard
focu
respons
initi
ie
develop
standard
coordin
implement
recommend
etc
aaaa
exchang
inform
best
practic
one
import
outcom
euu
bilater
collabor
would
also
facilit
appropri
use
resourc
expertis
therefor
avoid
duplic
effort
conflict
recommend
action
overlap
membership
initi
bbbb
may
fulli
effici
creat
confus
duplic
work
although
increas
coordin
divers
initi
would
benefici
certainli
challeng
need
thoroughli
structur
implement
also
critic
coordin
bodi
recogn
experienc
entiti
appropri
mandat
power
